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Abstract 
Eukaryotic translation elongation factor eEF1A2 is responsible for delivering 
aminoacylated tRNAs to the ribosome during protein synthesis. Heterozygous de 
novo missense mutations in EEF1A2 have been identified in individuals with 
epilepsy, autism and intellectual disability. The primary aim of this thesis was to 
assess whether these mutations operated through a loss of function, gain of function 
or dominant negative mechanism. To investigate this, I analysed eEF1A2 protein 
interactions, how these interactions varied between mutations and the functional 
consequences of changes in the interactome.  
I used affinity purification mass spectrometry to identify the interactome of 
eEF1A2 and compared the changes resulting from mutations in eEF1A2. Co-
immunoprecipitation experiments determined that mutations could be grouped by 
changes in their interaction with the cognate guanine exchange factor eEF1B. One 
group showed complete or partial loss of binding to all four subunits of the eEF1B 
complex, whilst another cluster showed no change in binding compared to wild-
type eEF1A2. No specific patterns of clinical features or phenotypic severity could 
be attributed to these groupings. My results suggested that protein synthesis would 
be impaired by this disrupted interaction. In vivo and in vitro protein synthesis 
experiments failed to detect any differences that could be attributed to the presence 
or absence of the D252H mutation. As no apparent differences in protein synthesis 
could be detected between muscle tissue from Eef1a2-/- and Eef1a2+/+ mice or 
between eEF1A2-/- and wild-type cells, it is likely that in both cases the protein 
synthesis assay employed was not performing adequately.  
Comparative analysis of Eef1a2D252H/D252H and Eef1a2-/- mouse phenotypes 
determined that there is a gain of function or dominant negative element to the 
eEF1A2D252H mutation, highlighting that this mutation does not operate simply 
through a loss of function mechanism. Interactome was unable to successfully 
identify what this might be. 
In conclusion eEF1A2 mutations may operate via both a loss and gain of function 
mechanism. Depending on the precise mutation, eEF1A2 may be compromised in 
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its ability to operate in protein synthesis, but at least some mutations may also 
result in a degree of toxicity.
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Chapter 1: Introduction 
1.1 Translation  
1.1.1 Translation elongation 
Protein synthesis is divided into 3 steps; initiation, elongation and termination. 
Met-tRNA is recruited to the 80S subunit of the ribosome for initiation of the 
polypeptide chain, mediated via a complex of initiation factors. Once peptide 
formation is established, further complementary aminoacylated tRNAs are 
recruited to the ribosome by elongation factors. Finally stop codon recognition 
terminates polypeptide elongation and induces the release of the polypeptide from 
the ribosome, facilitated by release factors (1).  
In eukaryotes, the eEF1 complex responsible for elongation can be subdivided 
into two components. eEF1A, a GTPase protein, delivers aminoacylated tRNAs 
to the ribosome in a GTP dependent manner. eEF1B – a complex of proteins - 
acts as the cognate guanine exchange factor for eEF1A.  
 
Figure 1.1: Schematic diagram of translation elongation. eEF1A-GTP directs 
aminoacylated tRNAs to the A site of the ribosome resulting in GTP hydrolysis. 
eEF1A-GDP disassociates from the ribosome and is bound to the eEF1B complex 
for GDP recycling. The eEF1B complex is displayed as its 3 constituent subunits 
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eEF1Bα, eEF1Bδ and eEF1Bγ. GDP recycling allows eEF1A to repeat the 
process, lengthening polypeptide chains. Figure: Li et al, 2013 (2). 
1.2 eEF1A 
1.2.1 Two eEF1A isoforms with differential expression patterns.  
Throughout eukaryotic species several isoforms of eEF1A are present. 
Drosophila and Xenopus have been reported to have 2 and 3 copies of eEF1A 
gene respectively (3,4). The presence of multiple isoforms appears not to be 
consistent within non-mammalian vertebrae. Zebrafish have been reported to 
express only one isoform (5,6). This has, however, been contested within our lab, 
with several isoforms reported in all tissues studied (personal communication 
with Nwamaka Idigo)  
In mammals the presence of a second isoform was first detailed in rat. Named 
as statin-1 (from here on called eEF1A2), the isoform demonstrated a 92% 
identical (and 98% similar) amino acid sequence homology with eEF1-α (from 
here on called eEF1A1) (7). In humans, EEF1A1 and EEF1A2 genes are located 
on chromosomes 6 and 20 respectively (8), and their proteins display distinct and 
reciprocal expression patterns. eEF1A1 is expressed ubiquitously throughout 
development, before being switched off in terminally differentiated myocytes, 
cardiomyocytes and neurons in mammals including rodents and humans (7,9,10). 
There is evidence that this switch is conserved in vertebrates. Drosophila express 
one isoform ubiquitously as a housekeeping gene (F1), and a second (F2) isoform 
during the pupal stage (3). In Xenopus a switch between two eEF1α isoforms is 
regulated post-translationally in muscle. In pigs, eEF1A2 expression was found in 
adult muscle, tongue, brain and heart. eEF1A1 is expressed prenatally and in 
most adult tissue – with downregulation in heart, liver and brain (11).  
Techniques such as immunofluorescence and immunohistochemistry allowed 
for analysis of eEF1A1 and eEF1A2 expression within specific cell populations 
in tissues. Initial immunostaining experiments by Pan and colleagues compared 
WT and Eef1a2-/- mice (discussed further in Section 1.5.1).  Although they found 
eEF1A1 expression in all developing neurons, upon terminal differentiation, most 
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staining in neurons was attributed to eEF1A2. eEF1A1 staining was limited to 
glial cells (12). Further examination of eEF1A2 expression in nervous system cell 
types was performed by Newbery and colleagues (13). Immunohistochemistry 
staining of eEF1A1 and eEF1A2 in mouse spinal cord and brain sections 
demonstrated reciprocal expression. eEF1A2 was expressed in terminally 
differentiated motor neurons and Purkinje cells, whilst eEF1A1 is expressed in 
glial cells. This was in agreement with Pan et al (12), however extends upon the 
results by confirming the complete reciprocal expression of these isoforms in 
different neuronal cell types.  
The timing of the switch in mice became well documented by studies of 
Eef1a2-/- mice (discussed in Section 1.5.1). However, less is known about the 
switch in humans. The use of databases such as Braincloud and Brainspan allows 
us to view transcriptome profiles collated from multiple RNAseq experiments 
(14,15). Figure 1.2 demonstrates a reciprocal expression pattern in neurons, 
showing eEF1A1 mRNA down-regulated postnatally, with up-regulation of 
eEF1A2 occurring at a similar timepoint. The expression change of isoforms is 
complete by ~2 years after birth.  
Chapter 1: Introduction  Page | 4 
 
Figure 1.2: RNAseq data demonstrating the mRNA expression of eEF1A1 (A) 
and eEF1A2 (B) in human throughout development. Graphs from the 
BrainCloud depository. C demonstrates the patterns of gene expression during 
development. Adapted from Tebbenkamp et al (15). 
1.2.2 Structural differences between eEF1A1 and eEF1A2 
Despite their high sequence homology, there are distinct structural differences 
between the variants which might explain the conserved presence of two 
isoforms. eEF1A is composed of 3 domains. The first domain forms two α helices 
and two anti-parallel β strands. A linker connects domain I to domain II, which is 
a β barrel structure composed of two β-sheets. Domain III is a second, larger, β-
barrel made of seven β-sheets, connected to domain II with a second linker (16). 
Soares et al provided structural analysis of the changed amino acid residues and 
found they were distributed between all 3 domains. 3D modelling determined that 
eEF1A has a “conserved” face, containing the residues which participate in 
eEF1B binding, and a “variable” face (see Figure 1.3B). This variable face has 
two clusters of amino acids which differ between the two isoforms. There is 
minimal amino acid variation both within and near the eEF1B binding sites, 
suggesting there is likely no functional difference to eEF1B binding capacity. 
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Changes however, are seen in both GTP and possible actin binding sites (17). 
Post translational modifications appear to cluster in a similar manner to the 
changed residues, further supporting that these clusters mediate the different 
functions of the isoforms (18). This structural analysis was supportive of 
experimental data. eEF1A1 and eEF1A2 show slightly increased affinities for 
GTP and GDP respectively, although similar overall translational kinetics are 
reported (19). In terms of actin binding, mutational analysis of yeast eEF1A 
showed that at least one of the residues changed in eEF1A2 is important in actin 
bundling (20). Additionally, recent evidence found different actin organisation 
properties of eEF1A1 and eEF1A2 (discussed further in Section 1.2.4.3) (21). 
Outwith protein synthesis and actin bundling, it is possible post-translational 
changes afford the opportunity for varied interacting partners. Panasyuk et al 
highlighted that eEF1A2 displayed increased tyrosine phosphorylation allowing it 
to interact with specific domains of signalling molecules such as RasGap, which 
eEF1A1 could not (22). Although changes in structure between the two isoforms 
result in slightly varied affinities with GTP, it is also reported that this does not 
impact upon global translational kinetics (19). Most structural changes between 
the two isoforms appear to modulate differing binding partners related to non-
canonical functions.  
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Figure 1.3: A alignment of the amino-acid sequences of eEF1A1 and eEF1A2 
using Clustal Omega, with varied residues in red. B Structural representation of 
eEF1A1 and the amino acids which differ in eEF1A2 (green). Adapted from 
Soares et al, 2009 (17). 
1.2.3 eEF1A2 structure in mammals 
The mammalian structure of eEF1A2 was determined by X-Ray diffraction 
after the protein had been purified from rabbit skeletal muscle. Like the yeast 
structure, it consists of three domains and binds GTP and eEF1B. The structure 
was pulled down as a dimer, suggesting this conformation is pertinent to some 
function(s) (23).  
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It was first proposed that eEF1A acts in its actin bundling function in dimer 
conformation. eEF1A in tetrahymena bound to actin in a 1:1 manner. For actin 
bundling to occur, eEF1A would have to cross-link two actin filaments. The 
authors hypothesised that as eEF1A only contains one actin binding site, anti-
parallel eEF1A dimer formation would enable the binding of two actin filaments 
in close enough proximity for actin bundling to occur (24). eEF1A dimer 
formation was experimentally proven in 2006 by Bunai and colleagues. They 
confirmed that eEF1A dimer formation was required for actin bundling. Bundling 
activity was dependent upon eEF1A dissociation from calmodulin. Calmodulin 
did not influence the association of eEF1A with actin, but did impair actin 
bundling activity (25). Interestingly, this work looked at actin bundling during 
cytokinesis. If eEF1A is essential for actin bundling in the cell division process, it 
is possible this function could be attributed to eEF1A1 rather than eEF1A2, and 
by extension the monomer to dimer ratio. More recent work in the mammalian 
forms confirms the existence of dimers. Trypsinolysis of eEF1A1 removed 69 
amino acids from its N-terminal (a portion of domain I). Work with this truncated 
protein demonstrated that only domain III binds to actin, but for bundling to 
occur, the missing portion of domain I was required too. The removal of this 
segment inhibited dimerisation, suggesting that eEF1A1 requires a dimeric 
structure for actin bundling (26). Comparison of dimerisation of the two 
mammalian isoforms found eEF1A1 was more likely to self-associate due to its 
increased hydrophobicity. This evidence fits nicely with the experimental 
evidence that eEF1A1 has more of a role in actin bundling that eEF1A2 (as 
discussed in Section 1.2.4) (27)   
1.2.4 Functional differences of eEF1A1 and eEF1A2 
1.2.4.1 Overview of functional differences between eEF1A1 and eEF1A2 
The two eEF1A isoforms must operate in different manners to an extent, so as 
to justify such a conserved switch. Evidence currently suggests there is no 
difference in the translational kinetics (19), even with slight difference in the GTP 
affinity of the two isoforms. The conserved presence of two isoforms is, 
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therefore, likely owing to their differing non-canonical properties (28). As the 
second most highly expressed protein in the cell, it is unsurprising that eEF1A 
has been implicated in several functions (29). However, the extent to which these 
are shared between the isoforms is debated. Table 1.1 summarises the reported 
non-canonical functions of both eEF1A isoforms.  
Table 1.1: Reported non-canonical functions of eEF1A and the role each isoform takes. 
Function Isoform Comments Reference 
eEF1A1 eEF1A2 
Heat shock X  eEF1A1 but not 
eEF1A2 has 
been shown to 
be instrumental 
















X ? eEF1A is 
involved in the 
nuclear export 
of translational 






X X Both isoforms 
have been 
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Aggresome 
formation 









X ? eEF1α interacts 





















X X Both eEF1A1 
and eEF1A2 
have been 
















X X Transport of 
mRNA in RNA 
transporting 




1.2.4.2 eEF1A at the synapse 
eEF1A has been implicated in local protein synthesis at the synapse. First the 
role of eEF1A is discussed, before evidence for the role of each isoform is 
examined.  Long term facilitation, a mainstay of synaptic function, can be 
subdivided into long-term potentiation (LTP), and long-term depression (LTD). 
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Long term potentiation can be further subdivided into early (immediate response 
to frequency stimulation) and late (a more permanent change to synapse structure 
as a result of persistent stimulation). Although early-phase LTP can be managed 
by post-translational modification (50), both late-phase LTP and LTD require 
local protein synthesis to facilitate synaptic changes (51). eEF1A function was 
first identified as integral to late-LTP by studies in aplysia. Aplysia eEF1A (Ap-
eEF1A) was identified as a late response gene which became up-regulated after 
serotonergic stimulation. eEF1A was not transported as protein to the synapse in 
response to serotonin, but instead as mRNA for local translation. The authors 
identified the increased Ap-eEF1A was dependent upon cAMP and the CREB1 
pathway – a well-established signalling pathway in synaptic plasticity (52). The 
targeting of Ap-eEF1A to specific stimulated synapses may be key to controlling 
specific synaptic maintenance. Early and late-response genes are transcribed and 
therefore expressed cell wide, but the targeting of Ap-eEF1A to specific synapses 
might help control synaptic maintenance at the translational level. Ap-eEF1A 
favoured translation of mRNAs with terminal oligo-pyrimidine (TOP) sequences 
in their 5’ untranslated region (UTR). Proteins associated with synaptic plasticity 
are enriched for the presence of these 5’UTR TOP sequences in their mRNAs, 
including structural (actin) and functional proteins (CamKII and calmodulin). Ap-
eEF1A was only required for synaptic maintenance (late-LTP) and not induction 
(early-LTP) as the latter does not involve protein synthesis. This result implicated 
eEF1A in potentiation of synapses required for memory storage (43).  
Mammalian eEF1A has been shown to work in a similar manner. N-Methyl-D-
aspartic acid (NMDA) receptor activation using high frequency stimulation 
(HFS) resulted in the phosphorylation of mammalian target of rapamycin 
(mTOR) and its downstream signaller p70S6K. This phosphorylation resulted in 
increased eEF1A. This affect was not seen in lower frequency stimulation, 
associated with early-LTP formation. Meaning eEF1A is implicated in the protein 
synthesis required for late-LTP.  The authors concluded that the increased eEF1A 
was a result of de novo protein synthesis and not a redistribution of residual 
eEF1A, as the application of a protein synthesis inhibitor before HFS prevented 
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this from happening. Furthermore, stimulation of isolated dendrites provided the 
same increase in eEF1A for 1-2 hours post HFS, suggesting that eEF1A mRNA is 
translated directly at the synapse and is not reliant of changes in expression at the 
soma (44). Further, Inamura and colleagues discovered that brain-derived 
neurotrophic factor (BDNF) stimulated not only initiation factors, but elongation 
factors eEF1A and eEF2. BDNF stimulates the mTOR pathway, phosphorylating 
eEF1A (stimulating activity) and eEF2 (inhibiting activity), the combination of 
which resulted in significantly increased ribosomal transit time (an inverse 
measure of protein synthesis).  Inhibiting mTOR suppressed this result, 
determining that BDNF signalling was again mediated through the mTOR 
pathway via stimulation of downstream signalling target p70S6K (45).   
Increases in eEF1A expression upon LTD induction have also been seen. 
Huang and colleagues used (S)-3,5-Dihydroxyphenylglycine (DHPG) to treat rat 
hippocampal slices. This drug stimulated metabotropic glutamate receptors 
(mGluRs) and resulted in increased eEF1A expression in dendrites as a result of 
de novo protein synthesis (46). This increase has been attributed to stimulation of 
the mTOR pathway in further studies (47). Huang and colleagues used HFS to 
induce LTP, which did not result in de novo protein synthesis of eEF1A, merely 
the redistribution of eEF1A into the dendrite. Despite increased eEF1A 
expression in both the LTP and LTD condition, no notable increase in protein 
synthesis could be detected. The authors conceded the method used may not be 
sensitive enough to detect changes in individual dendrites. However, the authors 
did note an increase in F-actin in response to DHPG treatment, a response which 
could be blocked (46). It is well established eEF1A interacts with actin (as 
discussed previously) and it is highly likely that it functions at the synapse 
outwith its canonical function of protein synthesis.  
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Figure 1.4: Mechanisms of eEF1A activation in late phase LTP and LTD for 
local protein synthesis. Increased eEF1A and phosphorylated-eEF1A have both 
been reported in dendritic synapses as a response to high frequency stimulation 
inducing-LTP and metabotropic stimulated LTD. eEF1A has been reported to be 
upregulated owing to several signalling pathways (43–47).  
eEF1A playing a role other than protein synthesis at the synapse is a well-
established idea supported by several arguments. 1) eEF1A is expressed in greater 
quantities than the subunits of its corresponding guanine exchange factor eEF1B 
(53). 2) eEF1A expression has been seen in early-LTP despite no known protein 
synthesis being reported at this time. This evidence proposes the idea that in 
early-LTP phase eEF1A participates in other functions.  
Both isoforms have been reported to inhibit M4 muscarinic receptor recycling 
from endosomes (54). eEF1A is has been identified as part of  ribonucleoprotein 
granules (RNPs) which are involved in the transport of RNA granules to the 
synapse (48,49). The alpha subunit of the M3M4 loop of glycine receptors was 
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seen to interact with eEF1A. This subunit has also been shown to interact to 
structural clustering protein gephyrin. Stimulation of glycine receptors implicated 
eEF1A in gephyrin-mediated glycine receptor clustering. Further, the authors 
discovered that when stimulating glycine or NMDA receptors in older cultured 
neurons, eEF1A was redistributed from synapses to the cytoskeleton (55). This 
evidence is supportive of a larger theory that eEF1A may play a significant role in 
actin bundling and restructuring at synapses, which is discussed in the next 
section.  
The specific role each isoform plays in neuronal activity is harder to 
determine. It is often difficult to identify which isoform is present, firstly because 
often commercial antibodies cannot distinguish the two isoforms when 
immunostaining, and secondly because glial cells express eEF1A1 making whole 
tissue lysate analysis via western blot impossible. In most of the previously 
mentioned studies, no reference to the isoform involved is made, so elucidating 
the role of each isoform in neurons is challenging.  
As eEF1A2 is the dominant neuronal isoform, it might be assumed that most 
of the eEF1A functions in differentiated neurons is mediated by this isoform. It is 
the case that eEF1A2 is the only isoform in terminally differentiated motor 
neurons (13). The up-regulation of eEF1A2 mRNA in human mRNAseq appears 
to coincide with synaptogenesis (Figure 1.2B & C (15)), also previously 
demonstrated for rat eEF1A2 (56). This suggests eEF1A2 is the dominant 
isoform for formation and maintenance of synapses. However, experimental 
evidence suggests eEF1A1 may play a role in developing neurons. eEF1A1 and 
eEF1A2 have both been found in post-synaptic densities (57,58). eEF1A1 mRNA 
is present in dendrites and was increased by neuronal depolarisation. This mRNA 
increase was accompanied with a greater increase in eEF1A protein, but the 
isoform is not specified (59). GFP-tagged eEF1A1 was targeted to dendritic 
spines by domain III. As domain III is most associated with actin bundling, the 
authors suggested that domain specific targeting might imply a function in spines 
(60)  eEF1A1 also appears to be a target for Cilostazol influencing neurite 
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outgrowth (61). The evidence suggests eEF1A1 protein certainly plays a role in 
neurons, at least some point during neuronal development. There is some 
argument that even in subtypes of mature neurons eEF1A1 may not be 
completely switched off. Both McClatchy et al and Khalyfa et al found some 
eEF1A1 staining in terminally differentiated neurons (42,62). Therefore, although 
the timing and conservation of the genetic switch suggests eEF1A2 is likely the 
dominant neuronal isoform, the role which eEF1A1 plays in neuronal 
development/maintenance has yet to be fully established.  
Interestingly as Bluem et al cultured their primary neurons a shift in eEF1A 
from synapses to actin filaments at 21-28DIV could be seen. Although it is 
impossible to tell if this is reflective of a change in isoform expression, it is 
intriguing that as neurons matured, a redistribution of eEF1A could be seen.  It is 
possible this redistribution is for alternative function (55). More work to 
determine the role of each isoform will be possible as techniques which do not 
rely on antibodies continue to be developed.  
1.2.4.3 eEF1A and actin interactions 
One well-established function of eEF1A is actin bundling (63). Actin bundling 
is conserved between prokaryotic and eukaryotic variants of the protein (64,65). 
eEF1A bundles F-actin in Tetrahymena in the absence of calcium/calmodulin 
(24). The bundling of actin by eEF1A may be crucial in cell division, 
maintenance and synaptogenesis.  
The roles of eEF1A in both protein synthesis and actin bundling might not be 
mutually exclusive. eEF1A has been shown to tether mRNA to actin filaments for 
local translation. There is a large body of evidence that the cytoskeleton may 
regulate the spatial control of translation by interacting with translational 
machinery (29). Translational impairments have been shown to be directly 
correlated with disruption to F-actin filaments (66). Mutagenic studies of eEF1A 
in yeast displayed dysregulation of growth and the cytoskeleton. This was 
partnered with a reduction in translation rate, however translation was inhibited at 
the initiation stage in the first instance, suggesting actin works to affect feedback 
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on translation at the initiation stage (67) with elongation as a secondary target 
(68).  
When comparing the activities of eEF1A1 and eEF1A2, it is possible that actin 
bundling is the major difference between the two isoforms. Recent experimental 
evidence supports this hypothesis. Functional analysis of the difference in 
eEF1A2 and eEF1A1 actin bundling has been recently reported. Novosylna et al 
examined both the Ca2+-calmodulin and actin binding properties of eEF1A1 and 
eEF1A2. They report that eEF1A2, unlike eEF1A1, did not bind to Ca2+-
calmodulin. In the case of eEF1A1, this interaction resulted in the inhibition of 
actin bundling. The authors further explored the consequence of this difference 
between isoforms by comparing the formation of F-actin bundles of each isoform. 
eEF1A1 and eEF1A2 created differently structured actin bundles, highlighting 
that this was an important difference between the two isoforms (21).  
Abbott et al suggested that eEF1A2 up-regulation might occur in terminally 
differentiated cells because a more stable cytoarchitecture is required. Less (or 
altered) actin bundling would be required to maintain this specific 
cytoarchitecture (28). 
1.3 eEF1B 
1.3.1 eEF1B complex 
eEF1B is a complex comprised of two guanine exchange factors (eEF1Bα and 
eEF1Bδ) and a structural anchoring protein (eEF1Bγ). Associated with the 
complex in mammals is valyl tRNA synthetase. Cognate (partner) guanine 
exchange factor eEF1B recycles eEF1A-GDP, allowing it to deliver amino-
acylated tRNAs to the ribosome. In Artemia it has been proposed that EF1βγ (the 
eEF1B equivalent) increases the rate of GDP recycling in EF1α by a factor of 
1000, making it the rate limiting step of protein synthesis (69). Although it is 
suspected to be less of a requirement in the mammalian protein (23), the presence 
of eEF1B and its binding to eEF1A is conserved. Initially it was proposed that 
only eEF1A1 bound to eEF1B (70). However, Cao et al discovered eEF1A2 also 
bound to all subunits (71). Cao et al showed siRNA mediated deletion of the 
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eEF1B subunits individually demonstrated no observable impact on cell cycle or 
survival in the short term (71). However, these knock-down experiments only 
examined the suppression of one subunit at a time. Given the conserved 
interaction of eEF1A and eEF1B, it seems likely to provide a function.  
Mutations in subunits of the eEF1B complex have been reported in mouse 
models. Mouse model with Eef1b2 exon deletion has been reported in the KOMP 
mouse phenotyping database 
(http://www.mousephenotype.org/data/genes/MGI:1929520#section-
associations). Mice are reported to have defects in bone growth and abnormal 
behaviour. Kaitsuka and colleagues also recently reported a knock out mouse 
model of the long neurological isoform of eEF1Bδ (eEF1BδL) (see 1.3.3 for 
further details). This mouse model also resulted in neurological deficits (72). It is 
important to note that both mouse models are compatible with life. Therefore, 
losing elements of the eEF1B complex may not be as critical to normal function 
for cell types as with neurons. 
1.3.2 eEF1Bα 
Gene EEF1B2 encodes the dominant form of the protein eEF1Bα, one of the 
two guanine exchange factor proteins in the eEF1B complex. The C-terminal of 
the protein has been shown to possess the catalytic activity (69), whilst the N-
terminus binds to anchoring protein eEF1Bγ. Indeed the N-terminal section may 
actually impede the GDP exchange activity of eEF1Bα, at least in its interaction 
with eEF1A2 (73). There are reports of an intronless gene, EEF1B3, transcribed 
only in brain and muscle in humans (56,74). 
1.3.3 eEF1Bδ 
The other guanine exchange factor eEF1Bδ (encoded by EEF1D) is similar to 
eEF1Bα. The two share a high level of similarity in their C-terminals, where the 
GDP exchange activity is controlled (75). Although the N-terminal of eEF1Bδ 
still binds to eEF1Bγ (76), the sequence varies from that of eEF1Bα (77). This 
divergence in sequence enables the N-terminal of eEF1Bδ to bind to Valyl tRNA 
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synthetase (discussed in 1.3.4) (78). Alternative splicing of the EEF1D gene 
provides 3-4 translated proteins. Three proteins around 38kDa appear to be 
expressed ubiquitously. A fourth isoform has been reported in brain and testes. 
This isoform is considerably larger, encoding the complete sequence of the 
previous 3 isoforms, with an extended 367 amino acid N-terminus which includes 
a nuclear localisation signal (71,79,80). This isoform, termed eEF1BδL is 
expressed in both the cytoplasm and the nucleus. During stress the isoform 
functions as a transcription factor for heat shock elements. Upon heat shock, the 
canonical isoforms are down-regulated to stop translation, and eEF1BδL is 
upregulated for heat shock element transcription (79). It is not yet clear whether 
eEF1BδL participates in the eEF1B complex in the same way as the shorter 
isoforms to contribute to translation. Kaitsuka and colleagues created an 
eEF1BδL knock-out mouse model and saw an increased performance in protein 
synthesis, which they argued suggested eEF1BδL inhibited protein synthesis. 
Further investigation into this would be interesting and is discussed in 3.5.2.  
1.3.4 eEF1Bγ 
Structural anchoring protein eEF1Bγ (EEF1G gene) has no guanine exchange 
activity itself, instead providing two binding sites for eEF1Bα and eEF1Bδ 
(81).The N-terminal of eEF1Bγ has been associated with tubulin, keratin and the 
endoplasmic reticulum, in keeping with its role in the as an anchoring protein 
(82–84).  
1.3.5 Valyl tRNA synthetase 
Although not a component of the eEF1B subunit, Valyl tRNA synthetase 
(ValRs) has been associated with the eEF1B complex in mammals and higher 
eukaryotes (85). ValRs is responsible for synthesising the aminoacylation of 
valine-tRNAs. It has been proposed that its association with eEF1B is due to the 
amino-acid channelling hypothesis, a principle by which the components of 
translation are ‘streamlined’ to the ribosome to reduce non-specific interactions in 
cytoplasm and optimise protein synthesis (86). 
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1.4. Translation and neurological disorders 
1.4.1 Neurons display a high requirement for protein synthesis 
The brain has a high metabolic requirement owing to its dynamic and active 
environment. Neurons also require a greater spatial and temporal control of 
protein synthesis than other cells. Neurons must modulate specific synapses in 
response to stimulation and require a timely translational response. With these 
cells reaching up to a metre from synapse to soma in humans, the transport of 
proteins from the cell body would not be sustainable for immediate response to 
synaptic stimuli. The answer to the above issues is local protein synthesis. It is 
not surprising that even slight disturbances in protein synthesis could 
disproportionately affect neurons over other cell types and result in neurological 
disorders. 
1.4.2 Translation initiation and neurological disorders 
Initiation, the first stage of translation, is the phase most implicated in 
neurological disorders. Notable targets include eIF2α, eIF4G and eIF4B. 
Phosphorylation of eIF2α inhibits protein synthesis (87). eIF2α, its cognate 
guanine exchange factor eIF2β, and associated kinases have all been associated 
with neurodegenerative diseases including Alzheimer’s disease and vanishing 
white matter syndrome (88–90).  
In terms of neurodevelopmental disorders, one of the most well-known to 
affect translation initiation is fragile X syndrome (FXS).  FXS is the leading 
inherited cause of intellectual disability (91). A trinucleotide amplification of 
over 200 CGG repeats in the 5’UTR of the FMR1 gene results in a functional null 
copy of protein fragile X mental retardation protein (FMRP) (92). FMRP 
normally binds to initiation factor complex eIF4F, repressing translation in favour 
of actin bundling. When FMRP is lacking, an increase in 15-20% of protein 
synthesis is seen in hippocampal neurons (93). This redistribution of initiation 
factor activity results in irregular synapse function and morphology (94).  
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Elongation factor eEF1A has also been associated with FMRP. Sung and 
colleagues determined that Xenopus FMRP directly interacted with EF-1A (the 
Xenopus equivalent of eEF1A) and negatively regulated the expression (95). Tsai 
and colleagues also found that in the absence of FMRP, eEF1A bound to E3 
ubiquitin-ligase protein MDM2. Under normal conditions MDM2 is responsible 
for post-synaptic density 95 (PSD-95) ubiquitination. Ubiquitinated PSD-95 is 
then transported to the proteasome and synapse elimination occurs. However, 
when eEF1A interacts with MDM2, PSD-95 is no longer ubiquitinated and the 
synapse is maintained (96). Synaptic pruning is key to healthy neuronal 
development, and too many synapses are associated with neurodevelopmental 
disorders such as Autism and possibly FXS (97,98). It has also been suggested 
FMRP might bind directly to the RPL5 subunit of the 80S ribosome, potentially 
inhibiting interaction of eEF1A during translation elongation (99). Therefore, 
even in disorders primarily affecting translation initiation, eEF1A may be an 
interacting component.  
1.4.3 Translation elongation and neurological disorders 
There is growing evidence that elongation factors are playing a role in both 
neurodevelopmental and neurodegenerative disorders. As with initiation, 
balanced translation elongation is key to optimal neuron performance. Mutations 
in gene EEF2 have been reported in individuals with spinocerebellar ataxia (100). 
eEF1A expression dysregulation has also been reported in Alzheimer’s and 
Parkinson’s diseases. Aβ42 treatment of hippocampal slices reduced eEF1A 
expression. Further, Aβ42-mediated LTP reduction was rescued with eEF1A 
treatment (101). eEF1A was implicated to have a role in aggresome formation 
following ubiquitin proteasome system upregulation. There are strong links 
between aggresome and aggregated protein inclusions, such as Lewy Bodies, in 
Parkinson’s disease (37). Given the age of onset, it is assumed the isoform 
implicated in these conditions would be eEF1A2. The role of eEF1A2 in 
neurodegeneration is discussed in more detail in Section 1.5.1. 
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Recent evidence has identified mutations in genes coding for translation 
elongation factors in individuals with neurodevelopmental disorders. eEF1A2 is 
the most reported, with over 50 individuals, as discussed in detail in 1.5.2.  
Genomic sequencing of individuals with neurodevelopmental disorders, 
including intellectual disability and microcephaly, has identified homozygous 
mutations in subunits of the eEF1B complex. Table 1.2 summarises the mutations 
discovered and condition of the affected individual(s).  
Table 1.2: Mutations in subunits of the eEF1B complex resulting in 
neurodevelopmental disorders 
































Elongation factors had not, until recently, been identified as causative genetic 
variants in neurodevelopmental conditions. Several components of the eEF1B 
complex have been implicated.  
Mapping of mutation Glu24Sers*26 on EEF1D gene demonstrates that this 
truncation appears to affect only the longer isoform eEF1BδL, which is expressed 
in brain and testes. eEF1BδL contains an identical C-terminal to the ubiquitously 
expressed shorter isoforms, where all the guanine exchange factor activity is, but 
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contains an additional N-terminal nuclear localisation sequence. This additional 
sequence allows eEF1BδL to function as a transcription factor for heat shock 
proteins. It is not clear whether this alternative function is in addition, or instead 
of, the role in eEF1A GDP exchange. The mutation causes a truncation which 
would ablate both functions. Dysregulation of both protein synthesis and heat 
shock mediated recovery have been associated with neurological disorders 
previously. Further evidence associating eEF1BδL in neurodevelopmental 
disorders has recently been published. Mutation p.Trp316* was reported in three 
siblings with severe neurodevelopmental disorder and epilepsy. The authors 
report that this mutation also lay within the neuronal specific eEF1BδL 
alternative splice product.  
A deletion on chromosome 2, which included most of EEF1B2, resulted in a 
similar intellectual disability phenotype (102). EEF1B2 is not a neuronal specific 
isoform; therefore, it is surprising that the clinical features are so specifically 
neuronal. VARS mutations also resulted in a similar neuronal specific phenotype, 
despite ubiquitous expression. The VARS and EEF1B2 evidence supports the 
hypothesis that neurons are more sensitive to protein synthesis disturbances than 
other cell types.  
VARS mutations join a growing number of mutations to amino-acyl tRNA 
synthetase genes which result in neurodevelopmental and neurodegenerative 
disorders. One of the most commonly reported conditions is the neuropathic 
disorder Charcot-Marie-Tooth disease, which has been reported in individuals 
with mutations in AARS, GARS, HARS, KARS, MARS and YARS (106). Table 1.3 
summarises some of the other research into ARS mutations reviewed and 
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Table 1.3: Aminoacyl synthetase genes with mutations reported to cause 
neurological disorders. 
Gene Condition Reference 
AARS Microcephaly, epilepsy and spasticity (107) 
Epileptic encephalopathy with peripheral 
neuropathy  
(108) 
DARS Leukoencephalopathy, hypomyelination in 
brain stem and spinal cord, and spasticity  
(109) 
HARS Usher syndrome  (110) 
KARS Charcot-Marie-Tooth disease  (111) 
RARS Hypomyelination with plasticity  (112) 
YARS Developmental delay, liver dysfunction, lung 
cysts, abnormal subcortical white matter and 
general failure to thrive  
(113) 
QARS Early onset encephalopathy  (114) 
Progressive microcephaly and epilepsy (115) 
 
Although ARS mutations are reported to affect other tissues, the CNS appears 
to be the most implicated system, despite ubiquitous expression of ARS genes. 
There are several possibilities for this phenomenon. 1) As discussed before, 
neurons have a higher metabolic requirement than other cells and are therefore 
more sensitive to disruption. 2) An ARS mutation might affect the expression 
profile in a cell-type specific manner, possibly in a codon-dependent manner 
(106). 3) The expression profile of certain tRNAs have been shown to be up-
regulated in central nervous system (CNS) tissues over other cell types. Mutations 
in the corresponding ARS gene would therefore disproportionately affect 
synthetase activity in these cells (106,116). 4) Tissue specific alternative splicing 
of tRNA synthetases for non-catalytic functions has been reported (117). If 
mutations are in alterative spliced products which are only present in neurons this 
could explain why cases present as with specifically neurological deficits. Any or 
a combination of these factors could explain the CNS specific pattern of clinical 
symptoms in ARS gene mutations.  
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1.5 eEF1A2 and neurological disorders 
1.5.1 eEF1A2 and neurodegeneration 
eEF1A2 was first associated with neurodegeneration when a spontaneous 15kb 
deletion on chromosome 2 occurred in mice in the Jackson laboratories. This 
deletion included the promoter for the Eef1a2 gene and resulted in no expression 
of eEF1A2 mRNA. Subsequent interbreeding resulted in a homozygous genetic 
null mouse, Eef1a2-/-. At P21 in Eef1a2-/- mice, when eEF1A1 is down-regulated 
to undetectable levels, muscular and neurodegenerative symptoms (including gait 
problems, ataxia and weight loss) begin to appear, with death occurring by P28 
(56). Newbery et al proved that the loss of Eef1a2 was solely responsible for the 
phenotype. Expression of the Eef1a2 gene in Eef1a2-/- mice rescued the 
phenotype (13). Expression of eEF1A2 in muscle only did not rescue this 
phenotype, demonstrating that the pathology is mediated primarily by 
neurodegeneration (118). 
Molecular examination of Eef1a2-/- spinal cord revealed extensive damage to 
motor neurons and neuromuscular junctions. Whilst changes to motor skills are 
only visible from roughly p21 onwards, damage could be seen at the molecular 
level from day 17. An increase in glial fibrillary associated protein (GFAP), a 
marker of neuronal damage, was noticeable in spinal cord sections. Further, a 
decrease in innervation of motor endplates in skeletal muscle was observed. After 
this, muscular denervation occurred, progressing more caudally along the spinal 
cord with age (119). These molecular changes mimic changes seen in 
amyotrophic lateral sclerosis patients.  
Unlike their homozygous littermates, heterozygous mice display no observable 
phenotype or molecular pathology when compared to WT mice. Even aged 
heterozygotes (one year to 21 months), displayed no discernible difference in 
molecular pathology or motor performance (120). This suggests the missense 
mutations in humans do not operate through haploinsufficiency in the main. 
However, aged heterozygous mice on the same genetic background as the  
Eef1a2-/- mice do display deficits in learning and memory compared to their WT 
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counterparts (121). Whilst there are no reported null mutations in patients, 
evidence from mice highlights the key role of eEF1A2 in maintenance and 
protection of neurons.  
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1.5.2 eEF1A2 and neurodevelopmental disorders 
Recent exome sequencing has identified heterozygous de novo missense 
mutations in EEF1A2. Individuals with these mutations all present with 
intellectual disability often concomitantly with autism and epilepsy. Table 1.4 
details the reported cases of eEF1A2 mutations, with variant pathogenicity 
predictions. Unless otherwise stated, all mutations are heterozygous de novo 
missense mutations. Reports of seizures and developmental delay are often 
reported from infancy. Often children are born with statistically small head 
circumference, suggesting prenatal developmental growth may be impaired.  
All mutations are at residues which are conserved, both in eEF1A1 and yeast. 
The EEF1A2 gene is in the top 5% of constrained genes according to the Exome 
Aggregation Consortium (ExAc) database, suggesting it does not tolerate 
polymorphisms as they would affect mutations.  Modelling analysis shows 
mutations cluster upon the ‘conserved face’ near functional sites including eEF1B 
and GTP binding sites (see Figure 1.5). 
Whilst most reported mutations are heterozygous and de novo, there has been 
one published case of inheritance of a mutation. The reported two children who 
died in infancy were both homozygous for the mutation P333L. Neither parent 
has officially been diagnosed with a neurodevelopmental disorder, although the 
father has three other children with a different partner, all which have been 
diagnosed with developmental disorders. This report suggests that in a 
heterozygous form, the mutation is mild. The inherited homozygosity, however, 
led to extreme epileptic seizures and death caused by dilated cardiomyopathy. 
The death of these children associates with a time roughly where RNAseq data 
(Figure 1.2 (15)) suggests eEF1A1 expression would have likely subsided, 
although this has not been formally tested (122). 
Clinical presentation varies between patients (summarised in table 1.4). Some 
individuals have a clinically mild presentation. The heterozygous parents in the 
P333L case do not present as severely affected (122). One of the patients with the 
E124K mutation attended mainstream primary school (123). Other individuals 
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have severe epilepsy, and developmental delay severe enough to impede head 
support. It is unclear, however, how much of this range is due to varying levels of 
mosaicism between individuals (although it is speculated to be low), or if 
mutations impact upon protein function to varying degrees. The first line of 
evidence would be to compare severity between individuals with the same 
mutation. As the numbers of cases in some mutations increase, this is becoming 
possible (G70S and E122K), but for the majority, mutations are still individual 
cases. Even in the cases with the same reported mutation, variation in reports 




Figure 1.5: Depictions of mutation distribution in eEF1A2 protein. A, a 
schematic diagram of the distribution of published mutations and their location 
relative to protein domains of eEF1A, as defined by Pfam. B-D, 3D modelling of 
the eEF1A2 protein – the crystal structure of which was determined by X-ray 
diffraction (23). Cyan residues show binding sites of eEF1B as defined in the 
yeast model. Yellow sites show GTP-binding area, and red demonstrates 
mutations (published and unpublished). The protein is displayed showing the 
“conserved face” (B), the “variable face” (C) and the GTP binding area (D). 
Information on protein structure was obtained from Protein Data Bank and 
modelled using Chimera program.  
 
Table 1.4: Summary of clinical presentations of eEF1A2 missense mutations. Mutations are reported with known symptoms, a 
summary of other features and a collection of prediction software. * indicates it is identified as a causative variant. – indicates data was 
not available.  
Mutation Number 
of cases  
Epilepsy Intellectual 
disability/Develop
mental delay  
Autism Head size/ 
cerebral 
imaging 
Other notes Variant predictions Reference 
cDNA Protein S P2 MT LRT 
c.55G>A G19R 1 Yes - - - - * * * * (124) 
c.71C>T T24M 1 Yes No No - Verbal * * *  (125) 
c.208G>A G70S 6 Yes Yes No Head 
circumference in 
the 91st 




* * * * (123) 





from age 6 
(126) 




left temporal and 
parietal lobes 
 (127) 
c.211A>C I71L 1 Yes Yes - Head 
circumference >
25 centile at age 
5 
Did not walk 
until 5 years 
old. 
* * * * (123) 
c.271G>A D91N 2 Yes Yes No 8.75 years was 






* * * * (123) 
Yes Yes - - Mosaic DDD 
 






* * * * (128) 
c.289G>A D97N 1 No  Yes Yes - - * * * * DDD 
c.292T>C F98L 1 Yes Yes No 50 cm at 





*  * * (123) 
c.364G>A E122K 6 Yes Yes No head 
circumference 








* * * * (123) 
Yes Yes Yes - Overlapping 
toe 
DDD 











aged 8.  
(129) 
Yes Yes No MRI normal at 
10 months 
Characteristic 
facial features,  
(130) 






c.370G>A E124K 2 Yes Mild/moderate  51 cm at 






*  *  (123) 






c.505G>A E169K 2 Yes Yes No - Maternally 
inherited 
* * * * DDD 
Yes Yes No - Maternally 
inherited 
DDD 





* * * * (129) 
Yes Yes - -  DDD 
c.796C>T R266
W 








* * * * DDD 








c.942C>G N314K 1 - Yes - - - * * *  (131) 
c.1164C>T
  
P333L 2 Yes 
(homozygou
s) 
Yes (homozygous) No 
(homozygo
us) 





death by 3 
years.  
* * *  (122) 
c.1145G>
A 
R382H 1 Yes Yes Yes - - *  * * (132) 











*  *  (123) 
Yes - - - - (133) 
 
c.1295C>T T432M 1 No Yes No - Ventricular 
septal defect 
* * *  DDD 
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1.6: Project Aims 
The aim of this project was to help in understanding the mechanism by which 
eEF1A2 mutations act and their role in epilepsy, autism and intellectual 
disability. More specifically, I aimed to assess whether mutations operated 
through a dominant negative, gain or loss of function mechanism, and what 
molecular functions were impacted.  
It was imperative to determine the type of mechanism missense mutations 
cause. Mutation consequence is key to an effective treatment strategy. Mutations 
which cause a gain or loss of function to the same protein can have differential 
results for the same drug treatment (134). Secondly, gain of function mutations 
are more likely to be treatable with drug treatments (135), whilst functional null 
proteins may be more reliant on gene therapy for a solution. It is also not as 
simple as just treating using gene therapy of eEF1A2 to compensate for mutant 
proteins; if proteins work in a dominant negative manner, the application of drugs 
to up-regulate endogenous eEF1A2 may exacerbate the phenotype.  
Using a variety of in vivo and in vitro techniques to assess eEF1A2 missense 
mutations, I investigated this aim. Initially, to gain an overall impression of the 
consequences of mutations, I assessed how protein interactions were altered in 
mutant forms of eEF1A2. Any gain of loss of binding may reveal a dominant 
negative, gain or loss of function. I aimed to explore the interaction disruptions, 
validate disruptions and investigate the functional consequences, with a view to 
understanding how eEF1A2 mutations impact upon protein function.  
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Chapter 2: Materials and Methods 
2.1 Materials 
2.1.1 Cell culture 
Table 2.1: Cell lines used in thesis. 
Cell Line Species Cell type eEF1A isoform 
expression 
HEK293T Human Embryonic Kidney eEF1A1 
SH-SY5Y Human Neuroblastoma eEF1A1 + eEF1A2 
LUHMES Human Foetal 
mesencephalon 
eEF1A1 + eEF1A2 
 
2.1.2 Primers and DNA oligomers 
2.1.2.1 CRISPR/Cas9 in LUHMES cells   
Table 2.2: All primer sequences for attempt at introducing the G70S mutation 
into EEF1A2 gene in LUHMES cells using CRISPR/cas9 (designed by myself 
and Faith Davies). 
G70S CRISPR guides 
Guide A top 5’- CACCGCTTCAGCTTGTCCAGCACCC -3’ 
Guide A bottom 5’- AAACGGGTGCTGGACAAGCTGAAGC -3’ 
Guide B top 5’- CACCGCTGAAGGCGGAGCGTGAGCG -3’ 
Guide B bottom 5’- AAACCGCTCACGCTCCGCCTTCAGC -3’ 
gRNA sequencing primer 
Forward 5’-GAGGCCTATTTCCCATGATTCC-3’ 
G70S PCR primers 
Forward Primer 5’-TGGTTGAGGAAGGGATCTGG-3’ 
Reverse Primer 5’- TGTGTCCACGTCCCCATC-3’ 
G70S Sequencing primers 
Forward Primer 5’-GTTTATCCCATCTGGCGGCT-3’ 
Reverse Primer 5’-ACTCTGACACTGGCTGGAT-3’ 
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Table 2.3: All primer sequences for attempt at introducing the G70S mutation 
into EEF1A2 gene in LUHMES cells using CRISPR/cas9 (designed by Faith 
Davies). 
D252H CRISPR guides 
Guide A top 5’-CACCGGCTTGTCCGTGGGGCGCGTG-3’ 
Guide A bottom 5’-AAACCACGCGCCCCACGGACAAGCC-3’ 
Guide B top 5’-CACCGCAGGACGTGTACAAGATTGG-3’ 
Guide B bottom 5’- AAACCCAATCTTGTACACGTCCTGC-3’ 
gRNA sequencing primer 
Forward 5’-GAGGCCTATTTCCCATGATTCC-3’ 
D252H PCR primers 
Forward Primer 5’-TTCCTCATCTCAAAGGGCACG-3’ 
Reverse Primer 5’-CAAGTTTAGCCTGAACAGCAGTA-3’ 
D252H sequencing primers 
Forward Primer 5’-CCCACAGAAGTGTGTGGTAAG-3’ 
Reverse Primer 5’-TTGGAGACAGCCAGTCTTG-3’ 
 
Table 2.4: Repair template constructs for homology directed repair of 
CRIPSR/cas9 mutations in LUHMES cells (designed by Faith Davies). 
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2.1.2.2 Site Directed Mutagenesis primers 
Table 2.5: Site directed mutagenesis primers for introduction of missense 




















D91N  5’-CACACAACATCGTGGTCATCGGCCACG-3’ 
E124K 5’-CACCATCATCGATGCCCCCG-3’ 
 
2.1.2.3 Genotyping  
2.1.2.3.1 Eef1a2/D252H genotyping primers 





2.1.2.3.2 Eef1a2/del22ex3 genotyping primers 
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2.1.2.3.3 Eef1a2/wst genotyping primers 
Table 2.8: Primers for genotyping Eef1a2/wst mouse line. 
Primer Sequence 
WT allele Forward 5’-TAGTGGCTCCTTGGAACAG-3’ 
WT allele Reverse 5’-CTACTCTCCCTGAATGCCTT-3’ 
Wasted allele Forward 5’-ATAAGCTCCCCAATGGTAGAGAA-3’ 
Wasted allele Reverse 5’-CGCGCCATTCTTGTATTGTT-3’ 
 
2.1.2.4 RT-PCR and qPCR of eEF1A2 mRNA 
Table 2.9: Primers for eEF1A2 mRNA quantification. 
Primer Sequence 
eEF1A2 exon 7-8 Forward 5’-CCCACATCAACATCGTGGTC-3’ 
eEF1A2 exon 7-8 Reverse 5’-CTCCACGTTCTTGATGACGC-3’ 
eEF1A2 exon 3 Forward 5’-ACATGATCACGGGTACATCCC-3’ 
eEF1A2 exon 3 Reverse 5’- CATTTGTTCACGCCCCACGA-3’ 
TOP1 forward 5’-GTCAGCGTTCTACCAGGCAA-3’ 
TOP1 Reverse 5’-TGACGACTCTAACAGGTGCG-3’ 
RPL34 Forward 5’-CCTTTGAGCTGGTGTAGGGG-3’ 
RPL34 Reverse 5’-AGGTCTTACAGCACGAACCC-3’ 
 
2.1.3 Buffers and solutions 
2.1.3.1 RIPA buffer 
Table 2.10: RIPA buffer composition. 1 Complete Protease inhibitor tablet 
(Roche) added to every 10ml of RIPA buffer directly before use. 
Reagent Concentration 
Sodium Chloride 150mM 
NP-40 1% (v/v) 
Sodium Deoxycholate 0.5% (w/v) 
SDS 0.1% (v/v) 
Tris-HCl (pH8.0) 50mM 
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2.1.3.2 Trypsin working reagent 
Table 2.11: Solution for trypsin digestion of proteins after affinity purification 
and prior to mass spectrometry 
Reagent Concentration 
Trypsin Protease (Pierce, MS grade) 42.9mM 
1M DTT 1mM 
UREA 2M 
1.5M Tris pH8 50mM 
MS grade ddH2O - 
 
2.1.3.3 Laemmeli buffer 
2.1.3.3.1 2X Laemmeli buffer 
Table 2.12: Recipe for 2X Laemmeli Buffer used in preparation of protein 
extracts for western blotting. 
Reagent Concentration 
SDS 10% (w/v) 
Glycerol 20% 
1M Tris-HCl (pH6.8) 120mM 
Bromophenol Blue 0.02% (w/v) 
H2O - 
 
2.1.3.4 Stripping buffer 
Table 2.13: Recipe for stripping buffer used in re-probing of western blot 
membranes. After composition in H2O, pH is adjusted to 2.2 before immediate 
use. 
Reagent Concentration 
1M Tris-HCl (pH6.8) 62.5mM 
20% SDS 10% (v/v) 
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2.1.3.5 Artificial cerebrospinal fluid (aCSF) for AHA-click it chemistry 
experiments  
Table 2.14: Recipe for HEPES buffered aCSF as described in (136). HEPES 
used as buffering agent. pH checked after making to ensure a pH of 7.8.  
Reagent Concentration 
Glucose 10mM 
Sodium Chloride 136mM 
Potassium Chloride 2.5mM 
Magnesium Chloride 1.3mM 
HEPES 10mM 
Calcium Chloride 2mM 
ddH2O - 
 
2.1.3.6 6x DNA loading dye 
Table 2.15: Composition of 6X DNA loading dye. 
Reagent Concentration 
Bromophenol Blue 0.25% 










GFP Abcam Goat 1:1000 
eEF1A2 ProteinTech Rabbit 1:250 
 
  
Chapter 2: Materials and Methods  Page | 38 
2.1.4.2 Western blotting 
2.1.4.2.1 Primary antibodies 
Table 2.17: Primary antibodies used in western blotting. The species, size, 





Species kDa Sample 
type 
Secondary Dilution 





Rabbit 52 Co-IP 
probe 
Tissues 
Light Chain 1:100 
Wester



















Light Chain 1:100 
eEF1Bδ ProteinTech 
Group 











Light Chain 1:500 











Light Chain 1:500 
ValRS St Johns 
Laboratory 
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samples 
-cells 

























































2.1.4.2.2 Secondary antibodies 
Table 2.18: Western blot secondary antibodies used throughout project. 














LI-COR Mouse Donkey Fluorescent 1:5000 




LI-COR Goat Donkey Fluorescent 1:5000 
Polyclonal 
anti-goat  
DAKO Goat Rabbit HRP 1:1000 
Polyclonal 
anti-rabbit 



















DAKO Mouse Donkey HRP 1:1000 
 
2.1.4.3 Immunocytochemistry 
2.1.4.3.1 Primary antibodies 
Table 2.19: Primary antibodies used in immunocytochemistry.  
Antibody Company Species Concentration 
EEF1A2 ProteinTech 
Group 
Rabbit  1:500 





2.1.4.3.2 Secondary antibodies 
Table 2.20: Immunocytochemistry secondary antibodies. 







AlexaFlour Goat 490/525 1:500 
Goat Anti-
Rabbit 488 
AlexaFlour Rabbit 490/525 1:500 




AlexaFlour Rabbit 561/594 1:500 
Goat Anti-
mouse 654 
AlexaFlour Mouse 633/647 1:500 
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2.2 Methods 
2.2.1 Cell culture  
Cell lines used for experiments have been summarised in table 2.1. All lines 
were incubated at 37oC and 5% CO2. Passaging was achieved by applying TryplE 
express (Life Technologies) to cells and incubating at 37oC for 1 minute. PBS 
was then added to wash cells. The cell suspension was spun at 1200 rpm for 5 
minutes to cause pellet formation. Cells were then seeded at the appropriate 
density for experiment.  
For freezing, cells were pelleted as above, and pellets resuspended in freezing 
media. Freezing media was prepared using respective media for each cell with 
20% Foetal Calf Serum (FCS) and 10% DMSO in cryotubes. Tubes were stored 
in a freezing container with isopropanol for 1 hour at -20oC and then -80oC until 
transfer into liquid nitrogen storage.   
2.2.1.1 HEK293T and SH-SY5Y cells  
HEK293T and SH-SY5Y cells were maintained in DMEM (Gibco) + 10% 
FCS. Cells were passaged when confluent and passage number maintained under 
20. Cells were seeded at appropriate densities for transfection in plates/wells of 
appropriate size for the experiment.  
2.2.1.2 LUHMES  
2.2.1.2.1 Proliferative state 
LUHMES cells were grown in proliferative state, allowing stocks to be 
generated and maintained as well as perform experiments. To allow cell adhesion, 
plates and flasks for LUHMES culture were coated using ddH2O with 50µg/ml 
poly-L-ornithine (PLO) (Sigma Aldrich) and 1 µg/ml fibronectin (GE healthcare). 
Coating solution was added, and flasks incubated between 3 and 18 hours at 
37oC. Flasks were then washed with sterile filtered ddH2O and dried using an 
aspirator. Proliferative media (described below) was added to flasks and re-
incubated for 1-2 hours.  
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Proliferative media was composed of Advanced DMEM/F12 (Gibco) with 
additions below. Advanced DMEM/F12 (Gibco) is warmed to 37oC before 
additives were supplemented. Media was sterile filtered using a 0.22µm syringe 
(Millipore).  
Reagent Company Concentration 
N2 supplement Life technologies 1% (v/v) 
FGF Biolegend 40ng/ml(w/v) 
L-Glutamax Thermo Fisher 1% (v/v) (200mM stock) 
 
Cells were seeded in prepared flasks/plates and left to proliferate. Passage 
number was maintained under p15. 
2.2.1.2.2 Differentiated state  
Using the tetracycline induction system, LUHMES cells could be 
differentiated to dopaminergic neurons according to the protocol described by 
Scholz and colleagues (137). T75 or T25 flasks were coated as described in 
2.2.1.2.1. Proliferation media was applied to flasks and heated at 37oC for 1 hour. 
Cells were then seeded in flasks and incubated for 24 hours.  Media was then 
exchanged for differentiation media (below). Differentiation media was prepared 
in Advanced DMEM/F12 (Gibco) and sterile filtered as above. Cells were left for 
48 hours in differentiation media. 
Reagent Company Concentration 
N2 supplement Life technologies 1% (v/v) 
FGF Biolegend 40ng/ml(w/v) 
L-Glutamax Thermo Fisher 1% (v/v) (200mM stock) 
GDNF R & D 20ng/ml 
cAMP Sigma 1mM 
Tetracycline Sigma 1µg/ml 
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In instances where cells were to be grown on coverslips, slips were prepared 
by acid coating for 48 hours in 1M HCL. Acid was removed and slips washed in 
running water for 25 minutes. Slips were stored in 70% ethanol solution and 
washed in ddH2O just prior to use.  
To prepare for re-seeding of differentiated cells, plates/coverslips/wells were 
prepared as previously with an additional Geltrex (ThermoFisher) incubation. 
After 3 hours of PLO/Fibronectin coating, plates/coverslips/wells were washed 
with sterile filtered ddH2O and dried. Geltrex (Thermo Fisher) was added to 
sterile filtered Advanced DMEM/F12 (Gibco) at a concentration of 1:500. The 
solution was immediately added to plates/slips/wells and incubated at 37oC for 
between 3 and 16 hours. The plates/slips/wells were then removed from the 
incubator and allowed to adjust to room temperature. Plates/slips/wells were 
washed with sterile filtered advanced DMEM/F12 (Gibco) and had differentiation 
media added. After a further 1-hour incubation at 37oC, plates/slips/wells were 
ready for re-seeding. Cells were trypsinised and spun at 500 rpm for 9 minutes. 
Cells were counted using Cellometer Vision (Nexcelom) and re-seeded at a 
density of 1.3x105 cells/cm2 or 7.5x104cells/cm2 for coverslips. After this, cells 
were left to differentiate in incubator for 12 days, with half of the differentiation 
media replaced with fresh differentiation media every 48 hours.  
2.2.2 gRNA cloning 
2.2.2.1 gRNA design and cloning 
Two rounds of CRISPR were designed and performed by Faith Davies and 
myself; The first round targeted exon 3 to produce the G70S mutation, whilst the 
latter targeted exon 5 to generate the D252H mutation. In both instances, nickase 
CRISPR/Cas9 engineering was used to increase the chance of homology directed 
repair (138). In both experiments one gRNA of each pair was cloned into 
pSpCas9n(BB)-2A-Puro (px462) and the other into pSpCas9n(BB)-2A-GFP 
(px461). Oligonucleotides were designed using the Zhang lab CRISPR design 
programme (https://zlab.bio/guide-design-resources) and are reported in tables 
2.2 and 2.3. Oligonucleotides were phosphorylated and annealed, to create a 
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double a double stranded fragment for ligation in plasmids. Phosphorylation 
mixture was made as below:  
Reagent Company Volume (µl) 
sgRNA top (100µM) Sigma Aldrich 1 
sgRNA bottom (100µM) Sigma Aldrich 1 
T4 ligation buffer, 10x  NEB 1 
T4 polynucleotide kinase  NEB 1 
ddH2O - 6 
 
The mixture was incubated in a Bio-Rad thermocycler at 37oC for 30 minutes, 
95oC for 5 mins and then cooled to 25oC at a rate of 5oC per minute. The solution 
was diluted 1:200 in ddH2O and the ligation reaction performed, one gRNA for 
each pair being cloned into PX461 and PX462. 
Reagent  Volume (µl) 
Diluted oligo duplex - 2 
Plasmid, 100ng - 1 
T4 DNA ligase HC NEB 0.5 
Tango buffer 10x NEB 2 
ATP 10mM - 1 
DTT 10mM - 1 
FastDigest Bbs1 Thermo Fisher 1 
ddH2O  6 
 
The mixture was incubated as below: 
Temperature Time Cycles 
37oC 5 minutes 
x5 
21oC 5 minutes 
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After ligation, plasmid mixtures were treated with ATP-dependent DNase to 
remove residual linearised DNA. The mixture below was incubated at 37oC for 
30 minutes and 70oC for 30 minutes. The reaction was then transformed. 
Reagent Company Volume (µl) 
Ligation reaction - 11 
PlasmidSafe Buffer Epicentre 1.5 
ATP, 10mM - 1.5 
PlasmidSafe endonuclease Epicentre 1 
 
2.2.2.2 Transformation of gRNA cloned plasmids 
Ligated plasmids were transformed into DH5α cells (Life Technologies). 50µl 
tubes of cells were thawed on ice and 2µl of sample was added to each tube and 
samples incubated on ice for 20 minutes. Samples were heat shocked at 42oC for 
50 seconds, before further incubation on ice for 2 minutes. The samples were 
transferred to 500µl of SOC media and incubated at 37oC and at 200rpm for 1 
hour to allow antibiotic resistance generation. 50µl of sample was then spread on 
agar plates with 100ug/ml kanamycin antibiotic. Plates were sealed and incubated 
at 37oC overnight. After colony formation, ~10 colonies per condition were 
picked. These were grown for 24 hours at 37oC in L-broth with 100µg/ml 
kanamycin. Samples were sent for miniprep and sequencing by the Human 
Genetics Unit technical services centre. DNA was sequenced using U6 
sequencing primer (table 2.2 and table 2.3). 
2.2.3 Transfections 
2.2.3.1 Transfection of SH-SY5Y and HEK293T cells 
Transient transfection of constructs was performed in both SH-SY5Y and 
HEK293T cells. Cells were seeded 24-48 hours prior to transfection, at a density 
no greater than 50%. 16-24 hours prior to transfection, media was substituted for 
serum free DMEM (Gibco). Cells were further incubated at 37oC and 5% CO2. 
Relative volumes of Turbofect (ThermoFisher) was mixed with appropriate 
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concentrations of DNA in serum free DMEM, according to the manufacturer’s 
instructions. Tubes were left for 15 to 20 minutes at room temperature and the 
mix was applied to cells. Cells were incubated for 48 hours prior to collection for 
protein extraction. 
2.2.3.2 Transfection of LUHMES cells with gRNAs 
Transfections of gRNAs were performed by Dr Faith Davies using basic 
primary neuron nucleofection kit (Lonza) and Lonza Nucleofector II™. The 
method of transfection had been optimised for LUHMES cells previously (139). 
Proliferative LUHMES cells were harvested and added to transfection tubes at a 
density of 1x106. 100µl of nucleofector solution was prepared for each sample as 
per the manufacturer’s instructions. 1µg of each gRNA in the pair was added to 
the solution, along with 2µl of 10µM of repair template (table 2.4). 
Electroporation of cells was done on program D-33. Cell suspensions were then 
transferred to 650µl of pre-warmed RPMI and incubated at 37oC for 5 minutes. 
The mixture was then transferred to one 6 well plate for each condition. In 
tandem, non-transfected and GFP-only controls were performed. Cells were 
incubated for 48 hours, prior to fluorescent associated cell sorting (FACS) 
analysis. 
2.2.4 Creation of CRISPR/cas9 edited cell lines 
2.2.4.1 FACS analysis of transfected LUHMES cells 
As PX461 plasmid contains GFP coding sequence, uptake of gRNAs could be 
measured using FACS. Pre-coated 96 well plates (Co-star) were washed, dried 
and had proliferation media added. Transfected cells were trypsinised, spun at 
500 rpm for 9 minutes and resuspended in sterile filtered PBS. FACS analysis 
was then performed using FACSJazz cell sorter (BD Biosciences) to sort 
fluorescent cells into individual wells of 96 well plate (Co-star). Cells were 
incubated for 14 days at 37oC.  
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2.2.4.2 Maintenance of cellular stocks, collection of genomic DNA and PCR 
analysis of genotypes  
After 14 days of growth, single cell colonies were transferred to pre-coated 24 
well plates. Cells were removed by pipetting up and down harshly. The cell 
suspension was transferred and left to grow for 48 hours. After confluency was 
achieved, cells were further transferred using standard trypsinolysis to a 6-well 
plate. After reaching confluence, cells were frozen and stored in liquid nitrogen. 
A small portion of cell pellet was isolated and stored at -20oC for genomic DNA 
extraction. Genomic DNA was extracted using the Qiagen cell/tissue DNA 
extraction kit as per the manufacturer’s instructions. Genotyping of lines was 
performed using the primers in tables 2.2 and 2.3, and the following reaction mix 
and cycling parameters. 
 
Component Company Volume (µl) 
Forward Primer (10µM) Sigma 1 
Reverse Primer (10µM) Sigma 1 
Superfi buffer 10X Thermo Fisher 1 
dNTPS(10mM) Invitrogen 0.4 
Betaine - 4 
Superfi-Taq Thermo Fisher  0.2 
ddH2O - 9.15 
DNA - 1 
 
Temperature (oC) Time Step/cycles 
98 5 minutes Initial denaturation 
98 5 seconds 
8 cycles 
68oC -1oC each 
cycle 
10 seconds 
72 10 seconds 
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98 5 seconds 
22 cycles 60 10 seconds 
72 10 seconds 
72 5 minutes Final Extension 
10 ∞ Storage 
 
Products were mixed with 6x DNA loading dye (table 2.12) run on a 1.5% 
agarose gel containing SYBR safe (Invitrogen) with 100bp ladder (NEB) at 120V 
for 1 hour and visualised. 
2.2.4.3 Sequencing of CRISPR/cas9 LUHMES cell lines 
PCR fragments generated above were cleaned using ExoSapIT (Affymetrix). 
5µl of PCR reaction was mixed with 2µl of ExoSapIT and incubated at 37oC for 
15 minutes and 80oC for 15 minutes. Sequencing was then performed using 
general sequencing protocol (2.2.5) using primers described in tables 2.2 and 2.3.  
2.2.4.4 TOPO cloning PCR fragments generated for testing genotypes of 
mutant LUHMES cell lines 
To identify the sequence of individual alleles, PCR fragments generated in 
2.2.4.2 were TOPO cloned using the Zero Blunt TOPO cloning kit (Invitrogen). 
PCR fragments were generated and cleaned as in 2.2.4.2 and 2.2.4.3. Reaction 
mixes were made as below: 
Reagent Volume (µl) 
PCR product 2.5 
Salt Solution 1 
Zero Blunt TOPO™ 1 
ddH2O 1.5 
 
Samples were incubated at room temperature for 5 minutes. 2µl of reaction 
was then applied to a vial of One Shot© competent cells (Thermo Fisher). Tubes 
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were incubated on ice for 25 minutes and transformed as in 2.2.2.2. Colonies 
were picked, grown and sequenced as in 2.2.2.2, using the sequencing primer 
provided by the manufacturer.  
2.2.5 General Sequencing protocol 
Sequencing PCR products and plasmids was achieved using BigDye, 
(ThermoFisher). Mixture reactions were set up as below and run on the following 
parameters on a Bio-Rad C1000 Touch Thermal Cycler.  
 
Reagent Volume (µl) 
Primer 3.2µM 1.5 
Big Dye 1 
Big Dye Buffer 1.5 
ddH2O 4 
PCR reaction 1 
 
Temperature (oC) Time Step/Cycles 
96 1 minute Initial activation 
98 10 seconds 
x30 cycles 50 5 seconds 
60 4 minutes 
10 ∞ Storage 
 
Clean up of sequencing products was achieved by adding 1µl of 125mM 
EDTA, 1µl 3M sodium acetate and 25µl of ethanol to each sample. The reactions 
were inverted and left at room temperature for 15 minutes. Tubes were 
centrifuged at 10,000rpm for 20 minutes. Supernatant was removed and replaced 
with 30µl of 70% ethanol. Samples were further centrifuged for 10 minutes 
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before supernatant removed. Tubes were dried and stored at -20oC before being 
read on a 3130 or 3730 Genetic Analyser (Applied Biosystems).   
2.2.6 eEF1A2-V5 construct preparation 
2.2.6.1 eEF1A2-V5 construct library 
eEF1A2-V5 construct was created by Justyna Jankiewicz by cloning the 
eEF1A2 cDNA sequence in to the backbone of the pcDNA3.1-V5 vector 
(Invitrogen). I introduced the D91N and E124K mutations using the Quik Change 
II site directed mutagenesis kit (Aligent Technologies); other mutant constructs 
were made by other lab members. The manufacturer’s instructions were followed 
using primers in table 2.5. After ligation of the mutant PCR construct, samples 
were transformed into DH5α cells (Life Technologies) as in protocol 2.2.2.2. 
Zeocin (Thermo Fisher) 50mg/ml was mixed 1:150 with melted L-agar and plates 
left to solidify. 
After overnight incubation, three colonies per mutant condition were picked 
and were grown in 150µg/ml Zeocin (Thermo Fisher) 2ml L-broth for 24 hours at 
37oC and 200rpm. The cell suspension was spun at 3000rpm for 3 minutes and 
the supernatant removed. The pellet was miniprepped using a Qiagen miniprep kit 
according to the manufacturer’s instructions. Constructs were sequenced to assess 
for evidence of the correct point mutation using standard sequencing protocol 
described in 2.2.5 and primers in table 2.5. 
Once the correct mutation had been identified, the DNA was transformed into 
DH5α cells (Life Technologies) as in 2.2.2.2 and grown in 500ml L-broth + 
150µg/ml zeocin for 24 hours. The cultures were used both for glycerol stock 
generation and maxi prepped using the Qiagen maxi prep kit. Collected DNA was 




Chapter 2: Materials and Methods  Page | 52 
2.2.7 Affinity Purification mass spectrometry 
2.2.7.1 Affinity purification mass spectrometry in SH-SY5Y cells 
2.2.7.1.1 Cell preparation, transfection and lysis 
SH-SY5Y cells were grown in flasks T75 (p12-14) until confluent. Cells were 
passaged when confluent and divided equally in to 4 flasks. Cells were left to 
proliferate for 24 hours and the media replaced with serum free DMEM (Gibco). 
Cells were transfected using the Turbofect (Thermo Fisher) protocol 2.2.3.1. 
20µg of DNA (WT, G70S, D252H and pcDNA3.1) was transfected into separate 
flasks. Flasks were incubated for 48 hours, trypsnised and pellets were stored at -
80oC. This was repeated twice obtaining 3 biological repeats in total. Pellets had 
500µl ice-cold RIPA buffer + protease inhibitor (Roche) (table 2.9) added and 
were lysed in a Bioruptor for 7 cycles of 30 seconds on and off at 4oC. The 
lysates were then spun in centrifuge at 13300xg for 20 minutes. The supernatant 
was removed and taken for immunoprecipitation. 
2.2.7.1.2 Co-immunoprecipitation using V5 tag 
To isolate eEF1A2-V5 and binding partners, samples were incubated at 4oC 
for 3 hours with V5 agarose magnetic beads (MBL international), using the 
KingFisher Duo II robot system. 120µl of beads were diluted 1:10 in PBS. 100µl 
of bead solution was added to each sample using the robot. After incubation, the 
robot washed the beads 3 times with 500µl of RIPA buffer (table 2.9) and a 
further 2 times in 500µl TBS. Finally, beads were deposited in trypsin working 
reagent made up as in table (2.10). Samples were left overnight to digest at 4oC 
and peptide fragments were collected.  
2.2.7.1.3 Peptide storage and LFQ mass spectrometry 
Peptide storage and mass spectrometry was performed by Jimi Wills. In brief, 
peptides were transferred to storage in small pieces of membrane using a 
centrifugation method. Samples were then maintained at -20oC until loaded on to 
Thermo-Q Orbitrap mass spectrometer for label free quantification.  
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2.2.8 Co-immunoprecipitation  
2.2.8.1 In vitro co-immunoprecipitation of eEF1A2-V5 constructs 
HEK293T and SH-Y5Y cells were cultured and transfected as in 2.2.3.1. After 
48 hours cells were trypsinised, spun and pellets were lysed in RIPA buffer with 
protease inhibitor (table 2.9). Appropriate volumes of RIPA buffer for different 
















1.2x106 50µl 5µl 10µl 100µl 
T25 
flask 
2.8x106 100µl 10µl 30µl 300µl 
T75 
flask 
8.4x106 200µl 20µl 50µl 500µl 
 
Cells were sonicated using the Bioruptor as in 2.2.7.1.1. Lysates were spun 
and supernatant collected. A bead solution was made by diluting V5 agarose 
magnetic beads (MBL International) 1 in 10 in RIPA buffer. Appropriate volumes 
of bead solution (above) were added to lysates and samples incubated for 3 hours 
at 4oC with rotation. Samples were spun in a centrifuge for 2 minutes at 8000 
rpm. Using a magnetic Eppendorf rack (Active Motif), beads were isolated and 
lysate extracted. These lysates were diluted 1:1 in 2X Laemmeli buffer (table 
2.13) and 10% 1M DTT, boiled for 10 minutes at 95oC and stored at -20oC as the 
‘input’ fraction. Beads were washed in RIPA buffer (table 2.9) 3 times and with 
TBS twice using volumes described above. 2X Laemmeli buffer and RIPA buffer 
were mixed 1:1 at a total volume as referred in the table above. This mixture was 
added to beads, and tubes were boiled for 10 minutes at 95oC. Tubes were re-
applied to the magnetic rack and supernatant collected. The sample was 
supplemented with 10% v/v 1M DTT and stored at -20oC as the IP fraction.  
For western blotting 15µl of IP fraction and 5µl of input fraction were used.  
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2.2.9 Western Blotting 
2.2.9.1 Protein extraction 
2.2.9.1.1 Protein extraction from tissue 
Tissue samples were removed from -80oC storage on dry ice, to prevent 
thawing. Slices of tissue were weighed and added to homogenisation tubes 
(Stretton Scientific). The appropriate volume of 0.32M sucrose plus protease 
inhibitor was added at a ratio of 100µl/mg. Samples were homogenised using a 
Precellys®24 shaker (Precellys) for 1 minute. Samples were transferred to 
centrifuge tubes and spun at 13300 rpm for 15 minutes at 4oC. The supernatant 
was extracted and either had protein concentration determined in 2.2.9.2, or 
directly prepared for western blot in 2.2.9.3. 
2.2.9.1.2 Protein extraction from cells 
Cells were removed from culture flasks using trypsin (Life Technologies) and 
spun as reported previously. Cells were diluted in RIPA buffer and sonicated at 
concentrations as reported in 2.2.8.1. Samples were spun at 13300 rpm at 4oC for 
15 minutes. The supernatant was removed and either had protein concentration 
determined in 2.2.9.2, or directly prepared for western blot in 2.2.9.3. 
2.2.9.2 Protein quantification  
To achieve equal loading of total protein in western blot analysis, protein 
concentration was measured using Pierce Bradford colorimetric analysis (Thermo 
Fisher). A standard curve of known protein concentrations was made using 
2mg/ml BSA with 8 1:1 dilutions and a negative control. Tissue samples were 
diluted 1:100 and cell extracts 1:50, to a total volume equal to the standard curve. 
Colorimetric detection reagents A and B were diluted 50:1 and 1ml of detection 
reagent added to each sample. Tubes were incubated at 37oC for 30 minutes. 
100µl of samples was added in triplicate to a clear 96 well plate (Co-Star). 
Absorbance was measured at 562nm wavelength on a Fluostar Omega plate 
reader.  
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2.2.9.3 Sample preparation 
Samples were diluted in lysis buffer to normalise protein concentration based 
on BCA analysis. After normalisation, samples had 2X Laemmeli buffer added. 
Tubes were boiled at 95oC for 10 minutes and had 10% v/v 1M DTT added. 
Samples were either added to gels immediately or stored at -20oC for later 
analysis. 
2.2.9.4 Acrylamide gels 
Acrylamide gels for protein separation were made by creating a 10% 
separating gel, with 4% stacking gel atop. Bio-Rad glass plates were assembled 
and secured tightly in a gel assembly holder. Separating gel was composed as 
below: 
Reagent Company Volume for 4 gels 
30% Acrylamide/Bis  Bio-Rad 10.4ml 
1.5M Tris pH8.8 - 8ml 
dH2O - 13.4ml 
20% SDS (w/v) - 160µl 
TEMED - 20µl 
25% AMPS - 80µl 
 
Separating gel was added to assembled glass plates. A layer of isopropanol 
was added on top to remove bubbles and achieve an even distribution. After 20 
minutes at room temperature, the isopropanol was poured off. Stacking gel was 
then composed and added on top.  





0.5M Tris pH6.8 - 5ml 
dH2O - 11.9ml 
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20% SDS (w/v) - 100µl 
TEMED - 10µl 
25% AMPS - 100µl 
 
A 10- or 15-well comb (Bio-Rad) was added to the top and the gel left to set. 
Gels were either used immediately or wrapped in moist paper and stored at 4oC 
for a maximum of a week. 
2.2.9.5 Gel Running 
Gels were assembled in Bio-Rad gel tank. 1 litre of running buffer was 
prepared by diluting 100ml of 10x TGS (Bio-Rad) in 900ml of dH2O. Running 
buffer was added to the tank, ensuring gels were immersed. Samples were loaded 
into individual wells, with one well reserved for 5µl of High-Range Rainbow 
Ladder (GE Healthcare). Except for Co-IP samples (specified separately), 12.5µl 
of samples were loaded into gels. Gel was run at 120V for ~2 hours, until loading 
dye could be seen at the bottom of the gel.  
2.2.9.6 Gel Transfer 
After samples had separated sufficiently, gels were removed from the tank and 
prepared for transfer. Transfer buffer was made by combining 700ml of H2O with 
200ml of methanol and 100ml of 10X TGS. Hybond-P PDVF membrane (GE 
Healthcare) was cut to the size of gel. The membrane was transferred to methanol 
for 1 minute to activate it, before being stored in transfer buffer for 3 minutes for 
equilibration. For each gel 2 sponges and 2 pieces of Whatman filter paper (cut to 
size) were assembled in a cassette (starting with the black side), along with gel 
and activated membrane in the following order: sponge, filter paper, gel, 
membrane, filter paper, sponge. Cassettes were pressed tightly to ensure the 
removal of air bubbles from samples. Cassettes were sealed and placed in transfer 
tank (Bio-Rad), along with an ice pack and transfer buffer. Transfer was set at 
100V for 1 hours at 4oC. 
 
Chapter 2: Materials and Methods  Page | 57 
2.2.9.7 SYPRO Ruby 
After transfer, membranes were removed from transfer cassettes using forceps. 
Membranes were placed on a sterile plastic film and dried at room temperature. 
Membranes were re-activated by being immersed in methanol. To measure total 
protein membranes were incubated in SYPRO Ruby prewash solution (7% Acetic 
Acid, 10% Methanol, ddH2O) for 15 minutes. Blots were then washed 4 times for 
5 minutes in ddH2O. Finally, blots were incubated for 15 minutes with SYPRO 
Ruby solution (Thermo Fisher) in the dark. Blots were washed for twice for 1 
minute in ddH2O to remove excess stain and then were imaged by a LI-COR 
imaging system on channel 600 for 2 minutes. This provided an image of total 
protein transferred to the membrane.  
2.2.9.8 LI-COR immunostaining 
The LI-COR system uses fluorescent secondaries for western blot detection. 
Blots were blocked in Odessy™ LI-COR blocking buffer for 1 hour at room 
temperature whilst rocking. Primary antibodies (one mouse, one rabbit) were 
diluted in LI-COR blocking buffer and incubated either at room temperature for 
1-3 hours or overnight at 4oC whilst rocking (see table 2.17). Blots were washed 
in TBS with 0.2% Tween20 (TBS-T) 3 times for 15 minutes each, at room 
temperature. LI-COR secondary antibodies (table 2.18) were diluted 1:5000 in 
LI-COR blocking buffer and incubated in the dark at room temperature for 1 hour 
whilst rocking. After 3 15-minute washes with TBS-T, blots were imaged in the 
LI-COR imaging system at channel 700 for rabbit and 800 for mouse or goat (2 
minutes per channel). 
2.2.9.9 HRP immunostaining 
For some antibodies LICOR staining did not work. In those instances, HRP-
conjugated secondaries were used. Further, co-immunoprecipitation samples 
required light-chain secondary antibodies, these were HRP conjugated.  
After SYPRO Ruby staining, membranes were blocked in blocking solution 
(5% milk powder in 0.2% Tween20 in TBS) for 1 hour at room temperature. 
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Antibodies were diluted in blocking solution and applied to membranes overnight 
at 4oC with agitation (table 2.17). Membranes were washed with TBST for three 
15-minute washes. All HRP-conjugated secondaries were diluted 1:1000 in 
blocking solution and incubated on membranes, whilst rocking, for 1 hour at 
room temperature (table 2.18). Blots were washed as previously described. 
Clarity™ ECL detection reagent (Bio-Rad) was made by diluting reagents A and 
B in a 1:1 ratio. Solution was applied to the membrane for 5 minutes in direct 
light. Membranes had the solution removed and sealed in plastic film. Blots were 
placed in a cassette and exposed in a dark room using autoradiography film.  
As only one antibody could be tested at a time, blots were stripped after 
exposure using stripping buffer. Stripping buffer was applied to membranes twice 
for 10 minutes each, TBS was then used to wash blots twice for 10 minutes and 
finally two washes with TBS-T were performed. Blot was then ready for further 
blocking and immunostaining, as above.  
2.2.9.10 Densitometry analysis 
HRP-Blots were scanned, and images were subjected to densiometric analysis 
using ImageJ software. Pixel intensity for each band in western blot was 
measured. These were standardised either against loading control protein or total 
protein. LI-COR images were taken from LI-COR imaging system and the same 
analysis was performed.  
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2.2.10 In vitro protein synthesis treatment 
2.2.10.1 Puromycylation treatment for western blot analysis 
To assess nascent protein synthesis, HEK293T and LUHMES cells were 
treated with puromycin before immunoblot analysis.  
HEK293T cells were transiently transfected with eEF1A2-V5 constructs as 
with in 2.2.3.1.  
Cells were grown in 6 well plates for HEK293T and T25 flasks for LUHMES 
cells. Control cells were pre-treated with 150µM cycloheximide for 20 minutes. 
Cells were then treated with 100µg/ml puromycin for 15 minutes. A vehicle 
condition was added as a negative control. Cells had media removed immediately 
after treatment and trypsinolysis was used to extract cells and centrifugation at 
5000rpm for 5 minutes pelleted cells. Cell lysis and protein extraction, BCA 
analysis and western blot was then performed as in 2.2.9. 
2.2.10.2  Immunocytochemistry of puromycin staining 
Differentiated and proliferative LUHMES cells were cultured on glass 24 well 
coverslips (Costar). Puromycin treatment was performed as above, including 
cycloheximide and vehicle treatments. Treatments were staggered to ensure equal 
incubation lengths, matching genotypes in each staggered repeat. After treatment 
was finished, media was removed and cells washed once with PBS. Cells were 
then fixed in 4% PFA for 15 minutes. Cells were washed twice with PBS and 
stored in PBS overnight at 4oC. 
Cells were permeabilised using 0.1% Triton-X100 for 5 minutes before a 
further washing step with PBS. Cells were blocked in 5% BSA in PBS for 1 hour 
at room temperature. Cells were then incubated with puromycin and eEF1A 
antibodies diluted in 5% BSA 0.1% PBST. A ‘no primary’ control was added for 
background fluorescence control. This was incubated in PBST. Slides were 
incubated for 1 hour at room temperature. Cells were washed 3 times with PBST 
for 10 minutes each. Afterwards, fluorescent secondary antibodies, diluted in 5% 
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BSA 0.1% PBST, were applied to slides for 30 minutes in the dark. After further 
washing 3 times with PBST, slips were removed from wells and were fixed to 
slides using ProLong gold Antifade mounting media with DAPI (Thermo Fisher). 
Slides were left at 4oC covered from light for 18 hours to allow mounting media 
to solidify.  
Cells were imaged on a Zeiss epifluorescence microscope at x63 objective and 
analysed using ImageJ software with blinding.  
2.2.10.3  AHA click-it protein synthesis 
Proliferative and differentiated LUHMES cell lines were cultured in a 96 well 
plate. Cells had media replaced with pre-warmed artificial cerebrospinal fluid 
(aCSF) (table 2.14). Cells were left for 2 hours at 37oC to allow methionine 
depletion. Anisomycin (Sigma) was used to treat control cells to inhibit protein 
synthesis at a concentration of 250µM.  
Click-it™ AHA protein synthesis kit (Invitrogen) was used as per the 
manufacturer’s instructions. Wells were imaged on a Zeiss live inverted 
epifluorescence microscope at x4 objective.   
2.2.11 Eef1a2 mouse lines 
2.2.11.1 Generation and Eef1a2/D252H, Eef1a2/del22ex3 and Eef1a2/G70S 
mouse lines 
CRISPR/Cas9 was used to generate missense mutations and deletions in mice. 
This work was done by other members of the lab and mouse lines have been 
extensively characterised previously, both in published work and other theses in 
the lab (121,140,141). In summary, nickase technology was used to edit missense 
mutations and deletions in C57BL/6 mice. Genetic editing resulted in mice with 
G70S missense mutations, but no surviving founders to generate a breeding line. 
Surviving founders were generated for Eef1a2/D252H and Eef1a2/del22ex3 lines. 
Table 2.21 summarises all mouse lines used during this thesis.  
Chapter 2: Materials and Methods  Page | 61 
Table 2.21: Description of mouse lines used in thesis.  
Line name Mouse line 
Eef1a2/D252H Line generated using CRISPR/cas9. Two founder mice with 
Eef1a2D252H/+ genotypes were used to generate breeding 
lines.  
Eef1a2/G70S Line generated using CRISPR/cas9. Founder mice only 
were generated: Eef1a2G70S/G70S, Eef1a2G70S/- and Eef1a2-/-.  
Eef1a2/wst Mouse line with 15kb deletion including promoter of 
Eef1a2 gene. Homozygote mice have a Eef1a2-/- genotype. 
Eef1a2/del22ex3 Line with 22bp deletion in exon 3 resulting in loss of 




2.2.11.2.1 Eef1a2/D252H genotyping 
Ear notches were taken by animal technicians at the BRF Unit, Western 
General Hospital. DNA was extracted by boiling for 10 minutes in 300µl 15mM 
NaOH. 25µl of Tris 1M pH8 was added to samples and tubes were shaken. DNA 
extracts were stored at -20oC until PCR analysis. A combination of PCR and 
restriction digest was used to characterise Eef1a2/D252H mice. PCR amplified a 
442bp product using primers in table (table 2.6). PCR was composed of the below 
components and run on cycling parameters on a Bio-Rad C1000 Thermal Cycler.  
Reagent Company Volume (µl) 
5x Platinum Superfi buffer  Thermo Fisher 4 
Platinum Superfi polymerase Thermo Fisher 0.2 
10mM dNTPs  Invitrogen 0.4 
10µM forward primer Sigma 1 
10µM reverse primer Sigma 1 
Betaine - 4 
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ddH2O - 9.15 
DNA - 0.25 
 
Temperature Time (seconds) Step/cycle 
98oC 60 Initial denaturation 
98oC 5 
X30 cycles 58oC 10 
72oC 15 
72oC 10 minutes Final extension 
 
After PCR amplification, samples were subjected to restriction digest by 
Hin1II (Thermo Fisher). Reactions were set up as follows: 
Reagent Company Volume (µl) 
Fast digest green buffer  Thermo Fisher 2.5 
Hin1II  Thermo Fisher  0.5 
PCR product - 15 
ddH2O - 7 
 
Samples were incubated at 37oC for 5 minutes in a Bio-Rad C1000 Touch 
thermal cycler. Products were run on a 2% agarose gel for 1 hour at 130V with 
100bp ladder (NEB). Restriction digest resulted in either 300bp and 122bp 
fragments for A WT allele, or a 202bp, a 128bp and a 122bp fragment pattern for 
D252H allele.  
2.2.11.2.2 Eef1a2/del22ex3 genotyping 
Ear notches were obtained, and DNA extracted as in 2.2.11.2.1 from the 
Eef1a2/del22ex3 mouse line (table 2.21). PCR amplification around exon 3 using 
primers in table 2.7 produced a 208bp band for a WT allele and a 186bp band for 
a mutant. Reactions were set up as below and cycling parameters in 2.2.4.2 were 
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used on a Bio-rad C1000 Touch thermal cycler. Samples were diluted with 6x 
DNA loading buffer and run at 130V on a 2% agarose gel with SYBR safe 
(Invitrogen) with 100bp ladder (NEB). 
Reagent Company Volume (µl) 
10x PCR Buffer  Invitrogen 2.5 
MgCl2  Invitrogen 1 
Taq DNA polymerase  Invitrogen 0.2 
10mM dNTPS  Invitrogen 0.5 
10µM forward primer Sigma 1 
10µM reverse primer Sigma 1 
Betaine - 7.5 
ddH2O - 10.3 
DNA - 1 
 
2.2.11.2.3 Genotyping Eef1a2/wst mouse line 
After it became impossible to breed del22ex3 homozygote mice for welfare 
reasons, I used the older more established Eef1a2/wst line (table 2.21) which had 
been well characterised previously (13,62) as control mice in protein synthesis 
experiments. Samples from the ‘wst’ mouse line were genotyped using two 
standard PCR amplifications with primers in table 2.8. Reagent mix was 
composed as in 2.2.11.2.2 and the samples were run on a Bio-rad C1000 Touch 
thermal cycler using the following cycling parameters.  
Temperature Time (minutes) Step/cycles 
95oC 3 Initial denaturation 
95oC 1 
X30 cycles 62oC 1 
72oC 1 
72oC 5 Final Extension 
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PCR products were diluted with 6x DNA loading buffer and run on a 1.5% 
agarose gel at 130V. WT allele PCR amplification resulted in 452bp product (62) 
and null allele PCR created a 200bp product (119).  
2.2.12 Animal phenotyping 
WT, heterozygous and homozygous littermates from Eef1a2/D252H and 
Eef1a2/del22ex3 lines were subjected to phenotyping analysis from postnatal 
days 16 to 24. Phenotype assessments were carried out according to the method 
of Guyenet and colleagues (142). In brief, mice were subjected to 4 
measurements and scores recorded daily; gait, degree of kyphosis, hind limb 
clasping and ledge test. Scores on severity were agreed between all three 
experimenters. To ensure consistency, a training period was undertaken where 
experimenters scored the same mice at the same time, but independently of one 
another to ensure scores were consistent. All experimenters were blind to mouse 
genotypes during phenotypic analysis. A training day at p15 was also undertaken, 
this was because artificially high scores on ledge test were being recorded for all 
mice, who were unable to perform the task straight away owing to their age.  
In addition to phenotype, weight of mice in grams was recorded daily.  
2.2.13 Animal treatments with puromycin 
Protein synthesis experiments were performed using SUnSET which had been 
adapted for in vivo usage, as reported previously (143). Mice were housed in the 
BRF animal unit of the Western General Hospital. Injections were performed by 
licensed animal technicians. Stock drug solution was prepared by solubilising 
Puromycin Dihydrochloride (Millipore) in sterile filtered PBS and aliquoted. 
Aliquots were stored at -20oC and thawed on ice. Mice were weighed and drug 
concentration of 0.04µmols/gram in 100µl sterile filtered PBS was made up. 
After successful anaesthetisation, mice had the drug solution administered 
subcutaneously. Animals were left under anaesthetic for exactly 30 minutes 
before culling by cervical dislocation. Heart, liver, skeletal muscle, brain and 
spinal cord were extracted. These were flash frozen in liquid nitrogen, before 
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being transferred to -80oC and stored for later analysis. Mice were treated 
consecutively to allow for exactly 30 minutes of treatment each.  
Muscle and liver samples were prepared using the method in 2.2.9.1.1. The 
subsequent protocol described in 2.2.9 was then followed including BCA analysis 
and using HRP-conjugated immunostaining technique. An IgG2a secondary 
antibody was used to remove non-specific background staining (143). 
Protein synthesis was measured by normalising relative puromycin signal to 
total protein concentration using densiometric analysis performed on ImageJ 
software. 
2.2.14 RNA extraction 
RNA for qPCR analysis was extracted from cells and tissue using the RNeasy 
Qiagen kit as per the manufacturer’s instructions.  
Cell pellets were stored at -80oC. Pellets were collected on ice and lysed in 
RLT buffer using a Bioconductor for 7 cycles of 30 seconds on and 30 seconds 
off at 4oC. Tissue was removed from -80oC on dry ice, sliced and weighed. 
Appropriate weights of tissue were added to specific volumes of RLT buffer as 
per the manufacturer’s instructions. These samples were lysed in homogenisation 
tubes (Stretton Scientific) on a Precellys®24 homogenisation shaker for 1 minute 
and returned to ice. RNA extraction using Qiagen kit was then followed for both 
sample types. On column DNAse digestion was performed using the Qiagen 
DNAse digestion kit, as per the manufacturer’s instructions. After RNA 
extraction, a second DNAse digestion step was performed using DNA-free 
DNAse removal kit (Invitrogen). 0.1 volumes of DNase I Buffer and 1µl of 
rDNase was added to the RNA. Samples were incubated at 37oC for 20-30 
minutes. 0.1 volumes of DNAse inactivation reagent was added and tubes were 
mixed. A further 2-minute incubation at room temperature was performed before 
tubes were centrifuged at 10000 x g for 2 minutes at 4oC. Supernatant was 
removed and stored as RNA. RNA quality and concentration were measured 
using the Nanodrop Optical Imager. RNA was stored at -80oC. 
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2.2.15 cDNA synthesis  
To convert RNA to cDNA, Aligent cDNA synthesis kit was used following the 
manufacturer’s instructions. All samples of RNA were diluted to a standard 
concentration (typically 1µg) in RNAse free water. Negative controls were also 
performed; -RT sample contained 1µl of RNA from all samples, but no reverse 
transcriptase (allowing for a genomic DNA contamination check), whilst a no 
RNA condition checked for contamination with PCR products 
2.2.16 qPCR 
qPCR was used to measure EEF1A2 mRNA concentrations in LUHMES cells. 
First, cDNA was diluted 1:100 in ddH2O. qPCR experiments were performed 
using Brilliant II SYBR Green qPCR master mix (Aligent) with the following 
reaction mix: 
Reagent Volume (µl) 
2x Brilliant II SYBR green 6 
6µM primer mix 0.5 
ROX reference dye (1:50 ddH2O) 0.375 
RNAse free water 1.125 
cDNA 4 
Reactions (triplicates per sample) were added to an opaque 384 well plate (Co-
star), spun in a plate spinner for 1 minute and run on the Light Cycler HT7900 
(Roche) using below cycling parameters, with dissociation curve step added post 
amplification.  
Cycles Temperature Time 
1 95oC 10 minutes 
40 
95oC 3 seconds 
60oC 1 minute 
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Negative control samples were also added to check for RNA or genomic DNA 
contamination. Results are presented as ΔΔCT values. These are a measure of 
how many cycles it took within the PCR for amplification of the product to reach 
a specific threshold and inversely correlate to RNA concentration. 
To establish the number of, and optimal, housekeeping genes for 
normalisation, GeNorm™ analysis was performed (144). This allowed for 
comparison of sample variability across different housekeeping genes. At least 
ten samples were added in triplicate to a plate and tested against six housekeeping 
genes. These were run as above and the GeNorm™ software was used to analyse 
the samples. This allowed for the selection of an appropriate number of genes 
which had the lowest inter-sample variability 
EEF1A2 and selected housekeeping genes were subjected to qPCR as above. 
In addition, standard curve of DNA was made for all primer pairs. One WT RNA 
sample was diluted 1:10 and then five subsequent 1:1 dilutions were performed. 
These standard curves were used to quantify ΔΔCT values.  
Samples were analysed by comparing ΔΔCT values to standard curve. The 
anti-log of samples was taken and the GEOMEAN function in excel was used to 
gather an average of housekeeping genes. The EEF1A2 values were then divided 
by this value in each respective sample. These values provided relative EEF1A2 
mRNA quantification values for all samples. 
2.3 Computational analysis 
2.3.1 Analysis of AP-mass spec 
Mass spectrometry results supplied a list of proteins identified in the pulldown 
along with label-free quantifications in each condition. Filtering analysis was 
performed in R using ‘dplyr’ package. Proteins with a unique peptide value less 
than 1 were omitted. Proteins with a mode of zero were also removed. The 
minimum value above zero was found for each protein and used to replace zero 
values. Average log2 fold change of all conditions as compared to empty vector 
was calculated. Proteins which showed a 3-fold greater increase in any condition 
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as compared to empty vector were kept. Z-scores for filtered protein set were 
obtained and ‘pheatmap’ package was used to visualise variance. Once 
background filtering was complete several normalisation analyses were 
performed.  
2.3.1.1 Bait normalisation  
eEF1A2 label free quantification (LFQ) values for all repeats were normalised 
against the first WT sample. The resulting ratio was then used to adjust all other 
proteins in the sample. Log2 fold change for mutations compared to WT for each 
protein were calculated. t-tests for every protein in mutant versus WT were also 
performed. P-values were adjusted owing to multiple testing using a 1% false 
discovery rate. Negative log10 of p-values was calculated and plotted against the 
log2 fold change for respective proteins using R package ‘ggplot2’ to create 
volcano plots.  
2.3.1.2 Total Area Sums normalisation 
The sum of all LFQ intensities in each sample (post background filtering) was 
obtained. These sums were divided against the sum of one WT repeat and a 
relative score for each condition obtained. These scores were used as a 
normalisation factor for all proteins in respective condition. Heatmap and volcano 
plots were visualised as previously. 
2.3.1.3 Most-Likely Ratio normalisation 
To counteract variable bait levels, most-likely-normalisation ratio (MLR) was 
performed as reported by Lambert and colleagues (145). The most representative 
sample of each technical repeat was determined by comparing the log10 of ratio of 
respective proteins with all other technical repeats in the genotype. The density of 
these values was plotted using ‘ggplot2’. Delta and histogram width were 
calculated and used as a measure of global data similarity. Comparing all these 
repeats allowed for determination of the most representative sample within each 
genotype. All other samples were then adjusted using the appropriate apex ratio 
to the ‘representative’ sample. This was termed the ‘technical normalisation step’ 
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This process was then repeated comparing all mutant repeats with all WT 
technical repeats. Again, using histogram analysis the most representative WT 
sample was identified and appropriate apex ratio was used to adjust all other 
samples. Density and volcano plots were visualised using ‘ggplot2’ and heatmap 
was prepared using ‘pheatmap’ package. 
2.3.2 Protein network analysis 
2.3.2.1 eEF1A2 AP-mass spectrometry  
Advice on the appropriate filtering and normalisation techniques for AP-MS 
was supplied by Dr Alex von Kriegsheim (ECRC, IGMM). I went on to explore 
further normalisation techniques, in addition to his advice, using the scientific 
literature as a guide, settling on Most-Likely-Ratio normalisation. 
To generate biological networks, all proteins identified after background 
filtering were inputted into the String database to obtain functional interaction 
scores. The interactions were added to Cytoscape. The ClusterONE plug-in was 
used to create clusters based on the edge weighted scores obtained in string 
database. Significantly identified clusters were then subjected to gene ontology 
analysis to identify functional enrichment using the GOrilla software.  
2.3.3 Statistical testing 
Statistical testing was performed in R and GraphPad software V8. t-tests, 
multiple correction calculations, one-way ANOVAs and 2-way mixed ANOVAs 
and non-parametric alternatives were used where appropriate.  
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Chapter 3: eEF1A2 interactome analysis and mutation consequences 
3.1 Introduction   
Analysis of the ‘interactome’ (everything a protein interacts with) is a powerful 
way of examining mutations and their consequences. Two common approaches 
used to assess the global protein interaction network are yeast-two-hybrid assays 
and affinity-purification mass spectrometry (AP-MS) (Figure 3.1A). Yeast two 
hybrid assays are practical for establishing binary interactions between two proteins 
(146). AP-MS, meanwhile, uses bait-pulldown followed by identification and 
quantification of interacting protein partners. This allows for the identification of 
protein interaction networks based on direct and indirect association (147). The 
second advantage to using AP-MS is the ability to use mammalian cells. All protein 
interactions are measured within the desired cell type. Unlike yeast two hybrid 
assays, which can induce artificial interactions which would normally not occur in 
a cell type, this is does not occur using AP-MS. 
AP-MS has been an insightful tool for other neurological conditions in both 
human and mouse studies. Using a multiple sclerosis mouse model LRP1 
interacting proteins were established (148). The mutant form of the protein 
huntingtin, the causative mutation in Huntington’s disease, showed altered protein 
interactions including translation apparatus. (149).    
The analysis of interactome changes is termed ‘Edgotyping’. Edgotyping uses 
network analysis to examine the impact of mutations on the interactome. Proteins 
are represented as nodes and their interactions are mapped as interconnecting 
edges. Zhong et al argued that edgotyping analysis is essential for understanding a 
complex array of pleiotropic phenotypes, resulting from different mutations in the 
same gene (150). Sahni et al discovered that whilst some missense mutations 
disrupt protein stability resulting in a ‘quasi-null’ protein, the vast majority of point 
mutations did not result in total loss of binding to all interactors, but instead edge 
specific changes (edgetic perturbations) (151). Different mutations in the same 
protein perturbed different edges, resulting in diverse phenotypes.  
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Figure 3.1: AP-MS to establish eEF1A2 interactome. A, schematic diagram of 
AP-MS process. Figure adapted from Dunham et al 2012 (152). B highlights the 
possible protein interaction disruptions which result from mutations. In some 
instances, mutations can result in no changes to binding partners (Quasi-wild-
type). In some cases, the opposite can happen, with mutations causing 
perturbations to all interactors (Quasi-null). Sahni and colleagues demonstrated 
that in many mutations a third consequence, edgetic perturbations, occurs Edgetic 
perturbations result disruption of specific interactors due to mutations. Location of 
disruption can impact which interactions are perturbed and mediate the severity of 
the condition. These have been displayed in figure B (adapted from Sahni et al 
(151)).  
I used AP-MS to isolate eEF1A2 and its binding partners. This allowed me to 
study the interactome of eEF1A2, and how it was disrupted with mutations. Any 
changes in interactions, as a result of mutations, might shed light on the molecular 
consequences. Firstly, the key interactors might illuminate the non-canonical 
functions of eEF1A2. Secondly, mutations may disrupt or enable binding proteins 
suggesting a loss or gain of function, and the molecular mechanisms implicated.  
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3.2 Aims of chapter 
1) Identify the interactome of eEF1A2 
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3.3 Identify the interactome of eEF1A2  
3.3.1 Experimental workflow of mass spectrometry experiment 
 
Figure 3.2: Affinity purification mass spectrometry experiment to assess the 
eEF1A2 interactome. A, Experimental workflow of the mass spectrometry 
experiment. B, An example western blot of transfected eEF1A2-V5 constructs in 
SH-SY5Y cells. V5 staining is shown at the correct size for eEF1A2-V5 (52kDa). 
GAPDH staining is shown at 38kDa. C, a heatmap of z-scores for all proteins 
identified as ‘confident interactors’ (above empty vector filtering). Hierarchical 
clustering groups background (EV) and WT repeats together, showing higher 
intensity in WT compared to EV. 
No commercial antibody can discriminate between endogenous eEF1A1 and 
eEF1A2 in cultured cell lines, and all immortalised cell lines express eEF1A1. 
Consequently, I used a tagged form of eEF1A2 with a C-terminal V5 tag. 
Exogenously expressing eEF1A2-V5 resulted in a band at 52kDa, identified with a 
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V5 antibody (Figure 3.2B).  Before filtering, 1081 proteins were identified by AP-
MS. After contaminants, low expression and background proteins were filtered, 
288 proteins were identified as high confidence interactors (a 27% identification 
rate). A heatmap of LFQ intensities for high confidence interactor in the empty 
vector and WT conditions shows successful filtering of background contaminants 
(3.2C). In this experiment, the whole cell lysate was applied to AP-MS. In future 
experiments a small volume of lysed sample was taken before 
immunoprecipitation, to assess transfection efficiency. As all cells were seeded 
equally and transfected at the same time for each biological replicate, endogenous 
levels of eEF1A2 are likely to be relatively consistent. Therefore, looking at the 
LFQ intensities of eEF1A2 provides an insight into exogenous levels of eEF1A2-
V5. It was clear from label-free quantities, that one G70S sample was an outlier 
and therefore discarded (see Appendix A.1).  
3.3.2 Gene Ontology and network analysis of eEF1A2 interacting partners 
I assessed the interactome of eEF1A2, which has never been examined before, 
to gain insight into the functions of eEF1A2.  
Functional enrichment analysis identified key areas consistent with previous 
knowledge of eEF1A2 function. Translation elongation factors from the eEF1 
complex and ribosomal subunits display the most significant enrichment of the 
cellular component (3.3A). Similarly, RNA binding and ribonucleoside binding 
proteins featured highly in the molecular function gene ontology (GO) terms 
(3.3A). Results supported the hypothesis that the role of eEF1A2 in protein 
synthesis would feature as the dominant pathway affected. 
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Figure 3.3: Gene ontology analysis of the eEF1A2 interactome. Using DAVID 
functional annotation software, the ten most significant GO terms in both 
molecular function and cellular component were identified (A). Significance of 
each of these GO terms is demonstrated by the negative log10 p-value score. B 
PANTHER functional enrichment of all proteins in eEF1A2 interactome. C is an 
examination of the GO terms included in the overall term ‘binding’ in figure B.  
Gene ontology analysis identified interactors associated with functions which 
were conceivably linked to eEF1A2. The GO term ‘binding’ contributed to nearly a 
third (32.4%) of eEF1A2 interactions (3.3B). When examined in closer detail, this 
term can be subdivided, with nucleic acid and protein binding genes responsible for 
interactions in this category (49% and 41% respectively). The nucleic acid term is 
largely taken up by mRNA binding proteins, mostly associated with RNA splicing 
prior to protein synthesis and RNA transport. The protein binding category includes 
cytoskeletal modifications (60% of the category), which is solely accounted for by 
actin binding proteins. The extent to which each isoform is involved in actin 
bundling is of particular interest, as actin bundling is the central hypothesis behind 
the conserved expression of two isoforms (28). Evidence is emerging that the pair 
have differing actin bundling properties (21). These results highlight that eEF1A2 
at the very least interacts with actin and actin bundling proteins, although no insight 
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is provided as to whether the two isoforms bundle actin to different degrees or in 
different ways.  
3.3.3 Mapping the eEF1A2 interaction network 
More information is determined on the eEF1A2 interactome by mapping protein 
interactions in a network. Clustering proteins into a network using prior knowledge 
of protein interactions can provide biological context to interactome data. To 
generate a network, topological analysis of the mass spectrometry data was 
performed. Topological analysis can either be performed using node centrality or 
clustering methods (153). Node centrality measures the importance certain proteins 
(nodes) play in a network. Given my network was centred around a bait protein, 
this was not the most appropriate method. A more appropriate technique was 
clustering analysis. This method grouped proteins based on previous knowledge of 
interactions. Clustering analysis simplified data by creating ‘clusters’ of proteins 
(nodes) and measured their interconnectedness (edges). Clusters could then be 
examined for biological functions to glean insight into the proteins associated with 
eEF1A2. 
I analysed the proteins identified in the AP-MS experiment by obtaining the 
known protein interaction scores from the String database (edge scores). Using 
edge-weighted clustering analysis, protein complexes were identified, and the 
network was visualised in Cytoscape (Figure 3.4).  
Nine clusters of proteins were reported as significant in this analysis (p<0.05). 
These clusters were subjected to gene ontology analysis to identify functional 
enrichment (table 3.1). Functions identified both supported the previous enrichment 
results and helped identify smaller clusters of proteins with which eEF1A2 might 
interact. By far the most substantial cluster was cluster ‘a’ (Figure 3.4 (p<0.0001)). 
This cluster includes all the ribosomal subunits and other proteins involved in 
translation. It was unsurprising this would be the largest and most significant 
cluster, given the role eEF1A2 plays in protein synthesis. Other functions in which 
eEF1A2, or more generally eEF1A are implicated in have also been reported. 
eEF1A mediates the processing of unfolded or misfolded nascent polypeptides to 
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the proteasome (29). Cluster ‘b’ in Figure 3.4 (p<0.0001), identifies heat shock 
proteins and chaperones (table 3.1). eEF1A1 but not eEF1A2 has been implicated 
in the induction of the heat shock response (30). Heat shock proteins have been 
shown to regulate translation at the elongation phase, especially during an 
augmented stress response, by interacting with elongation factors including 
eEF1A2 (154). This binding to heat shock factors likely reflects a different function 
of eEF1A2. Another cluster related to a previously acknowledged function of 
eEF1A2 is protein transport. Interacting proteins were identified clustered in a 
group associated with protein transport, specifically ER-Golgi (green cluster Figure 
3.4 & table 3.1). There is some, but limited, work on eEF1A and its role in protein 
transport, but the isoforms responsible have not been identified. These results 
speculate eEF1A2 may have a role in both protein transport and the proteolysis of 
malformed peptides.   
One cluster identified as significant was less expected: a complex of proteins 
which included transcription factors (turquoise (d); p<0.0001). eEF1A is 
predominantly a cytoplasmic protein, with little to no nuclear expression. There is 
evidence of eEF1A having a role in nuclear export (31–33). However, in the 
reported instances, eEF1A binds to the nuclear export machinery to facilitate the 
removal of components of the translational apparatus. To do this eEF1A interacts 
with Exportin 5 and Snail transcription factors. Neither of these were identified in 
the AP-MS experiment. Instead, proteins reported in the ‘Turquoise’ cluster include 
DNA replication licensing factors (MCM2, MCM3, MCM4, MCM5, MCM6 and 
MCM7). Immunostaining provided no evidence that transfected eEF1A2-V5 was 
expressed in the nucleus (see appendix A.2). However, the MCM complex and 
eEF1A2 have previously been linked as interactors. eEF1A2 was pulled-down as 
an interacting partner of the MCM complex in a mass spectrometry experiment 
(155).  
RNA binding proteins were unsurprisingly identified in clusters (f & h, p<0.01, 
Figure 3.4). eEF1A has previously been associated with RNA binding proteins, 
likely relating to its canonical function and RNA transport (48,49). If valid, this 
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result would be the first evidence for the involvement of the eEF1A2 variant in 
these interactions.  
After filtering, the protein interactors in the AP-MS sample were a densely 
clustered group of proteins associated with both reported canonical and non-
canonical functions of eEF1A2 including protein synthesis, RNA binding, protein 
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Figure 3.4: eEF1A2 protein interaction network. eEF1A2 and interacting partners 
were added to the string database, to gain functional interaction scores. Clusters 
were generated using edge-weighting analysis in Cytoscape based on interaction 
scores 
Table 3.1: Gene ontology analysis of interactome clusters identified in network 
analysis. Clusters from Figure 3.4 had gene ontology analysis applied, clusters with 
significantly enriched GO terms are reported.    
Cluster Letter Gene Ontology classification 
-log10 P-
value 
Colour p-value    

























Green p<0.001 c 






ER to Golgi vesicle-
mediated transport 
12.0 
Turquoise p<0.0001 d 





GO:0003677 DNA binding 9.83 











Red p<0.001 f 
GO:0008380 RNA splicing 7.88 
GO:0051028 mRNA transport 5.33 
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GO:0006396 RNA processing 4.87 





Orange p<0.01 h 
GO:0006397 mRNA processing 10.6 
GO:0051028 mRNA transport 6.03 
GO:0008380 RNA splicing 8.39 
Yellow p<0.01 i 
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3.3.4 Comparison of experimental results with previously reported interactors 
of eEF1A2. 
As a first step to validate the identified proteins in my AP-MS, I compared 
experimental results to previously published interactors of eEF1A2. I compiled an 
interactome network of eEF1A2 from protein interaction databases String, BioGrid, 
GPSprot and IntAct. I then compared these proteins with the AP-MS hits to assess 
overlap. Figure 3.5A shows that only 5% of the proteins pulled down in my 
experiment had previously been associated with eEF1A2. Proteins in common 
include ribosomal constituents, eEF1B subunits and DNA replication factors, all 
constituents of statistically significant clusters in my own analysis. The overlap 
overall is disappointingly low and suggests there is an overestimate of interaction 
partners in this network.  
 
Figure 3.5: Comparison of AP-MS and published eEF1A2 interactions. A Overlap 
between previously reported interactions (eEF1A2-pub) and proteins identified in 
the mass spectrometry experiment (AP-MS). B list of overlapping genes. 
Proteins which do share an overlap are of particular interest, however. The list of 
genes identified in Figure 3.5B includes subunits of the eEF1B complex, ribosomal 
protein subunits and molecular chaperone proteins. It can be concluded that these 
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proteins likely are true interactors.  These proteins were, therefore, noted to be of 
most interest and were prominent in follow-up validation. 
Cao and colleagues established that eEF1A2 interacts with the eEF1B complex 
just as eEF1A1 does (71). eEF1A is known to interact with the ribosome (156,157), 
presumably during its role in translation.  eEF1A2 was identified as an interacting 
partner of 14-3-3 epsilon in a similar AP-MS experiment as part of a larger 
translation complex (158). The MCM complex has also been previously associated 
with eEF1A2 (155). The role these interactors may have when interacting eEF1A2 
has been discussed in detail in Section 3.5.1.  
Furthermore, all published interactions come from pull-downs where eEF1A2 was 
the identified interactor. eEF1A is known to be one of the most common 
contaminants in mass spectrometry experiments due to its prevalence. Whilst several 
papers have reported using yeast-two-hybrid assays to confirm the interaction of 
eEF1A2 with specific proteins (70,159,160), there has never been an AP-MS 
pulldown of full-length eEF1A2.  One AP-MS experiment using the M-domain of 
eEF1A1 as bait has been reported.  This research aimed to examine the non-
canonical functions of eEF1A1 by isolating the domain not responsible for 
translation (161).  However, there is a limited amount of research on interactors of 
eEF1A2 and my results supply the first known interactome using eEF1A2 as the bait 
pulldown protein.  
In summary, the interactome I identified using affinity purification mass 
spectrometry supports eEF1A2 in protein synthesis as well as its non-canonical 
functions, including protein transport, actin bundling and unfolded protein 
mediation. Whilst there is little overlap between my results and published 
interactions, the interactions which do overlap are high confidence, and little 
published work focusses on eEF1A2 as the primary target.   
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3.4 eEF1A2 mutations alter eEF1A2 protein interactome 
To establish the possible functional consequences of mutations in eEF1A2, I 
examined how mutations affected protein interactions. To do this, two mutations 
were selected and I examined their interactome in comparison with WT eEF1A2 (see 
experimental workflow in 3.1A). Any loss or gain of binding might explain possible 
loss or gain of functions. If mutations also yielded different interactome profiles, this 
might explain the severity variation between eEF1A2 mutation cases. Two mutations 
(D252H and G70S) were selected because experimental data in the lab had suggested 
they did not result in protein instability and because they were also being studied in 
mouse models. Work on the G70S mutation included a trial CRISPR mouse model 
attempt, in which I showed that the protein was expressed in vivo at levels similar to 
that of WT age-matched mice (140). These mutations, therefore, were deemed good 
candidates to test interaction analysis on, as they would not simply degrade, acting as 
a quasi-null protein. 
3.4.1 Normalisation techniques for AP-MS data 
For comparison of label free quantification intensities (LFQs) between genotypes, 
background filtering and normalisation of the dataset was required. Normalisation of 
label free quantification (LFQ) intensities was required to compare against different 
experimental conditions. Different normalisation strategies can be applied to affinity 
purification mass spectrometry (145). Normalising data correctly is imperative for 
proper interactome analysis, because each normalisation technique can manipulate 
the data in different ways, yield slightly different results and introduce bias. I 
examined different normalisation strategies appropriate to affinity-purification mass 
spectrometry, including bait normalisation, total area sums (TAS) and most likely 
ratio. Figure 3.6 displays the bait and TAS normalisation strategies. Whilst bait 
normalisation is the most established normalisation technique for AP-MS, variable 
levels of bait protein can skew results, by boosting contaminants in samples with low 
bait expression. Samples had a much higher intensity of eEF1A2 peptides in WT 
compared with G70S or D252H (0.07 and 0.1 log2 fold higher respectively) (Figure 
3.6D). This discrepancy, although small sounding, can have a greater global impact, 
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as shown in the boxplot and heatmap in Figure 3.6B & H. eEF1A2 normalisation 
greatly reduced signal intensity of all proteins in the WT condition, augmenting what 
is likely background contamination in the mutant conditions. This normalisation 
strategy is the most appropriate for the experimental design, and true interactors 
should express in a linear fashion with bait proteins. However, an examination of the 
fold change analysis of each mutant when compared to WT showed how much this 
analysis technique biased data. Volcano plots for both D252H and G70S mutants 
showed a significant data bias to a greater fold change (when compared with the 
respective WT condition) instead of a normally distributed data set (Figure 3.7 C & 
D). This is likely to lead to the identification of false positive differential 
interactions.  
Another technique employed to analyse data for AP-MS experiments is ‘total area 
sums’ (TAS) normalisation. In this technique, LFQ intensities for all interactors in a 
dataset are summed for each repeat. A ratio between the sum of the condition with 
the largest total and all other condition sums is produced. This ratio is then used as a 
normalisation factor for each respective condition. Whilst this analysis did result in 
the clustering of replicates by genotype in hierarchical clustering, analysis of TAS 
normalised data, between genotype differences were greatly amplified. The principal 
of affinity purification mass spectrometry dictates that unless a protein acts as a 
quasi-null, changes resulting from mutations will only result in interaction 
differences for a small number of proteins (162). Again, analysis resulting from TAS 
demonstrated a shift of mutant protein interactions towards the right, leading to a 
higher number of significantly greater interactions (green data points) than would be 
anticipated (Figure 3.7 A&B).  
It is worth noting that in both normalisation techniques, a cluster of proteins has 
been found to be significantly reduced in the D252H condition when compared to 
WT (the eEF1B subunits). This consistency between different normalisation 
techniques is encouraging, and suggests this result is so strongly significant that it is 
not influenced by manipulation of the data. However, normalisation clearly 
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introduces great bias into this data set, and may occlude the discovery of smaller 
interaction changes, which may nonetheless be of interest.  
 
 
Figure 3.6: Normalisation strategies of AP-MS experiments. A comparison of raw 
data (A, D and G), bait normalised data (B, E and H) and total area sums 
normalisation (C, F, and I). A-C highlights box plots demonstrating log2 data 
distribution for each sample with noted normalisation. D-F shows LFQ intensity 
values for eEF1A2 pre-normalisation (D), bait normalised (E) and TAS normalised 
(F). Heatmap of z-scores for each protein in raw, bait and TAS normalised samples 
is shown in G-I.   
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Figure 3.7: Volcano plot for both TAS (A & B) and bait (C & D) normalisation for 
both mutations. Log fold changes for each mutation compared to WT for individual 
proteins are compared to the negative log 10 of their respective p-values. P-values 
were calculated using one t-test per protein with a 1% FDR correction for multiple 
testing. Blue points represent non-significant differences. Significant differences 
(defined as a log fold change greater than a log fold change of 1, and p <0.05) were 
displayed as green points.  
I examined an alternative normalisation strategy, developed by Lambert and 
colleagues (145), specifically for AP-MS when bait levels are deemed too variable 
for standard bait normalisation techniques. Called the Most-Likely Ratio 
normalisation (MLR), it is based upon the theory that there will be fewer proteins 
changing than remaining constant and uses this rationale to scale the data 
accordingly. The analysis works by comparing the log10 of ratios between replicates, 
with the understanding that replicate comparisons with minimal variance will display 
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normal distribution, with small kurtosis and peak around zero. Distributions are 
visualised and scaled appropriately based on the sample which is deemed most 
comparable with all other samples. There are two stages to scaling, firstly, technical 
repeats are compared, and scaled within their groups. Then biological replicates are 
compared, and an appropriate WT sample which varied least with both G70S and 
D252H was used for scaled normalisation. The full results of each step in the MLR 
analysis pathway are in appendix A.2. Figure (3.8A) displays an explanation of most 
likely ratio normalisation adapted from Lambert et al. B-D show the normalisation 
stages. Intensity ratios are compared to one WT sample in each instance to show 
how they vary. In raw input (B), variance is at its highest, with the data in most 
mutant conditions showing a density peak greater than zero, highlighting the overall 
higher intensity in data of mutant proteins. The first step of normalisation (C), scales 
and normalises technical repeats. Here closer alignments can now be seen between 
technical repeats when compared to one WT sample. Whilst this step of replication 
reduced the bias in D252H samples, aligning them better to WT, G70S samples still 
show a higher expression compared with WT. Biological normalisation (D) corrects 
this, shifting all values into normally distributed density plots which centre around 
zero, indicating that most protein intensity distributions have been normalised. This 
normalisation does appear to have made an impact of the global average protein 
expressions (E), however eEF1A2 levels still appear higher in two of the WT 
samples. Globally, however, the sample appears more normalised, with two of every 
genotype clustering together, although one WT and one D252H do not cluster. 
Importantly, this is more than with bait normalisation, and MLR appears to have 
corrected the distribution issue, which was likely boosting background contaminants 
in the mutant conditions.  
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Figure 3.8: Most likely ratio normalisation analysis of the AP-MS data. A, an 
explanation of how MLR analysis adjusts replicates in data sets to minimise global 
variance and identify outlying interactors which are likely to be most affected. B 
demonstrates the distribution of raw log10 intensity ratios between respective 
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proteins for each replicate compared with one WT sample. Each density peak 
represents an individual repeat compared to one WT repeat, with peaks coloured by 
genotype. C highlights comparison of each replicate to the same WT sample post 
technical repeat normalisation. D shows the same intensity comparisons once 
biological-repeat normalisation. E is a boxplot displaying data distribution once 
MLR normalisation is complete, and F highlights a heatmap of z-scores for each 
protein across technical and biological repeats.  
Using MLR normalised data, both mutations show a normal distribution of fold 
changes with some significant interactors, making these proteins likely of most 
interest to study. Mutations do not appear to display identical interactome 
disturbances, indicating that changes in the interactome profiles may be specific, 
depending on the location of a given mutation. This result is the first evidence that 
protein interaction changes might illuminate which biological mechanisms are 
affected or the extent to which this happens. Of most note in the G70S mutation 
condition was an enhanced interaction with a cluster of ribosomal subunits (Figure 
3.9B), whilst in the D252H condition by far the most significant result was a log2 ~9-
fold decrease in the subunits of the eEF1B complex - EEF1B2, EEF1G, EEF1D and 
VARS, (Figure 3.9A). Additionally, a gain of interactions to a group of ribosomal 
subunits is seen, although, a smaller number than is seen for G70S.  
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Figure 3.9: Volcano plots show distribution changes of D252H (A) and G70S (B) 
mutations after MLR normalisations. Log2 fold change of each mutation compared 
to WT was plotted against the corresponding -log10 p-value. P-values were 
calculated using one t-test per protein with a 1% FDR correction for multiple 
testing. Proteins were defined as significant (green) when there was a log2 fold 
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change greater than 1 and p < 0.05. These proteins have been annotated with their 
respective gene names for identification. Non-significant proteins were identified in 
blue.  
MLR is probably over-conservative in its assessment of differential interactors, 
however the normalisation strategy managed to shift data towards a more normal 
distribution reducing the influence of background contaminants in the sample. 
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3.4.2 Interactome mapping differences resulting from mutations 
Whilst ‘top hits’ can be identified in investigations such as volcano plots, more 
subtle protein complex changes could be overlooked.  I further explored how 
interactions changed within the context of the eEF1A2 interactome.  Log2 fold 
changes for each mutation were mapped onto the interactome using a coloured scale 
to represent loss and gain of interaction. Figure 3.10A and B are the interactome 
disruptions for most-likely ratio normalised interactomes for eEF1A2D252H and 
eEF1A2G70S respectively.  
Figure 3.10B displays MLR normalisation induced changes to the eEF1A2 
interactome as a result of the G70S mutation. There is no significant difference in 
eEF1B subunit interactions in AP-MS between WT and G70S conditions. Validation 
experiments also show that there is no discernible difference between binding of WT 
and G70S to eEF1B subunits (Section 3.5.5). This casts some doubt on solely relying 
on the MLR normalisation technique to identify changes. I decided to compare 
changes resulting from both MLR and bait normalisation techniques. Examining 
changes mirrored in the two normalisation techniques is the most likely strategy for 
determining real proteins of interest. Log2 fold changes after bait normalisation were 
determined and mapped using a colour scale to the eEF1A2 interactome (Figure 
3.10C and 3.10D). Because of the bias towards increased interactions, a higher fold 
change score was set identifying a protein as having an increased interaction (see 
legends of Figure 3.10C and 3.10D). This allowed for an examination of the most 
extreme changes and increased the likelihood of finding clusters with meaningful 
differences. 
In Figure 3.10D the down-regulation of eEF1 subunits in cluster a is not present, 
but there is still an increase to all ribosomal subunits. Other clusters showing the 
same increased interaction pattern in both normalisation techniques, were clusters ‘h’ 
and ‘i’. Cluster ‘h’ demonstrated increased interaction to RNA binding proteins. GO 
terms associated with mRNA ‘i’ functional enrichment identified proteins associated 
with cofactors. Along with the enriched association to translation proteins, these 
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results provide insight into two molecular functions potentially impacted by the 
G70S mutation.  
Figure 3.10C expands upon the results of the most significantly different 
interactors resulting from D252H identified in Figure 3.9A. The clear loss of eEF1B 
subunits is apparent within the network (cluster ‘a’), however this phenomenon does 
not extend to the rest of the proteins in this cluster, which showed up-regulation. All 
proteins identified were associated with translation. The cluster is primarily 
composed of ribosomal subunits and translation initiation factors. The cluster is 
significantly enriched, and all subunits (excluding the eEF1B subunits) show the 
same increase in association, meaning it is likely that the D252H mutation influences 
interactions with the ribosome and translation initiation factors.  
As with G70S, two clusters which show the same pattern of increased binding in 
both normalisation strategies are clusters ‘h’ (RNA binding) and ‘i’ (co-factor 
binding). Because all 3 of these clusters show the same pattern of increased 
association in both mutations regardless of normalisation strategy, these results 
identify proteins of interest which are likely to be implicated in molecular 
dysfunction. Both normalisation strategies show an increase in binding in cluster ‘j’ 
in mutant D252H relative to WT. Functional enrichment analysis resulted in no 
identification of relevant GO terms (likely owing to the size of the cluster). Proteins 
included involved more ribosome associated proteins (RSL1D1, RRS1 and RBM28) 
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Figure 3.10: Colour mapping of Log2 fold changes of mutant versus WT LFQ 
intensities in AP-MS.  A, eEF1A2 interactome (MLR normalised) with colour 
mapping of log2 fold changes in the D252H conditions compared with WT. Because 
fold changes for the eEF1B subunits were so extreme, using a full range scale 
resulted in under amplification of more subtle changes in interaction. Therefore, the 
fold change scale was set between -3 to 3 (log2), this scale covered the fold change 
scores for all proteins excluding the eEF1B subunits, which are displayed as 
saturated (see Figure 3.4). B, eEF1A2 interactome (MLR normalised) with colour 
mapping of log2 fold changes in the G70S condition compared with WT. C, eEF1A2 
interactome (bait normalised) with colour mapping of log2 fold changes in the 
D252H condition compared with WT. Because fold changes for the eEF1B subunits 
were so extreme, using a full range scale resulted in under amplification of more 
subtle changes in interaction. Therefore, the fold change scale was set between -3.75 
to 3.75 (log2). This scale covered the fold change scores for all proteins excluding 
the eEF1B subunits, which are displayed as saturated. To reduce influence of data 
normalisation bias (discussed kin Section 3.5.1), a 1-fold (log2) score was set at 
minimum for identification as an increased interactor. D, eEF1A2 interactome (bait 
normalised) with colour mapping of log2 fold changes in G70S condition compared 
with WT. To reduce influence of data normalisation bias (discussed in Section 3.5.1). 
A 1.2-fold (log2) score was set as the minimum for identification of an increased 
interactor. 
In both instances, protein interactions which display the most dysregulation are 
associated with RNA regulation and protein synthesis. Critically, D252H shows 
altered protein interaction disruptions to eEF1B subunits, a binding disruption not 
seen in G70S. Altered interactions due to location of the mutation within the protein 
is the principle of Sahni and colleagues edgetic interactions theory (163). It is key to 
explore this discrepancy between mutations in greater detail, as it might underpin the 
variation in severity seen between cases (see Chapter 4).   
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3.4.3 Loss of binding to guanine cognate exchange factor 
By far the most significant result, regardless of normalisation strategy, was the 
loss of binding to eEF1B subunits in the D252H mutation but not G70S (Figure 
3.11B). eEF1B is composed of guanine exchange factors eEF1Bα and eEF1Bδ 
which are anchored by structural subunit eEF1Bγ. Valine tRNA synthetase (ValRs) 
is not a component of the eEF1B complex but is associated via an interaction with 
eEF1Bδ (Figure 3.11A) (85). All subunits were identified in the mass spectrometry 
and displayed a consistent pattern of interaction in each mutation (Figure 3.11B). 
Transiently transfected eEF1A2-V5 in a co-immunoprecipitation assay validated this 
finding (Figure 3.11C). All four subunits associated with eEF1B, show no signal in 
the eEF1A2D252H condition, despite equal expression of the proteins in the unbound 
(input) fraction, and the presence of eEF1A2-V5 in the bound (IP) fraction. As with 
the AP-MS, the eEF1A2G70S mutation displayed no difference in binding to any 
eEF1B subunits (Figure 3.11D). It also appears that WT eEF1A2 interacts with 
eEF1B subunits in a stoichiometric manner, as one WT sample shows less eEF1B 
subunit signal in response to less V5 (bait) staining. Taking stoichiometry into 
account is one of the key ways of identifying valid and important interactors within a 
mass spectrometry experiment (164). 
A loss of binding to its cognate guanine exchange factor would likely hinder 
eEF1A2 in GDP recycling and consequently impair protein synthesis. It seemed 
imperative to explore this discovery further. Possible loss of protein synthesis in the 
D252H mutation would indicate a loss-of-function mechanism. I therefore expanded 
upon these results (Chapter 4 and Chapter 5).  
For eEF1A2G70S, the most significant result was an increased interaction with 
ribosomal subunits compared to WT. This result was investigated further by testing 
these interactions using co-immunoprecipitation (Figure 3.11D). Co-
immunoprecipitation failed to find an interaction of eEF1A2-V5 with ribosomal 
subunits in any condition. This suggests that either the differential interactions 
identified in the AP-MS are false positives, or the interactions are too transient, weak 
or infrequent for co-immunoprecipitation to identify. It has been previously 
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established that eEF1A2 interacts with the ribosome (156,157).  It may be the case, 
however, that any interaction is not observable using co-immunoprecipitation. It may 
be of interest to examine changes to ribosome function as a consequence of the 
mutation eEF1A2G70S using an alternative method (such as ribosomal profiling). 
Given the negative co-immunoprecipitation results, I focussed my follow-up 
research on the loss of binding to the eEF1B complex in eEF1A2D252H. 
  
 
Chapter 3: eEF1A2 interactome analysis  Page | 102 
 
 
Figure 3.11: eEF1A2 mutations and their respective interactions with components 
of translation machinery. A, a schematic of the eEF1 complex, including eEF1A2, 
and the subunits (and associated proteins). B, the LFQ intensities of each subunit in 
WT and mutant eEF1A2 conditions. P-values were identified using one-way ANOVA 
per protein comparing WT, G70S and D252H mutations. Tests for all subunits 
reported a significant interaction: eEF1Bα F(2,5)=84.81, p<0.001, eEF1Bδ 
F(2,5)=191.9, p<1x10-4, eEF1Bγ F(2,5)=119.4, p < 1x10-4, VARS p<1x10-5. Post-
hoc analysis was performed using Tukey tests. ‘****’ refers to p<0.0001. C displays 
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the co-immunoprecipitation experiments in SH-SY5Y cells. eEF1A2-V5 was isolated 
using the V5 tag. Subunits were then probed for using western blot. Input fraction 
(1/8th concentration of IP loaded) is displayed on the left, with the IP fraction on the 
right. Subunits were probed for using protein-specific antibodies. eEF1A2-V5 bait 
was confirmed with V5 staining D demonstrates co-immunoprecipitation 
experiments to examine the interaction of eEF1A2-V5 and ribosomal subunits.  
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3.5 Discussion 
In this chapter, I examined the protein interaction network of eEF1A2 using 
affinity purification mass spectrometry. As the interactome of eEF1A2 had not 
previously been studied using this technique it was a useful tool for examining the 
possible functions of eEF1A2 and the effect specific mutations in eEF1A2 have on 
the interactome.  
3.5.1 The eEF1A2 interactome 
I used AP-MS to assess the protein interactions of eEF1A2. After background 
filtering, functional enrichment analysis was used to assess the make-up of the 
interactome. GO terms associated with eEF1A2 interactors were, in the main, 
associated with known functions of eEF1A2. Structural constituents of the ribosome 
and translation elongation factor subunits were identified, as would be expected. It 
has previously been established using the proximity ligation assay that eEF1A2 
binds to eEF1B subunits (71). It is also unsurprising that ribosomal associated GO 
terms are enriched. eEF1A2 has previously been found to co-complex with a number 
of ribosomal proteins (156).  
Principally, eEF1A2 interactors could be categorised as involved in catalytic 
activity, translation or protein binding. Whilst the first two could be attributed to its 
role in protein synthesis, it was worth examining the ‘binding’ category in more 
depth. In this category the majority of proteins are responsible for protein and 
nucleic acid binding. The nucleic acid binding term highlighted the number of RNA 
binding proteins eEF1A2 interacts with. It is unsurprising that eEF1A2 should co-
complex with so many proteins in this category, given its ability to bind to 
aminoacylated tRNAs. Not only is it associated with tRNA delivery, but it has also 
been identified as a component of RNA granules (165). eEF1A, more generally, has 
been identified as a constituent part of RNA granules in both axons (166) and 
dendrites (48,49).  Although the isoform is not specified in these publications, as the 
experiments are performed in developed neurons it is likely eEF1A2 is involved. 
RNA transporting granules are of particular importance in neurons, as RNA must be 
transported to distal parts of the neuron for rapid local protein synthesis.  
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The protein binding category contained proteins involved in cytoskeletal function. 
Actin bundling is one of the most discussed functions of eEF1A (29).  It is 
hypothesised that the differences in actin bundling properties is the reason for the 
conserved presence of two isoforms in vertebrates. Abbott et al argued that in 
terminally differentiated cells, where cytoskeleton may require a more stable 
cytoarchitecture. The isoform switch may occur to spare terminally differentiated 
cells, such as neurons, from the same actin bundling activity as in proliferating cells 
(21,28).  
AP-MS results isolated actin and several actin binding proteins (profilin, cofilin 
and destrin) from the eEF1A2-V5 complex. The experiment cannot determine 
whether this interaction represents an actin bundling property of eEF1A2, or whether 
there are differing actin bundling properties in eEF1A2 compared to eEF1A1. Actin 
and profilin concentrations have been shown to correlate with relative expression of 
eEF1A in maize endosperm. Suggesting there is a relationship between the proteins 
(167). If this is the case, eEF1A2 might share this interaction with eEF1A1.  
One interesting difference between the two isoforms is their reported differing 
interactions with Ca2+-calmodulin, and how this might influence the actin bundling 
properties of the proteins. Computationally it was predicted that amino acid variance 
between eEF1A1 and eEF1A2 would alter the flexibility of the putative calmodulin 
binding region Asn311-Gly327. Less flexibility of this region in eEF1A1 suggests it 
has an increased affinity for calmodulin than eEF1A2. These results were confirmed 
experimentally using ELISA analysis (168). Novosylna expanded on this research, 
confirming that eEF1A1 but not eEF1A2 results in interaction with Ca2+-calmodulin. 
The authors expanded upon this result, demonstrating that the interaction of eEF1A1 
with Ca2+-calmodulin blocked both its actin and tRNA binding sites, negatively 
influencing ability of eEF1A1 to bundle actin. The authors suggest that eEF1A1 and 
eEF1A2 have different Ca2+-modulated actin bundling properties (21). It is worth 
noting that in my AP-MS results, no evidence of calmodulin binding was found. My 
results, therefore, support the growing evidence that calmodulin interactions differ 
between isoforms, which may consequently mediate differences in actin bundling.  
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Overall, although specific protein interactions require validation, my results 
provide the first networked example of the eEF1A2 interactome. By clustering 
proteins using functional interaction scores, groups of proteins associated with 
canonical and some known non-canonical functions of eEF1A2 have been identified.   
3.5.2 Analysing changes in the interactome due to mutations 
My results identified protein interaction dysregulation in both the D252H and 
G70S mutations. These altered interactions were, however, not the same in both 
mutations. Sahni and colleagues studied edgotype disruptions resulting from 
missense mutations. They found mutation location to be the biggest predictor of 
how the edgotype would be disrupted (163). It is possible the differing level of 
severity in clinical cases is due to the varying locations of mutations in the protein. 
eEF1A2D252H is located within the eEF1B binding site, whilst eEF1A2G70S, although 
close to the binding site, is not. Most mutations on the surface of the protein cluster 
near sites of known functions of eEF1A2 (eEF1B and GTP binding). It was 
important to expand upon these results, to determine whether edgetic disruptions 
control clinical case severity. One caveat to be considered is the level of mosaicism 
in patients. In most cases, no mosaicism is detected, however the degree of 
mosaicism is not known for all patients and, if present, could greatly moderate the 
severity of any phenotype. Spatial analysis of mutations and how they might affect 
protein function is further examined in Chapter 4. It is interesting however, that 
preliminary experiments show a difference in interaction profiles, disruptions which 
can be directly correlated with location in the protein structure. This may serve as a 
useful predictor of eEF1B binding disruptions in other mutations. 
One differential interaction between mutations identified in the AP-MS 
experiment was the increased affinity for ribosomal subunits in eEF1A2G70S as 
compared with WT. This result was not reported to such an extent in the 
eEF1A2D252H condition. Upon validation with co-immunoprecipitation, no 
interaction with ribosomal subunits could be found in any IP fraction. It is well 
established that eEF1A2 delivers amino-acylated tRNAs to the ribosome in protein 
synthesis.  The exact nature of the interaction between eEF1A2 and the ribosome is 
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not fully elucidated, however. It is not known whether eEF1A2 interacts with the 
ribosome during tRNA delivery, or if eEF1A2 interacts with the ribosome in 
another capacity.  Given the negative co-immunoprecipitation results, it is entirely 
possible that these interactions were false positives.  It is also possible that the 
transience or weakness of these interactions makes studying the eEF1A2-ribosomal 
relationship impossible using co-immunoprecipitation.  Given that these results 
were not able to be validated, I focussed follow-up experiments on the functional 
impact of the loss of eEF1B in eEF1A2D252H.  
In artemia, it has been shown that the loss of eEF1B results in a 1000 fold 
decrease in spontaneous GDP release (69). The yeast eEF1B equivalent, EF-Tu, is 
required for proper protein synthesis. Mutation E122K (interestingly - the same 
amino acid residue as one of the reported clinical cases) leads to greater translational 
infidelity and growth deficits (169).  
Although less dependency on eEF1B is expected in the metazoan complex (23), 
loss of binding would still likely impact the ability of eEF1A2 to function in protein 
synthesis. Cao and colleagues found knocking down eEF1B subunits using siRNA 
did not impact cell growth or viability in the short term (71). However, due to the 
nature of the experiment, it was not possible to examine the long-term effects of 
these knockdowns. Furthermore, only one subunit was knocked down at a time, 
something which could potentially cause a less severe phenotype than loss of 
binding to all subunits.  
There is certainly clinical evidence to support the requirement of eEF1B function 
in neurons. Mutations in other eEF1B subunits (as discussed in Section 1.4.3) have 
been found in individuals with neurodevelopmental disorders (170). Unlike eEF1A2 
these mutations are homozygous, often the result of consanguineous parents. In 
eEF1Bδ mutation cases, reported mutations affect only the neuronal specific isoform 
(103). Whether this impacts just the heat-shock element or impacts global translation 
elongation rates is still under investigation. Recently Kaitsuka and colleagues 
demonstrated results to the contrary, suggesting the knock-out of the eEF1BδL 
isoform resulted in increased global translation as measured both by puromycin and 
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35S methionine labelling. However, the protein synthesis assays were not carried out 
on untreated mice, so background levels cannot be determined. My results in chapter 
5 suggest that larger samples of mice for protein synthesis measurements in vivo 
would be required to detect differences, with only 3 for each sample being presented 
by Kaitsuka and colleagues. Further study must be done to determine whether 
eEF1BδL plays a role in protein synthesis. The authors did argue that the loss of 
eEF1BδL resulted in phenotypic differences between WT and knock-out mice. It is 
possible therefore that the intellectual disability displayed in the terminating 
mutation of the long isoform is a result of disruption to heat shock response and not 
translational imbalance.  
A homozygous deletion in chromosome 2 which included half of the EEF1B2 
gene (gene encoding the eEF1Bα subunit) has been reported in a consanguineous 
family. Individuals present with a neurodevelopmental disorder including intellectual 
disability (102). It is surprising that such a homozygous deletion would be 
compatible with life and provides a suggestion that eEF1A can function partially 
without its cognate GEF. However, the individuals are still affected by the loss of the 
gene. Similarly, a recently reported mouse model with homozygous deletion in 
Eef1b2 resulted in a viable mouse model which presented with neurological deficits 
(http://www.mousephenotype.org/data/alleles/MGI:1929520/em1(IMPC)J). This 
evidence, in conjunction with the reports of mutations in EEF1D, suggests that 
impacting the function or interaction with eEF1B could impact upon neuronal 
protein synthesis rates. It would be interesting to determine whether this is because 
neurons have a higher homeostatic requirement for protein synthesis than other cell 
types, or because eEF1A2 relies upon the action of eEF1B more than eEF1A1. 
This is not the first evidence that disrupted protein synthesis would impact upon 
neurological function. Mutations in many other proteins associated with translation 
have been implicated in similar neuronal disorders. In some cases, like eEF1A2 and 
mutations in eEF1BδL these have been found in neuronal specific isoforms. 
However, this is not always the case. There are many cases of amino-acyl synthetase 
mutations which cause neurological disorders. An explanation for why these might 
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disproportionately affect neurons is provided in the introduction of this thesis 
(Section 1.4.3). 
If loss of binding to eEF1B causes impaired protein synthesis, then D252H 
mutation causes a functional null, in terms of canonical function at least. Another 
possibility is that all the mutations render the protein non-functional. The 
discrepancy between G70S and D252H interactome profiles implies that D252H but 
not G70S would result in protein synthesis disturbances. This should result in a more 
severe phenotype for the D252H mutation than the G70S, if the mutations were 
operating under a loss-of-function mechanism alone. This, however, appears not to 
be the case. There are two possible reasons for this; 1) all clinical mutations render 
eEF1A2 non-functional and therefore binding to the guanine exchange factor is 
irrelevant, 2) an additional or other function of the protein is impacted by mutations. 
This leads to the question do mutations simply act as loss of function mutations or is 
there an additional toxicity element?  
3.6 Conclusions 
AP-MS proved an insightful technique for establishing the interactome of 
eEF1A2. Comparison of WT and mutant forms of eEF1A2 demonstrated protein 
interaction disruptions in both G70S and D252H conditions. These disruptions were 
not uniform between mutants, supporting the edgetic perturbations theory proposed 
by Sahni et al. In D252H, binding analysis results, indicate that protein synthesis 
would be impacted.
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Chapter 4: Further analysis of interactome disruptions  
4.1 Introduction 
AP-MS analysis created a possible interaction network for eEF1A2 and enabled 
me to examine changes resulting from mutations (Chapter 3). The most significant 
finding demonstrated a loss of binding of mutant eEF1A2D252H to the subunits of 
cognate guanine exchange factor (GEF) eEF1B. Mutation eEF1A2G70S however, did 
not display the same interaction disruption. These findings were validated in vitro in 
SH-SY5Y cells by exogenous tagged IP-pulldown. Disruption of binding to the GEF 
would likely result in lower rates of GDP recycling, impacting upon the ability of the 
protein to perform protein synthesis. An assessment of the impact of mutation 
eEF1A2D252H on protein synthesis is examined in Chapter 5. The disparity between 
eEF1A2D252H and eEF1A2G70S interaction profiles suggests several possibilities. 1) 
As both D252H and G70S mutations result in a clinically severe phenotype, 
mutations render the protein non-functional. 2) eEF1B interaction is not required for 
efficient protein synthesis by eEF1A2, and an additional causal mechanism is 
responsible for the protein malfunction. 3) Mutations impact upon the proteins 
ability to perform protein synthesis, but this is not the only effect of mutations, 
meaning an additional gain-of-function, in combination with a loss-of-function 
mechanism is at play. I explored these possibilities further using both in vitro and in 
vivo experiments.  
Firstly, the interaction profile disparity of mutant forms of eEF1A2 was explored 
in greater detail. Computational analysis was performed to assess whether online 
tools could predict disruption in mutants. An array of mutations located throughout 
the protein were subsequently tested for interaction with eEF1B subunits to see if 
any pattern between interaction disruption and phenotype or amino acid localisation 
could be identified. 
Secondly, using Eef1a2D252H/D252H and Eef1a2-/- mouse models, an assessment of 
phenotype was performed. If the loss of binding to cognate guanine exchange factor 
eEF1B in the case of eEF1A2D252H led simply to a reduction in protein synthesis, 
then mice should demonstrate a partial or complete functional null phenotype. 
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However, a more severe phenotype in mutant mice than Eef1a2-/- would implicate an 
additional molecular consequence.  
These experiments were designed with the aim of further identifying the 
consequences of eEF1A2 missense mutations on neuronal function.  
4.2 Aims of chapter 
1) Identify whether interaction profiles can be predicted. 
2) Experimentally test eEF1B interactions with more eEF1A2 mutations. 
3) Assess the phenotype of Eef1a2D252H/D252H mice to see if it is consistent with a loss- 
or dominant negative/gain-of-function mechanism. 
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4.3 Determine interaction profiles of other mutants 
4.3.1 Computational analysis of interaction profiles of eEF1A2 mutations 
Given the disparity between D252H and G70S interactome profiles, I performed 
analysis of the relationship between eEF1B and other mutations in the eEF1A2 
protein. I wanted to ascertain if either D252H or G70S was an outlier in its 
interaction profile, or whether mutations could be grouped based on the relationship 
with interacting proteins. Initially predictive analysis of all mutations was 
implemented in several software prediction programmes. Given the array of 
mutations, experimental validation would be a labour intensive and costly task. 
Predictive analysis programmes claim to be a method of circumventing this 
experimental step, using calculations based on known interactors, changes in charge, 
structural alterations and internal bond disruptions. Many methods have been 
developed to use data and experimental knowledge to provide insight in to possible 
outcomes of mutations on binding (171). I used predictive analysis to see if 
consistency in predicted disruptions was found between different computational 
methods, and whether computational analysis would mirror experimental results, 
making it a good predictor for all mutations.  
Prediction software assessing protein interactions can rely on several different 
sources of information to assess potential disruptions. These include, but are not 
limited to, conservation of the gene, whole gene order, evolutionary relationship, 3D 
protein structure, domain information and primary protein structure (172). I chose 
three protein interaction tools to identify whether the predictions they gave would 
match experimental results. Table 4.1 shows results from software tools which 
assessed structure and interactions of eEF1A2 missense mutations. 
ELAPSIC is a computational pipeline which works to identify protein interaction 
disruptions by identifying the pfam domain boundaries of the protein, modelling 
domain-domain interactions and using this information to predict the energetic 
impact of mutation on a single domain or the affinity between two domains. The 
main output of the program is a predicted change in Gibb’s free energy (ΔΔG) of 
folding or binding for every domain affected by the mutation. This allows ELAPSIC 
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to predict whether changes are likely to affect interfaces responsible for protein 
interactions or the core stability of the protein (173). ELAPSIC analysis identified a 
cluster of mutations predicted to disrupt binding to eEF1B. These were grouped 
together and located near the eEF1B binding site. Although this would make sense, 
experimental results prove this prediction analysis to be incorrect. Results 3.4.2, 
show that contrary to the predictions of interactions with the G70S and D252H 
mutant forms of the protein (Table 4.1), the reverse is true. Section 4.2.2 provided 
further results which differ to computational findings. Mutations which demonstrate 
a reduction in eEF1B interaction in co-immunoprecipitation experiments have been 
highlighted in blue, whilst those which retain their interaction with the guanine 
exchange factor have been shown in red (Table 4.1). 
A second prediction software, BeAtMUsIC also calculates the change in binding 
free energy (ΔΔG) and predicts the effect on binding intensity changes (174). ΔΔG 
values were calculated for all mutations and resulting predictions made by the 
program are summarised in Table 4.1. In addition, BeAtMUsIC enables the user to 
calculate the potential binding disruptions of all amino acid residues in the protein. 
The top 25 mutations which resulted in the greatest increase and decrease in binding 
affinity were calculated. These have been reported in appendix B.1. I highlighted 
these residues on the protein structure using Chimera software (Figure 4.1).  
Many of the residue changes which resulted in the greatest increase or decrease in 
ΔΔG were where mutations occurred (Asp.252 and Ile.71). Furthermore, examining 
these residues on the 3D structure identifies that the most affected area is the 
‘conserved face’ (4.1A), where aminoacyl-tRNA and eEF1B interactions occur. The 
individual predictions about changes in affinity for each specific mutation do not 
agree with experimental findings, however (Table 4.1), with increases in affinity 
predicted in D252H and P333L. Although BeAtMUsic did not predict the binding 
affinity changes for mutations accurately, it did identify the area of the protein in 
which ΔΔG changes, as a result of mutations, would have the greatest impact. This 
area aligns with the location of many of the mutations, and key eEF1B interaction 
sites.  
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Figure 4.1: Structural modelling of eEF1A2 protein with the top changes in 
binding affinity demonstrated, as measured by BeAtMUsic (174). Green amino 
acids highlight the greatest increase in binding affinity. Red amino acids represent 
the greatest decrease in binding affinity. The 3D structure is rotated to demonstrate 
the ‘conserved face’ of the protein where amino-acyl tRNA and eEF1B binding 
occurs (A), the ‘variable face’ of the protein, where amino acids differ from eEF1A1 
(B) and the GTP binding site (C).  
A final interaction programme, MutaBind, was also used. This programme uses a 
combinatory approach to assess ΔΔG, including calculations on solvent accessibility, 
conservation score, changes to atomic forces and differences in unfolding free 
energy. Again, this prediction software was unable to accurately determine which 
mutations resulted in loss of eEF1B binding.  
Computational analysis software did not serve as an accurate predictor of whether 
mutations would interact with eEF1B. Instead, co-immunoprecipitation experiments 
were performed on a range of mutations. 
 
 
Table 4.1: Predicted binding interactions of eEF1A2 missense mutations. Mutations in bold and blue were identified significantly decreased 
eEF1B interactions in co-immunoprecipitation assays. Mutations in italics with red shading are proven to have no significant difference in 
eEF1B binding affinity.  






Interface Binding site 
affected 
H15D Core, eEF1Bα 0.15 0.68 Decrease No Ntox46 
G19R Core, eEF1Bδ, 
eEF1BδL 
0.93 1.38 Decrease No No binding site 
T24M Core -1.30 0.44 Increase No No binding site 
A65V Core 0.50 1.06 Decrease Yes eEF1Bα 
R69C eEF1Bα, eEF1Bδ, 
eEF1BδL 
2.02 -0.06 Decrease No eEF1Bα 
HBS1 
eRF3 
G70S Core, eEF1Bα, 
eEF1Bδ, eEF1BδL 
1.72 1.16 Decrease Yes No binding site 
I71L Core 0.33 1.03 Decrease Yes eEF1Bα 
D91N Core, eEF1Bα, 
eEF1Bδ, eEF1BδL 
-0.65 0.59 Increase No eEF1B 
A92T Core, eEF1Bα, 
eEF1Bδ, eEF1BδL 
-0.33 0.35 Increase No eEF1B 
 
 
D97N Core, eEF1Bα, 
eEF1Bδ, eEF1BδL 
-0.48 -0.31 Increase No eEF1Bα 
eRF3 
HBS1 




Decrease No eEF1Bα 
eEF1B 
eRF3 




Decrease No eEF1Bα 
eRF3 
eEF1B 




Decrease No eEF1Bα 
eRF3 
T104R Core 0.42 0.91 Decrease Yes eEF1Bα 
eRF3 
E122K Core -0.12 0.08 Increase No No binding site 
E124K Core -0.09 0.12 Increase No No binding site 
A125E Core 0.16 0.08 Decrease No No binding site 
E169K Core 0.15  Decrease   
D252H Core -1.26 0.39 Increase Yes No binding site 
R266W Core -0.40 0.99 Increase Yes No binding site 
G275R Core 0.90 0.57 Decrease No No binding site 
N314K Core 0.33 0.36 Decrease No No binding site 
P333L Core -0.08 0.25 Increase No No binding site 
R382H Core 0.02 -0.29 Decrease No No binding site 
G384R Core 0.66 0.98 Decrease No No binding site 
R423C Core 0.33 0.66 Decrease No No binding sites 
T432M Core -0.09 1.0 Increase Yes No binding sites 
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4.3.2 Defining the relationship with mutant eEF1A2 and eEF1B 
To assess the relationship between eEF1B and eEF1A2 mutants, co-
immunoprecipitation experiments were performed. This work was performed by 
Ningyuan Sun (a MSc student in the lab) and myself. I designed experiments, carried 
out cell culture and transfections, performed co-immunoprecipitation and western 
blot experiments for several subunits. Ningyuan Sun performed cell culture, 
transfections, co-immunoprecipitation and western blot experiments following my 
experimental design and instruction. Results are displayed collated together in Figure 
4.2. Owing to the low transfection efficiency of SH-SY5Y cells and the 
consequential high sample volume required, experiments were performed in 
HEK293T cells. HEK293T cells, unlike SH-SY5Y, do not express endogenous 
eEF1A2. However, both cell lines express all eEF1B subunits. HEK293T cells were 
easier to transfect, requiring less sample volume. To confirm that cell type did not 
influence the interactions between exogenous eEF1A2 and the eEF1B subunits, both 
D252H and G70S mutations were included to affirm their eEF1B relationship did 
not change. Co-immunoprecipitation analysis (Figure 4.2) confirms the same results 
for D252H and G70S in both HEK293T and SH-SY5Y cells, enabling me to be 
confident that the cellular background did not influence the relationship of eEF1B 
interactions with transfected eEF1A2. 
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Figure 4.2: Co-Immunoprecipitation of eEF1A2-V5 constructs expressed in 
HEK293T cells performed in biological triplicate. Staining for eEF1B subunits and 
eEF1A2-V5. A, IP fraction of pulldown and B input fraction (15% fraction of IP). C 
shows a separate experiment following the same design as above with IP and input 
fractions combined on the same blot. Experiments were performed in triplicate 
biological repeats (performed by Ningyuan Sun). D shows quantification of eEF1B 
subunit binding in A-C normalised to bait level (V5 staining) (for clarity, image of 
blots in C have been segmented, however all samples were run on the same gel and 
all images are of the same blot). Graph shows mean +/- SEM. As data was not 
parametric, results for each eEF1B subunit were subjected to Kruskil-Wallis testing, 
comparing the relative band intensities of mutant and WT conditions. Analysis 
predicted a significant interaction in all subunits (eEF1Bα; chi-squared =12.575, df 
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=7, p <0.05, eEF1Bδ; chi-squared =13.535, df = 7, p <0.05, eEF1Bγ; chi-squared 
=14.314,  df =7 , p<0.05). Post-hoc analysis was performed on all subunit data 
using the Dunn test; ‘*’ indicates p<0.05, ‘**’ p<0.02 and ‘***’ p<0.01 when 
compared with WT. A smaller experiment testing other eEF1A2 mutations in 
HEK293T cells only examined the interaction of mutant and WT eEF1A2 with 
subunit eEF1Bδ (E) (performed by Fiona McLachlan). Quantification for this and 
significance testing is provided in figure F (mean +/- SEM). This data met the 
parametric requirements and was subjected to ANOVA (F(6, 14) = 3.76847, p 
<0.02). Tukey post-hoc analysis was performed with ‘*’ representing p<0.05 
compared with WT. 
Results from experiments testing all subunits of the eEF1B complex (A-C) 
showed subunits interacted in the same pattern within each mutation. This gave me 
confidence to test a wider range of mutations, only probing for eEF1Bδ (E) and 
conclude that other subunits likely interact in a similar manner.  
Analysis revealed two clusters of mutations which mirrored the results of D252H 
and G70S. Mutations D252H, I71L, F98C and P333L all showed significantly lower 
interactions with eEF1B subunits (p<0.05) whereas all other mutations tested 
showed no significant difference when compared with WT binding intensities. No 
obvious differences in clinical phenotype could be identified between mutations with 
or without their eEF1B interaction. Two mutations – D252H and I71L – are both 
published and are reported to be severely impactful. Patients have severe intellectual 
disability and, in the case of D252H, autism. Care must be taken with autism 
diagnoses as they are more readily reported in some countries than others. Further, 
some cases are too severe for autism to be detected (129,176). Conversely, mutation 
F98C is reported to present with only intellectual disability and no seizures (141). 
There is very little clinical information known about this case, making it difficult to 
discern how much this mutation differs from D252H and I71L. More is known about 
mutation P333L. A published report detailed the case of 2 homozygous children who 
passed away before aged 3. The children presented with severe epilepsy and 
intellectual disability. As a homozygous case, this mutation is severe. However, both 
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parents (i.e. the heterozygous cases) do not present with severe phenotypes. It is 
reported that the father “was unable to make eye contact and would smile 
inappropriately during medical encounters” but no official diagnosis of a 
neurodevelopmental disorder was reported. Three other children between the father 
and another woman were reported to exhibit significant speech delay, but genotype 
was not determined (122). In heterozygous cases, P333L appears to be a very mild 
mutation as compared to D252H and I71L. No link between clinical symptoms or 
severity and the loss of binding to eEF1B can be discerned. Similarly, some of the 
mutations which retain binding to eEF1B are severely affected. Mutation G70S is 
more severely affected than D252H. R423C has been published reporting severe 
seizures and developmental delay (123).  
As no correlation was seen between mutation eEF1B interaction and clinical 
severity, the loss of eEF1B binding proposes several hypotheses. 1) eEF1A2 can 
function independently of its guanine exchange factor in protein synthesis, making 
this binding disruption obsolete. 2) The protein is a functional null in all cases. 3) 
There are elements of loss-of-function and gain-of-function mechanism which result 
from mutations, with the additional toxic effect enough to cause clinical symptoms.  
To see if the 3D structure of eEF1A2 predicted the relationship between eEF1B 
and eEF1A2 for respective mutations, mutations were plotted with eEF1B and GTP 
binding sites (Figure 4.3). Most mutations cluster around sites associated with 
specific functions. Mutations P333L, D252H, I71L and F98C all lie close to, or are 
residues involved in eEF1B binding. Although this suggests that spatial location of 
mutations would be a good predictor of eEF1B interaction disruption, there are 
several mutations near the same binding site residues which do not demonstrate the 
same disruption. For example, G70S and I71L show opposing eEF1B relationships 
despite being consecutive amino acids. In addition, proximity to binding site residues 
does not completely predict severity of clinical cases. E122K is one of the most 
severe cases and the mutation lies within the GTP binding site. However, E124K 
(whilst not in the GTP binding site) demonstrates a drastically less severe phenotype, 
despite being only 2 residues away. 
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Although mapping the location of mutations on the 3D structure of the protein 
provides information which at times agrees with experimental data, and location of 
mutation in relation to binding sites might influence interaction profile, it is not the 
case in every instance.  
 
Figure 4.3: Spatial representation of mutations on eEF1A2 protein. Mutations 
(red) were plotted on the eEF1A2 protein structure, along with eEF1B (blue) and 
GTP binding sites (yellow). Mutations which resulted in loss of binding have been 
italicised and underlined. Unaffected mutations remain in normal text.  
Overall computational analysis was not insightful in predicting protein interaction 
changes. Experimental testing revealed a cluster of mutations which lost binding to 
eEF1B. No discernible clinical presentation or severity could be gleaned from 
comparing these mutations. Secondly, spatial analysis did not completely reveal a 
distinct connection between location of mutations and prediction of interaction 
disruptions.  
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4.3.3 Summary of eEF1A2 mutation interactomes 
Expanding upon the interaction analysis of D252H and G70S in Chapter 3, a 
group of eEF1A2 mutations with disrupted interactions to eEF1B were found. 
Despite this, no discernible clustering could be made to sort mutations by 
relationship to eEF1B. One possibility for these differing interactions is all mutant 
forms of eEF1A2 are non-functional, not performing protein synthesis – in essence, 
acting as null proteins. Phenotype testing to answer this hypothesis is reported in 
Section 4.3.   
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4.4 Assessing the phenotype of Eef1a2 mutant mice  
4.4.1 Summary of the Eef1a2/wst mouse line 
The use of mouse models to explore the function of eEF1A2 began when a 
spontaneous deletion of a genetic region which included the EEF1A2 promoter 
occurred in Jackson laboratory mice. The deletion resulted in a loss of expression of 
eEF1A2. Breeding of this mouse to develop a mouse line (termed Eef1a2/wst in this 
thesis), resulted in homozygote null mice. Eef1a2-/- mice develop normally until p21 
when eEF1A1 down-regulation in terminally differentiated cells begins; death occurs 
before p28. eEF1A1 expression is undetectable in neurons and muscle after p24. 
This down-regulation is accompanied with a muscle tremors, gait abnormalities, 
ataxia and weight loss in the mice. Pathology shows muscular atrophy, and spinal 
cord and brainstem motor nuclei neurodegeneration (56). This homozygote mouse 
was well-established as a loss-of-function model for eEF1A2.  
4.4.2 Generation of Eef1a2/D252H and Eef1a2/del22ex3 mice using 
CRISPR/cas9 
To examine the phenotypic effects of mutations, the Abbott lab used 
CRISPR/Cas9 genetic editing to create Eef1a2/D252H, Eef1a2/del22ex3 and 
Eef1a2/G70S mice. The generation of the Eef1a2/G70S mouse line resulted in the 
creation of several Eef1a2G70S/- mice and one Eef1a2G70S/G70S homozygote. This round 
of CRISPR yielded no Eef1a2G70S/+ animals which would have reflected the human 
phenotype and would likely have led to a less severe phenotype, which might have 
established a breeding colony. Nonetheless, we gleaned useful information from this 
line which has been published previously (140). Eef1a2/D252H and 
Eef1a2/del22ex3 lines were designed and generated by Faith Davies. Line 
maintenance, genotyping and phenotyping analysis was performed by Faith Davies, 
Jilly Hope, Francis Nunez, Laura Dumont and myself. Figure 4.4 shows the 
information related to the generation of the Eef1a2/D252H and Eef1a2/del22ex3 
mice including an example restriction digest results of genotypes (A & C) and 
example western blot analysis examining eEF1A2 expression (B & D). 
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Figure 4.4: DNA and protein characterisation of Eef1a2D252H and Eef1a2-/- mouse 
lines. Example genotyping restriction digest (A) and protein expression analysis (B) 
for Eef1a2D252H mouse lines. A, Hin1II restriction digest of PCR product resulted in 
digestion of a WT band into 330bp and 112bp bands, and D252H product into a 
202bp and 128bp band. A heterozygous mouse therefore shows a combination of 
both digest fragments. B, Western Blot analysis of eEF1A2 expression and total 
protein concentration shows bands in all mutant Eef1a2D252H skeletal muscle mouse 
samples. WT liver and -/- mouse muscle are both added as negative controls to 
confirm specificity of the eEF1A2 antibody. C, representative genotype analysis of 
del22ex3 mouse line. A 22bp deletion results in a smaller PCR fragment being 
generated (186bp) than WT (208bp). Heterozygote mice, again, show both PCR 
products. Western blot analysis shows complete ablation of eEF1A2 expression in 
skeletal muscle despite equal total protein concentrations (D).  
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Of most note, D252H homozygote mice and D252H/+ heterozygote mice express 
eEF1A2. Western blot analysis of del22ex3 line (4.4D) also shows the complete 
ablation of eEF1A2 expression resulting from the deletion. More extensive analysis 
of protein and RNA expression of eEF1A2 in Eef1a2/D252H and Eef1a2/del22ex3 
lines was performed by Jilly Hope as part of her doctoral thesis (121).  
4.4.3 Phenotypic Analysis of Eef1a2/D252H and Eef1a2/del22ex3 lines 
The aim of characterising the phenotype of these mouse lines was to provide a 
comparison of severity between the eEF1A2D252H mutation and the complete loss of 
eEF1A2 (Eef1a2/del22ex3). If the phenotype was indistinguishable, it would suggest 
that the D252H mutation operated through a loss-of-function mechanism. By 
comparing Eef1a2/D252H and Eef1a2/del22ex3 lines (which were generated in the 
same CRISPR/Cas9 experiment in a C57/BL6 mouse), genetic background was 
controlled for. To assess phenotype severity, measurements of gait, hind-limb 
clasping, ledge balance and kyphosis were taken on a daily basis (142). In addition, 
the weight of each mouse was measured. Scores and weights for all genotypes in the 
Eef1a2/D252H and Eef1a2/del22ex3 lines were collated, compared and are 
displayed in Figure 4.5. 
Assessment of the Eef1a2/del22ex3 line demonstrated a similar reported 
phenotype to that of the Eef1a2/wst line. Homozygote mice demonstrate no 
significant difference in phenotype severity or weight before p19 and p23 
respectively (4.5C and G). The difference in phenotype severity also significantly 
increases in homozygotes compared to WT and +/- mice as days progress, 
suggesting a steady decline in health. This reported phenotype corresponds with the 
known information about the down-regulation of eEF1A1 in muscle and neurons. As 
with Eef1a2/wst line, heterozygous mice appear unaffected by deletion and are not 
significantly different from WT littermates in phenotype or weight profile.  
In contrast to Eef1a2/del22ex3 mice, D252H/D252H mice show a significant 
difference from WT littermates substantially earlier in development (4.5B & F). 
Homozygotes weigh significantly less than WT littermates from p14, a difference 
which increases substantially over time (F). Mice also demonstrate a significantly 
 
Chapter 4: Further analysis of interactome disruptions Page | 127 
more severe phenotype from p16 (B) – 3 days earlier than the Eef1a2/del22ex3 mice. 
In addition, D252H/+ mice show a weight deficit as compared to WT mice. This 
begins at p14, just as with homozygote littermates. Unlike homozygote littermates, 
which fail to show an increase in weight during the period, heterozygous mice show 
a weight increase throughout development. Nevertheless, on each postnatal day 
heterozygous Eef1a2/D252H mice show a significant reduction in weight as 
compared with WT littermates (F). 
The differences between the two mouse lines was directly compared by 
examining the weight and phenotype scores for Eef1a2-/- and Eef1a2D252H/D252H mice 
(D&H). D252H/D252H mice display a significantly more severe phenotype than -/- 
mice at several points throughout the postnatal testing window (D). This difference 
increases with age of the mice. Additionally, D252H mice show a significantly 
reduced weight at several points in the testing period compared to null mice (H). 
Unlike homozygote mice which show normal weight gain until p23, D252H mice 
fail to gain weight throughout the testing period.  
The testing period was ceased at p23 as it was deemed necessary to cull 
Eef1a2D252H/D252H mice. After the testing period, it is of note that Eef1a2-/- mice show 
a rapid increase in phenotype severity and weight loss. They then die ~p26, a little 
earlier than the Eef1a2/wst mice. 
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Figure 4.5: Phenotypic and weight analysis of Eef1a2/D252H and 
Eef1a2/del22ex3 mouse lines. Analysis scoring severity of mouse phenotype was 
performed by experimenters (Faith Davies, Laura Dumont and Fiona McLachlan) 
who were blinded to genotype. Severity assessments for all lines are plotted in A. A 
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two-way mixed ANOVA with Tukey post-hoc analysis of all genotypes on each 
postnatal day was performed. ANOVA was found to have a significant interaction 
(F(35,712) = 13.70, p<0.001). Both postnatal day and genotype were deemed 
significantly responsible for this (Genotype; F(5, 721) = 6.140, p<0.0001,  Postnatal 
Day; F((7, 712), p<0.0001). Weights were taken for mice on each postnatal day. 
Two-way mixed ANOVA testing identified a significant interaction (F(45, 1150) = 
3.864, p<0.0001). Both age (F(9, 1150) = 34.40, p<0.001) and genotype (F(5, 1150) 
= 100.5, p <0.0001) were responsible for this. Tukey post-hoc tests elucidated 
significant differences between genotypes on each day for both weight and 
phenotype severity. ‘****’, ‘####’ or ‘++++’, p<0.0001, ‘***’, ‘###’ or ‘+++’, 
p<0.001, ‘**’, ‘##’ or ‘++’ p<0.01 and ‘*’, ‘#’ or ‘+’ p<0.05). ‘*’ reflects a 
significant difference between Eef1a2D252H/D252H and WT littermates, or, Eef1a2-/- 
mice and WT littermates. ‘+’ reflects a significant difference between Eef1a2D252H/+ 
and WT littermates, ‘#’ reflects a significant difference between Eef1a2D252H/D252H 
and Eef1a2-/- mice.  
4.4.4 Summary of Eef1a2 mouse line phenotyping 
Given the differences between null and D252H homozygotes, it is clear that the 
D252H mutation does not operate solely through a loss of function mechanism. After 
the down-regulation of eEF1A1 (~p21), both Eef1a2D252H/D252H and Eef1a2-/- mice 
health decline, however the deficit is clearly noticeable in D252H/D252H mice prior 
to the eEF1A1 down-regulation. This suggests an additional element of toxicity to 
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4.5 Discussion 
4.5.1 Expanded edgotyping analysis for an array of mutants in eEF1A2  
Given the disparate interaction profiles with eEF1B between mutations G70S and 
D252H tested in Chapter 3, it was imperative to explore how this difference would 
be reflected in other mutations. I wanted to expand upon these results and find out if 
the relationship with eEF1B correlated with severity of clinical presentation. 
There is a wealth of structural analysis programmes available which use 
information on the location of a mutation in relation to functional domains, the 
charge of the substituted amino acid, and location in the 3D structure of the protein 
to calculate changes in binding energy (ΔΔG) which result from mutations. Given 
the ease of using these programmes, and the potential benefit of predictive analysis, I 
investigated whether computational prediction programmes would aid in classifying 
mutant proteins. Results from computational software and co-immunoprecipitation 
experiments were opposing, reporting many interactions as disrupted in mutants 
where no statistically significant difference was reported in either AP-mass 
spectrometry or co-immunoprecipitation. Computational predictions have proven to 
be insightful in the past, but my interaction analysis shows that in this case they do 
not predict results which agree with experimental data. The disparity between 
computational and experimental protein interaction analysis has been reported 
previously (177). Given this disparity, experimentally validating interactions with 
eEF1B in eEF1A2 mutants appears the most reliable course of action.  
Structural analysis of all residues in the protein did identify that amino acids with 
the greatest changes in ΔΔG were associated around the ‘face’ of eEF1A2 – where 
eEF1B and aminoacyl-tRNA bind. Many mutations are located at or close to 
residues with the greatest ΔΔG. Clusters of likely pathogenic mutations can be 
identified by using ΔΔG energy modelling changes (178), and it would appear 
eEF1A2 fits with this phenomenon.   
A brief review of clinical presentations was summarised in results Chapter 4.2.2. 
No association between severity and eEF1B affinity could be found. Subtle 
phenotypic differences would almost certainly be missed given the small sample 
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size, the limited clinical information and the possibility of undetected mosaicism. 
However, this initial overview with a small sample size does not suggest any 
obvious correlations.  
The loss of eEF1B subunits in a cluster of mutations was identified in both the 
AP-mass spec results and co-immunoprecipitation experiments. The potential 
consequences of such disruptions are of significant interest and have been discussed 
further both in Chapters 3 and 5. 
My results show that there is interaction profile variation from different mutations 
located throughout a single protein. Given the extreme variance in clinical severity 
reported within mutations, it was interesting to explore if mutation location within 
the protein, and resulting interaction differences, could be a factor influencing 
phenotypic severity. Differing phenotypes resulting from similar or identical 
mutations is widely reported (variable expressivity) (179). Variable expressivity is 
reported in a family presenting with autism caused by microdeletions in the MBD5 
and NRXN1 genes (180). There are several mechanisms which can control 
phenotype severity. As mentioned previously, varying levels of mosaicism within 
patients with de novo mutations is likely to be a contributing factor which has not 
fully been accounted for. Genetic background will obviously be a contributing 
factor.  Genetic background was found to be the driving force behind phenotypic 
variability in a mouse model of del22q11 syndrome (181). In patients of mendelian 
disorders genetic background and modifier genes are reported to play a significant 
role in phenotypic variability (182,183). Interestingly, Vu and colleagues explored 
identical genetic mutations in different strains of c. elegans to determine which 
genes were more susceptible to phenotypic variation. Their results showed that genes 
involved in protein synthesis and RNA binding were most likely to produce variable 
results in different genetic strains (184). Given these results, it is important to 
consider that the heterogenous background of individuals will have an influence. 
Another explanation for phenotypic variance in coding variants is alternative splicing 
(185). This is less likely to be a contributing factor as no alternative splice forms of 
eEF1A2 are known. Epigenetics is reported to play a role (186) and cannot be 
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excluded in our case. This work, however, supports the growing body of evidence to 
suggest that spatial location of the mutation can impact protein-interaction 
differences between mutants (150,151,163), resulting in phenotypic variation. 
Although no discernible clinical difference can be identified between mutant groups, 
more work and a greater sample size may unpick subtler differences.  
4.5.2 Gain-of-function element of D252H mutation identified using 
phenotypic analysis of Eef1a2D252H mouse line  
Interactome results for the D252H mutation suggested that the most substantial 
interaction changes (loss of eEF1B binding) would result in impaired protein 
synthesis and a loss-of-function mechanism. The phenotypic severity and weight 
gain of mutant (Eef1a2-/- and Eef1a2D252H/D252H) mice and their heterozygous and WT 
littermates was tested. Comparing a D252H with a null expression mouse line 
provided a key piece of evidence in evaluating the effect of missense mutations on 
eEF1A2 function. If, as interaction analysis had predicted, eEF1A2D252H simply 
resulted in a non-functional protein, Eef1a2D252H/D252H mice should be phenotypically 
indistinguishable from Eef1a2-/- mice. Both weight and severity scoring proved this 
not to be the case. Having the eEF1A2D252H mutation resulted in a gain-of-function 
or dominant negative element. This result agrees with reported structural analysis of 
eEF1A2 mutations. Mutations operating through loss-of-function mechanism are 
more likely to affect the structure of the protein, resulting in degradation and 
haploinsufficiency. Conversely, dominant negative or gain-of-function mutations are 
more likely to cluster around surface areas critical to protein function. 
Haploinsufficiency mutations can also cluster at critical domains, but this occurs less 
frequently than in gain-of-function mutations (187). eEF1A2 mutations are generally 
clustered with functional domains. Further, expression analysis in both in vivo 
(Section 4.3.1), in vitro (Section 5) and Hope (2018) (121) demonstrate that mutation 
eEF1A2D252H is expressed at levels similar to WT. eEF1A2G70S has also been shown 
to be expressed at concentrations not significantly different from WT (140). The 
mutations, therefore, do not cause structural disorganisation which results in 
complete protein degradation. Although the selected prediction software could not 
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accurately predict binding interaction disruptions resulting from specific mutations, 
structural analysis of the protein and mutation locations supports a gain-of-function 
or dominant negative mechanism.  
Reported mutations are all heterozygous (except for the P333L homozygous 
lethal cases), which means that if mutations rendered proteins non-functional, 
haploinsufficiency would be responsible for the neurodevelopmental clinical 
presentation. Eef1a2+/wst mice do not display any form of the neurodegenerative 
phenotype seen in homozygotes, proving that haploinsufficiency does not result in 
the same neuronal degeneration. In the Eef1a2/D252H line, however, Eef1a2D252H/+ 
mice do show significant differences from WT littermates. Although no difference in 
severity is witnessed, D252H/+ mice show a weight gain deficit as compared with 
WT mice. No such deficit is seen in +/wst mice, suggesting a difference in 
mechanism. This means that the protein must have, at least in part, an additional 
element of toxicity, causing neurodevelopmental/neurodegenerative damage. 
Most reported gain-of-function mutations associated with epilepsy are 
channelopathies (188). Increased channel activity causes an imbalance in ionic influx 
and efflux, affecting the electrophysiological properties of neurons and resulting in 
seizures (189,190). Other neurodevelopmental disorders including intellectual 
disability have reported gain-of-function mutations as well (191,192). Gain-of-
function mutations have also been reported in relation to protein synthesis. RNA 
binding protein FUS was reported in association with frontotemporal dementia 
(FTD). Gain-of-function mutations reportedly drive disease by causing up-regulation 
of the stress response resulting in suppression of axonal protein synthesis and 
resulting in neuronal death (193).  
The unknown toxicity element which exacerbates mutant phenotype is unlikely 
the only consequence of the D252H mutation. Once eEF1A1 is completely down-
regulated in both Eef1a2-/- and Eef1a2D252H/D252H mice, both mouse lines present with 
a similar neurodegenerative phenotype resulting in death. Therefore, when there is 
no compensatory elongation factor, eEF1A2D252H is unable to sustain appropriate 
levels of protein synthesis. Consequently, mutations likely operate through gain and 
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loss-of-function mechanisms. Other combinatory loss- and gain-of-function 
mechanisms have been reported in neuronal dysfunction. Mutations in the TDP-43 
gene demonstrated both a loss of canonical function and a toxicity which resulted in 
cytotoxic aggregations partly responsible for driving the disease in motor neurons 
(194).  
4.5.3 Summary and conclusions 
AP-MS was a highly insightful tool for identifying eEF1B interactions as 
disrupted in some mutations. Although no identifiable differences could be gleaned 
from the mutations based on their eEF1B interaction, this grouping should be studied 
in greater detail once more clinical cases and a greater depth of clinical information 
is reported. It is possible that subtle phenotypic differences could be reported 
between groups once confounding variables such as mosaicism are accounted for. 
Although the most significant result from mass spectrometry and co-
immunoprecipitation experiments suggested a loss-of-function, phenotypic analysis 
of CRISPR generated Eef1a2D252H mice suggests an additional gain-of-function or 
dominant negative element. I decided to follow up on the functional impacts of 
protein interaction disruptions by examining protein synthesis. The functional 
consequences of mutations is explored in Chapter 5. 
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Chapter 5: Functional implications for interaction disruptions in eEF1A2 
missense mutations 
5.1 Introduction 
The results of Chapter 3 and 4 provide two conclusions and suggest several other 
possible hypotheses. Firstly, there is a class of mutations which result in significant 
loss of interaction to eEF1B. Although no correlation between this eEF1B 
interaction and clinical characteristics could be identified, it was by far the most 
significant disruption and was therefore important to follow up. Secondly, 
phenotypic analysis of the Eef1a2D252H mouse line clearly shows, that in addition to a 
loss of function mechanism, mutations also operate through a gain of function/toxic 
element. Given the reported consequences of disrupted protein synthesis in neurons, 
and the clear non-functional element of the protein it was important to test the impact 
of the mutations on protein synthesis. Mutations in genes responsible for mRNA 
metabolism and protein synthesis predispose to neurodevelopmental disorders (195)  
Therefore, I carried extensive optimisation of protein synthesis experiments. I 
hypothesised that the loss of eEF1B interaction would result in reduced protein 
synthesis in Eef1a2D252H mice and eEF1A2D252H neurons.  
5.1.1 Aims of chapter 
1) Generate and characterise mutant eEF1A2 LUHMES lines for functional assays. 
2) To establish whether global protein synthesis is impacted by eEF1A2 mutations in 
vitro and in vivo. 
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5.2 Generation and characterisation of mutant eEF1A2 LUHMES cell lines 
5.2.1 Previous experimental results from eEF1A2D252H CRISPR/Cas9  
LUHMES cells are an immortalised neuronal precursor cell line, genetically 
edited to include the tetracycline system. This biological switch enables the 
differentiation of cells into dopaminergic neurons (137). The advantage of these cells 
over IPSCs is a shorter differentiation time and substantially lower cost. As all 
immortalised cells express eEF1A1, even when they would not in vivo, it was 
imperative to see if protein synthesis deficits would be detectable in LUHMES cells 
despite this confound. Pilot experiments to introduce eEF1A2D252H/D252H and 
eEF1A2-/- mutations into LUHMES cells were performed by Faith Davies as part of 
her doctoral thesis (141). Faith successfully generated one eEF1A2D252H/D252H and 
one eEF1A2-/- cell line. Owing to the limited sample availability, I created a greater 
number of cell lines to assess whether eEF1A2 mutations could result in a disrupted 
phenotype. 
5.2.2 Generation of eEF1A2 mutant LUHMES cell lines 
I aimed to generate LUHMES cell lines containing both eEF1A2G70S and 
eEF1A2D252H mutations. Figure 5.1A displays a schematic representation of genetic 
loci targeted in each CRISPR/Cas9 experiment. CRISPR/Cas9 was performed by Dr 
Faith Davies and myself. I was responsible for experimental design (jointly with Dr 
Faith Davies), gRNA cloning, genotyping, sequencing, RNA and protein expression 
analysis.  
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Figure 5.1: Induction of eEF1A2 mutations in LUHMES cells using 
CRISPR/Cas9. A, schematic representation of the EEF1A2 gene exons with location 
of point mutations indicated above. Mutation p.G70S is in exon 3, whilst p.D252H is 
in exon 5. B and C schematic diagrams demonstrating the CRISPR/Cas9 targeting to 
induce missense mutations G70S and D252H respectively. The DNA sequence shown 
is the repair template in each instance. gRNA guide sequences are highlighted in 
yellow with adjacent PAM sites highlighted in green. Mutations are highlighted in 
orange and base pair changes to induce silent mutations in the repair template are 
highlighted in blue. PCR exon 3 (D) and 5 (E) in LUHMES lines which had 
undergone CRISPR/Cas9 genetic editing.  PCR amplification of genomic DNA 
around the cut site was performed. PCR was used to establish genetic modification, 
and an initial assessment of whether lines were polyclonal. PCR amplification in D 
resulted in a 816bp fragment in the WT allele. E resulted in a 409bp product in the 
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Table 5.1 summarises the sequencing and TOPO cloning of lines obtained from 
CRISPR genetic modification. A full alignment of sequencing results for each line is 
reported in appendix C.1.  
Table 5.1: Results of CRISPR/cas9 experiments in neuronal cell line LUHMES. 
Attempts to generate G70S mutation (experiment 1) and D252H (experiment 2) 
created cell lines of varied genotypes. These were identified using sequencing and 
TOPO cloning of PCR fragments.  
Cell line name Genotype 
Allele 1 Allele 2 
2.5 27 bp deletion 200 bp deletion 














125 bp deletion 
2.18 WT WT 
 
Two rounds of CRISPR were performed, firstly in exon 3 to target amino acid 
p.Glu70. This failed to yield any Glu70Ser missense mutations but did succeed in 
generating eEF1A2 -/- and +/- lines. The second round of CRISPR targeted exon 5 to 
generate the Asp252His mutation. D252H was successfully introduced in two lines, 
one homozygote and one D252H/null. LUHMES lines were characterised in 
preparation of functional analysis. Figure 5.2 shows a schematic representation of 
the genetic editing which occurred in LUHMES clonal lines. 
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Figure 5.2: Schematic diagram of LUHMES lines generated through 
CRISPR/Cas9 experiments. Shown are exons of eEF1A2 with deletions (red dotted 
line), random missense mutations (blue rectangle) and targeted missense mutations 
(blue triangles).   
5.2.3 Protein expression of LUHMES clones 
All immortalised cell lines express eEF1A1, even when this would be down-
regulated in vivo. As there is no commercial antibody which can differentiate the two 
eEF1A isoforms in cells using western blot, I stained for eEF1A (which could be 
either or both isoforms) in all lines. I tested eEF1A expression in all LUHMES cell 
lines both in a proliferative and differentiated state. Protein expression in 
proliferative extracts varied greatly, making quantification unreliable. Bands could 
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be seen in all conditions, as expected, given that the antibody detects both isoforms 
of the protein.  
 
Differentiated protein extracts displayed more consistent total protein. Owing to 
low concentration of some samples, two protein extractions were performed (C and 
D). For quantification and analysis, the two blots were normalised to the same WT 
sample. A significant reduction of eEF1A expression in lines 2.5 and 2.8 could be 
seen when compared with WT CRISPR line 2.18. However, no significance between 
potential null lines and WT LUHMES was detected. eEF1A2D252H/D252H line 2.13 did 
not show significantly different expression of eEF1A as compared to WT. This is in 
agreement with the in vivo results showing that mutant D252H eEF1A2 protein is 
expressed and therefore relatively stable.  
 
Expression of eEF1A in LUHMES cells had been previously tested by Faith 
Davies and showed a significant reduction of eEF1A staining in eEF1A2-/-, but not 
eEF1A2D252H/D252H cells (1). As eEF1A1 is expressed in immortalised cells at a much 
greater concentration (~1000 fold) than eEF1A2, it was determined that protein 
analysis to detect significant levels of eEF1A2 was not reliable. To verify the 
concentration of eEF1A2 in LUHMES clones, I examined eEF1A2 mRNA. 
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Figure 5.3:  eEF1A expression in LUHMES cells. A, shows the eEF1A expression 
of LUHMES lines in a proliferative state. The resulting quantification of normalised 
eEF1A expression is shown in B. The expression of eEF1A in differentiated 
LUHMES clones is shown in C and D. Quantification of this is presented in E. 
ANOVA analysis for differentiated LUHMES clones indicated a significant 
interaction (F(5, 15)=4.16, p<0.05. Tukey post-hoc analysis was performed and is 
indicated on the graph, with ‘*’ reflecting p<0.05.  
5.2.4 RNA expression of LUHMES clones 
As protein expression was inconclusive, I analysed RNA in order to see if 
mutations affected steady state eEF1A2 mRNA levels. GeNorm analysis performed 
to determine which housekeeping genes should be used for normalisation. Two 
housekeeping genes (TOP1 and RPL34) were selected. The melt curves and standard 
curves for these and eEF1A2 PCR reactions are in appendix C.2. A summary of 
RNA normalised expression values is provided in Figure 5.4A. 
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Because mutations had been engineered in different exons of the gene, I elected to 
perform a qPCR analysis on all lines by amplifying an area of exon 7-8 of eEF1A2 
mRNA. This would not be affected by the location of any of the mutations I had 
made, and would allow an equivalent assessment of eEF1A2 mRNA expression in 
all lines. The results of the qPCR analysis are displayed in Figure 5.4A. A significant 
reduction in eEF1A2 mRNA was seen in proliferative cells in null lines 2.5 and 2.8 
as compared to WT lines. 2.16 also showed a significant reduction with nearly no 
expression of eEF1A2 mRNA. Differentiated cell lines demonstrated no significant 
difference. 2.5 (-/-) differentiated mRNA appeared to show a reduction in mRNA but 
this did not achieve significance, perhaps owing to the low n number.  
As it was important to establish mRNA concentrations of eEF1A2 in 
differentiated cell lines, further analysis was performed. To assess mRNA 
concentrations around the mutation site, RT-PCR was performed. In the case of exon 
3 this was because the deletion in one allele in 2.5 line was so big (200bp), that any 
PCR spanning the deletion would be too large for qPCR analysis in an intact allele 
(B). Quantification of the results confirmed a significant reduction in eEF1A2 
mRNA in line 2.5(-/-) as compared to both WT and 2.18 (WT), suggesting the line is 
a null (C).  
In both qPCR and RT-PCR analysis no significant difference between line 2.13 
(D252H/D252H) and WT was seen in either the proliferative or differentiated state. 
2.16 shows a significant reduction in qPCR in the proliferative state (A). Given the 
drastic up-regulation of eEF1A2 mRNA in the differentiated cells and the presence 
of bands in the RT-PCR (B), it is likely that the PCR simply failed in some 
biological replicates in the proliferative qPCR.  
 
Results confirm that lines 2.5 (-/-) and 2.8 (-/-) showed significantly down-
regulated eEF1A2 mRNA based on analysis both at the mutation site and further 
down-stream. D252H mutations did not result in a genetic null, with lines expressing 
mRNA at the same concentration as WT.  
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Figure 5.4: Analysis of eEF1A2 mRNA in LUHMES cell lines. A, All LUHMES 
cell lines had RNA extracted and cDNA synthesised (2-3 biological repeats per 
genotype). After GENORM analysis for appropriate housekeeping gene selection, 
genes eEF1A2 mRNA was amplified using primers spanning the exon 7 – exon 8 
junction. mRNA was normalised to housekeeping genes TOP1 and RPL34. Graph 
shows mean +/- SEM. One-way ANOVA analysis was performed on all lines. 
ANOVA demonstrated significant difference in levels of eEF1A2 mRNA F(12, 14) = 
6.922, p<0.001.  As only one biological replicate for each negative control was 
performed these were excluded from ANOVA analysis. B, RT-PCR of LUHMES 
differentiated samples at exon 3. RT-PCR of exon 3 generated an 310bp fragment. 
Housekeeping gene TOP1 was amplified to create a 224bp fragment. Normalised 
exon 3 samples were quantified (C) and an ANOVA analysis was performed. ANOVA 
indicated a significant interaction F(4, 6)= 4.22, p<0.05. Tukey post-hoc testing was 
performed for all ANOVAs. Significance values are displayed on graphs. ‘*’ p<0.05, 
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5.3 Protein synthesis measurements in in vitro and in vivo conditions with 
mutant and loss of eEF1A2 
Protein synthesis assays were conducted using a variety of methods in vitro, as 
well as in vivo. One technique reported recently was puromycylation, or the 
‘SUnSET’ technique (196). This technique takes advantage of the amino-nucleoside 
properties of the antibiotic puromycin. At high concentrations the drug blocks 
nascent polypeptide chains and inhibits protein synthesis. At lower concentrations, 
however, puromycin is incorporated into nascent polypeptide chains. The use of a 
monoclonal puromycin antibody can then be applied to protein extracts/fixed 
samples to assess nascent polypeptide synthesis.    
An alternative technique, AHA-click chemistry, was also used to assess protein 
synthesis. This technique uses fluorescent labelling, with a greater similarity to the 
classic radioactive metabolic labelling techniques used for protein synthesis 
measurements. In a methionine free environment, an amino acid analogue of 
methionine is incorporated into polypeptide chains. As this was not possible in vivo, 
this technique was used on LUHMES cell lines. 
I hypothesised that loss of binding to guanine exchange factor eEF1B in mutation 
eEF1A2D252H would impair protein synthesis. This was tested both in vivo and in 
vitro, comparing WT, eEF1A2D252H and null LUHMES cells and Eef1a2 mutant 
mice for protein synthesis disruptions. 
5.3.1 Puromycylation of proliferative LUHMES cell lines  
Initial experiments were performed in proliferative LUHMES cells to assess the 
effectiveness of puromycylation as a measure of nascent protein synthesis. Results 
demonstrated a significant reduction in nascent protein synthesis in line 2.13 
(D252H/D252H) compared to WT cells (A and B). The same significance was not 
achieved when examining WT and null line 2.5 (C and D). Whilst this was a 
potentially interesting result, agreeing with the gain-of-function element discovered 
in phenotype analysis reported in Chapter 4, the method appeared crude and would 
likely produce variation in repeats. I therefore decided to optimise the 
puromycylation experiments for greater sensitivity. 
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Figure 5.5: SUnSET assay in proliferative LUHMES cells to assess nascent 
protein synthesis. Initial assays were run to assess whether puromycylation would 
be an appropriate measure of protein synthesis in LUHMES cells. A, shows the 
relative signal intensity of puromycin incorporated into nascent proteins with the 
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total protein loaded into the experiment as a control. Positive control cells were pre-
treated with 150µM cycloheximide (CHX) to inhibit protein synthesis. This and the 
negative control vehicle condition are displayed along with D252H and WT 
LUHMES lines.  A quantification of relative puromycin signal intensity (normalised 
to the total protein signal for each repeat) is provided in B. One-way ANOVA 
analysis reported a significant interaction F(3,12)=3.45, p<0.05. Tukey post hoc 
analysis was used to explore significant differences. The notation system for this is 
described below. A second experiment comparing eEF1A2 WT and null cell lines 
was performed as is shown in C. As above puromycin signal intensity, and total 
protein staining for WT, null and control conditions. The normalised puromycin 
signal intensity is reported in D. One-way ANOVA analysis reported a significant 
interaction, F(3,11)=3.657, p<0.05. Tukey post-hoc testing was performed for both 
experiments. Significant differences are marked on the respective graph. ‘*’ p<0.05, 
‘**’ p<0.01 and ‘***’ p<0.001. 
5.3.2 Immunostaining of puromycin treated LUHMES cells 
Whole lysate analysis was a highly variable and crude method which did not yield 
reproducible results (Section 5.2.3). Other papers have reported using the 
puromycylation technique coupled with immunocytochemistry (193,197).  I decided 
to visualise the distribution of protein synthesis in differentiated LUHMES cells. In 
addition to providing an increase in sensitivity, this technique enables visualisation 
of protein synthesis distribution. The principal behind this theory was to see if 
differences in axonal/synaptic or somatic synthesis could be examined between 
genotypes. The staining from four biological repeat experiments is reflected in 
Figure 5.6 (A-I).  
Staining of puromycin identified that cell bodies produced a signal intensity far 
greater than in the neuropil. This agrees with the expected distribution of protein 
synthesis in neurons, the vast majority of which would be performed in the soma. 
Images have therefore been presented at two different contrast intensities for 
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Figure 5.6: Puromycin treatment to assess nascent protein synthesis in 
differentiated LUHMES cell lines. A-H, are representative images taken from 
LUHMES cell lines as follows (WT, WT + Cycloheximide, WT + vehicle treated, 
2.13 (D252H/D252H), 2.18 (WT which had undergone CRISPR), 2.5 (-/-), 2.8(-/-) 
and no primary control (WT cells). Images are shown both separated into channels 
and as a merged acquisition. As protein synthesis was far more prominent in the cell 
body, two different exposures were used to image cell body and axons. In each case, 
a portion of the imaged axons is shown at the higher exposure. This portion is 
identified by a white box on the merged image. Quantification of the signal intensity 
in cell bodies in all technical repeats is shown in I. Each point represents a cell body 
which was quantified. Quantification of puromycin signal in the neuropil in each 
condition was also measured. Technical replicates are shown in J as described 
previously.  The technical replicates of cell body measurements (between 3 and 5 for 
each genotype) were averaged, plotted and statistical analysis performed using a 
one-way ANOVA (no primary and vehicle conditions were excluded from statistical 
analysis) (K). One-way ANOVA demonstrated significant interaction (F(5, 17) = 
9.299, p<0.001). The mean and SEM of signal intensity in the neuropil for each 
genotype is reported in L. One-way ANOVA analysis determined a significant 
interaction (F(5, 14) = 5.403, p<0.01).  Post-hoc Tukey multiple comparison testing 
was used in both cases to determine significant differences between conditions. 
Significance is denoted by ‘*’ symbol. ‘*’ p<0.05, ‘**’ p<0.01, ‘***’ p<0.001..  
The treatment of cells with cycloheximide prior to puromycin administration 
produced significantly lower levels of nascent protein synthesis as compared to all 
LUHMES cell lines (excluding 2.8(-/-)), validating the experiment (Figure 5.6K).  
Comparison of technical repeats for both cell body and neuropil demonstrated 
reasonable clustering within genotypes. No significant difference was found between 
technical repeats in all genotypes.  
In both neuropil and cell body measurements, no significant difference could be 
seen between any lines and WT. In cell body quantification, 2.18 (WT CRISPR) was 
seen to be significantly increased compared to 2.8 (-/-). However, it was not different 
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from other null line 2.5, and WT cells did not achieve the same significance. In 
neuropil examinations, 2.13 (D252H/D252H) showed an increased protein synthesis 
rate compared with 2.8, likely suggesting the LUHMES cell line 2.8 shows lower 
protein synthesis than other lines and suggests the driving force behind changes in 
protein synthesis is clonal variability.  
There is no significant difference between WT and line 2.13. It is possible that 
with more lines we may be able to conclude that there is no difference between 
D252H neurons and WT in terms of protein synthesis capacity. This result, however, 
is at odds with the preliminary results produced in 5.3.1. Given the clonal variability 
and discrepancy between methods of puromycylation, results suggest that LUHMES 
cells are not a viable model for measuring protein synthesis. This is likely owing to a 
mixture of the presence of eEF1A1 and clonal variability.    
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5.3.3 AHA click-it chemistry of LUHMES cell lines 
Click-it chemistry experiments were performed in conjunction of puromycylation 
to ascertain if clones behaved in a similar manner using a different technique. This 
technique mirrored the more traditional radioactive labelling measurements but used 
a fluorescent analogue of methionine. As cycloheximide had not totally ablated 
protein synthesis signal in 5.3.2, I opted to use an alternative protein synthesis 
inhibitor, anisomycin. Compared with WT LUHMES cells, anisomycin and other 
negative control conditions showed a significant reduction in fluorescence intensity 
(5.5 A-C). 
In this assay reduction in nascent protein synthesis between D252H/- line 2.16 
and WT was observed. However, the deficit between WT and line 2.8 which had 
been seen in puromycin staining (5.3.2) was not reproduced. In addition to clonal 
variability, LUHMES cells may also show variability in protein synthesis levels 
based on experimental conditions. Taking all results together, it seems that 
LUHMES cells are not an appropriate model for testing protein synthesis as a result 
of eEF1A2 mutations/deletions. 
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Figure 5.7: Click-IT AHA metabolic labelling to detect protein synthesis in 
differentiated LUHMES cells. Using methionine analogue AHA, the Click-IT 
protein synthesis kit (Invitrogen) assesses nascent protein synthesis using a 
fluorescent reporter system. Fluorescence as a measure of protein synthesis was 
imaged using the FITC channel (488/519 excitation/emission). Cell number was 
controlled by staining for nuclei using Hoescht. Images for each condition are 
represented in A and B. After background correction in each channel click—it signal 
was normalised to respective Hoescht signal. The resulting levels of nascent protein 
synthesis are represented in C (mean +/- SEM). For control conditions n = 3 and for 
genotype lines n = 10-14. One-way ANOVA analysis demonstrated a significant 
interaction (F(6, 34) = 4.683, p<0.01. Tukey post hoc analysis was performed to 
assess which conditions significantly different. ‘*’ represents p<0.05, ‘**’ p<0.01. 
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5.3.4 In vivo puromycylation to assess protein synthesis rates in Eef1a2D252H and 
Eef1a2-/- mouse lines 
As LUHMES cells were not a viable model to measure protein synthesis, attempts 
to assess protein synthesis were made in vivo. Puromycin can be administered at a 
very low dose to mice for a 30-minute period before tissue is collected and measured 
for puromycin signal intensity. As puromycin cannot pass the blood brain barrier, I 
tested skeletal muscle, as a representative tissue that exclusively expresses eEF1A2. 
To maximise the chance of detecting a deficit, I chose to test mice with severe 
phenotypic deficits and after the down-regulation of eEF1A1 (p21). 
Initial experiments treated Eef1a2/D252H and Eef1a2/wst lines at p21-p24 when 
mice were available. Testing of these samples however determined that mice treated 
on different days were not comparable, with variation between treatments on 
different days making conclusions impossible. I was therefore only able to test a 
cohort of mice all born within one day of each other and had no control over the 
genotype distribution of samples. By chance, several large litters from 
Eef1a2/D252H and Eef1a2/wst were born within one day of each other. These were 
all tested at p22 / p23. Only one of the mice was a D252H homozygote.  
Figure 5.8 shows puromycin signal intensity and total protein staining in skeletal 
muscle of mice (5.6A). Testing Eef1a2 null mice provided a validation of the 
technique. eEF1A1 is down-regulated in skeletal muscle by p21 (56) and with no 
eEF1A2 to compensate, the mice would be expected to show a reduction in  protein 
synthesis. 
No significant difference between Eef1a2-/- mice was seen in comparison with 
heterozygous littermates. No significant difference is seen between WT and 
heterozygous mice from Eef1a2/D252H line either. Mice show a total down-
regulation of eEF1A1 in muscle at p21 and are normally culled due to severity at p24 
for Eef1a2/D252H and p26-p27 for Eef1a2/wst mice. Given this narrow time-
window for testing, the in vivo SUnSET technique did not appear to be compatible 
with our model. Even when small cohorts of littermates are tested at the same time, 
no observable differences in puromycin signal intensity are seen. This is perhaps 
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owing to the sample numbers, but my results cast doubt as to whether the technique 
measures protein synthesis accurately.   
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Figure 5.8: In vivo measurements of nascent polypeptide synthesis using 
puromycin administration. Skeletal muscle extracts from mice from Eef1a2/wst and 
Eef1a2/D252H lines treated with 0.04µmols/kg puromycin for 30 minutes. 
Puromycin staining is seen in A. eEF1A2 and total protein staining are below. 
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Quantification has been reported in B. Graph shows mean of normalised puromycin 
staining +/- SEM. One-way ANOVA analysis reported a significant interaction F(6, 
9)=10.69, p<0.01. Tukey post hoc analysis was performed to assess which 
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5.4 Discussion 
5.4.1 Generation and characterisation of mutant eEF1A2 LUHMES cell lines  
I aimed to generate both G70S and D252H mutations in CRISPR/Cas9 cells for 
functional testing.  Although CRISPR/Cas9 activity was efficient and demonstrated 
genetic editing in nearly all lines, the number of surviving clones was limited, giving 
a smaller number of biological repeats than would be ideal for larger experiments. 
This is likely owing to the high mortality rate and low transfection efficiency of 
LUHMES cells during transfection. The optimal LUHMES transfection method, 
reported by Shah et al, was followed during the experiment (139). However, even 
with this optimisation, neuronal cell lines are renowned for being difficult to 
transfect and even using the optimised method, Shah et al only reported a 25-30% 
incorporation of CRISPR/Cas9 guides. As I aimed to test if LUHMES cells were a 
viable model, I continued with a smaller number of clonal lines. However, if 
LUHMES cells had been proven to be a viable model for testing protein synthesis, a 
larger number of clones would be required for conclusive testing. 
The repair template including the D252H mutation was successfully incorporated 
in to two cell lines – 2.13 (D252H/D252H) and 2.16 (D252H/-). In contrast, the 
G70S experiment failed to yield homology directed repair and incorporation of the 
G70S mutation. One notable difference between the G70S and D252H repair 
templates was the incorporation of silent mutations into the PAM sites of the D252H 
repair template. This likely prevented further cutting of the PAM sites by gRNAs 
without affecting the protein coding sequence, enabling more efficient homology 
directed repair.  
mRNA testing demonstrated a down-regulation of eEF1A2 mRNA in 2.5 (-/-) and 
2.8 (-/-) cell lines, highlighting successful knock-down of eEF1A2 at the mRNA 
level. However, despite this, eEF1A2 mRNA and eEF1A protein concentration 
varied between different clones. Most notably, 2.18 (WT) showed a significant up-
regulation of eEF1A2 mRNA compared to null clones at exon 7 when WT clones 
did not. Given there is no genetic difference between WT and 2.18 (WT) lines, the 
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variability in eEF1A2 mRNA may well be the driving force behind the clonal 
variation seen in protein synthesis assays.  
Clonal variability has been reported in neuronal cell lines previously (198). If 
LUHMES cells were to be used in the future to assess impact of eEF1A2 deletions 
and missense mutations, an experimental design measuring basal levels and response 
to treatment/change in condition would likely be the most appropriate strategy.  
5.4.2 Protein synthesis assays  
Local protein synthesis impairments in axons and dendrites are sufficient to 
mediate neurological deficits (199). Fragile X syndrome (FXS) has been implicated 
as a result of local protein synthesis deficits in both dendrites and axons (200,201). 
Given the function of eEF1A2 in neurons and my interaction results, it was 
imperative to test global and local protein synthesis changes resulting from 
eEF1A2D252H and eEF1A2-/- mutations. 
Several techniques are available for measuring protein synthesis. Two of the most 
utilised are metabolic labelling and puromycin tagging (202). These were both used 
in vitro and puromycylation was additionally used in vivo. In differentiated 
LUHMES cells, I used imaging-based methods of these treatments to enable the 
assessment of protein synthesis in both the neuropil and cell body. Neither technique 
managed to find a deficit in D252H neurons globally. Additionally, puromycin 
tagging revealed no deficit in neuropil puromycin staining. Although puromycin 
staining was reduced in one eEF1A2-/- line (2.8), this can likely be attributed to 
clonal variability, as line 2.5(-/-) did not share this deficit. It is very possible that the 
techniques were not sensitive enough to measure any deficit changes with so much 
eEF1A1 expressed and likely enabling normal protein synthesis. As all immortalised 
cells, even differentiated neuronal iPSCs produce eEF1A1, these results support the 
idea that measuring protein synthesis deficits as a result of eEF1A2 mutations and 
deletions is not possible in vitro.  
Given the impossibility of measuring protein synthesis in vitro in our case, I 
looked at in vivo options. Several papers have reported using the puromycylation 
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technique in vivo, by treating mice with low doses of puromycin. This technique has 
been reported to successfully work in skeletal muscle (143) and cardiac muscle 
(203), both tissues expressing eEF1A2. On samples available for testing 
simultaneously, no deficit could be seen between genotypes from within the 
respective Eef1a2/D252H and Eef1a2/wst littermates. Given the high chance of a 
protein synthesis deficit in Eef1a2-/- muscle, my results throw in to question the 
accuracy of SUnSET using western blotting. 
 A recent study looked at protein synthesis rates in patient derived fibroblasts 
from FXS patients and determined a subset of individuals in which protein synthesis 
was increased compared to controls. The authors argued that this subset may respond 
to translational inhibition treatment, but that the variability in protein synthesis 
explains why other FXS individuals do not respond to the same treatment (204). This 
result would make biological sense given that FXS patients have reduced FMRP 
protein and consequently have a reduction in protein synthesis inhibition. However, 
the authors fail to identify what method they used for classifying FXS individuals 
into ‘high’ and ‘low’ protein synthesis groups. No testing was performed confirming 
that these ‘high’ and ‘low’ patient groups are statistically different from one another. 
Furthermore, the technical repeats shown suggested that the difference between 
‘high’ and ‘low’ protein synthesis groups was mediated by technical repeat 
variability in the ‘high’ condition. The authors also demonstrate that this variation in 
protein synthesis rates between patients did not correlate with FMRP levels, 
suggesting this variance comes from a different source. This evidence lends credence 
to my theory that western blotting lysate of puromycin samples is too variable and 
crude a method between technical repeats and cannot detect subtle levels of changes 
in protein synthesis.   
Another, albeit slim, possibility is that cells in Eef1a2-/- and Eef1a2D252H/D252H 
mice have undergone energy starvation due to dysregulation of protein synthesis. It 
has been reported that energy starved cells are not suitable for use in SUnSET 
experiments (205). 
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It is also possible that deficits in protein synthesis would be more noticeable in 
neurons than skeletal muscle. Wider research based around my results supports this 
hypothesis. D252H mutation results in a lack of eEF1B binding. eEF1B deletions in 
humans and mice show a neuronal specific phenotype. Deletion of an Eef1b2 exon 
knocks-out eEF1Bα expression in homozygous mice. These mice are reported to 
show neurological deficits 
(http://www.mousephenotype.org/data/alleles/MGI:1929520/em1(IMPC)J). A 
recessive deletion of part of the EEF1B2 gene was reported in a pair of siblings from 
consanguineous parents. These patients were reported to have intellectual disability 
(102). This suggests eEF1B is not required for protein synthesis in all but higher 
neuronal function. Given this evidence, the D252H mutation may impact more upon 
protein synthesis in neurons than in muscle.  
Puromycin cannot pass the blood brain barrier, making subcutaneous 
administration impossible for testing neurons. Brain slices can be treated ex vivo 
with puromycin, however I decided against this, as brain contains a high level of 
glial cells which express eEF1A1 and would influence results (although 
immunofluorescence of fixed slices may overcome this). Another possibility is to 
measure puromycin incorporation in sciatic nerves. Successful staining of puromycin 
incorporation in sciatic nerves has been demonstrated by Lopez-Erauskin and 
colleagues (193). Given these approaches do not involve radiation, they should be 
examined as possibilities in the first instance. It might, however, be the case that 
measuring protein synthesis through radioisotope labelling is required for measuring 
deficits. This treatment can be applied to brain slices to measure protein synthesis 
rates (206), but as with ex vivo administration of puromycin, glial cells expressing 
eEF1A1 would be a confound.  
In conclusion, I believe the immunostaining of puromycin treated in vivo neuronal 
samples (sciatic nerve or brain slices) is likely to provide the best technique for 
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5.4.3 Conclusions  
LUHMES cells were successfully genetically modified to induce null and 
eEF1A2D252H mutations. Although null cells demonstrated a knock-down of eEF1A2 
mRNA, levels of eEF1A protein varied between clonal lines. This was likely the 
driving factor in clonal variability in LUHMES lines. No discernible difference in 
protein synthesis could be measured by puromycin incorporation in vivo in 
Eef1a2/D252H or Eef1a2/wst mouse lines.
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Chapter 6: Discussion 
6.1 Project Summary 
Recent exome sequencing has identified heterozygous de novo missense 
mutations in eEF1A2 which result in epilepsy, autism and intellectual disability. This 
project aimed to expand upon the role of these mutations in causing 
neurodevelopmental dysregulation. By examining the protein-protein interactions of 
WT and mutant eEF1A2, protein clusters associated with canonical and non-
canonical eEF1A2 functions were identified. Changes to this protein interaction 
network map as a result of specific mutations eEF1A2D252H and eEF1A2G70S were 
assessed. 
The D252H mutation demonstrated a loss of binding to guanine exchange factor 
eEF1B. eEF1B mediates the GDP recycling after eEF1A delivers aminoacyl tRNAs 
to the ribosome. It is unclear the extent to which eEF1A2 relies upon eEF1B for 
GDP recycling versus levels of spontaneous GDP release. siRNA experiments 
knocking down eEF1B subunits showed no deficit in cell growth in the short term 
(71). However, eEF1A2 has a greater affinity for GDP than eEF1A1 (19), suggesting 
spontaneous release rates would be lower. Additionally, clinical mutations and 
knock-out mouse models support the theory that eEF1B is required for healthy 
neuronal function (72,102,103). Whilst the extent to which eEF1A1 and eEF1A2 
rely on eEF1B still needs to be fully elucidated, these results would suggest the 
protein interaction is required, at least in neurons, for proper functioning. 
The G70S mutation did not display loss of eEF1B binding. If the relationship with 
eEF1B mediated clinical severity, it would be hypothesised that the D252H mutation 
would be more severe than the G70S. Indeed, the opposite appears to be the case. 
Clinical reports demonstrate that all G70S patients develop early onset severe 
epilepsy, whilst the D252H cases do not report seizures until later in childhood. 
Given the number of patients this evidence is speculative, however it is an interesting 
observation. The results from the AP-MS experiment were validated and expanded 
upon by testing other mutant forms of eEF1A2 for interaction to eEF1B. Clusters of 
mutations which did and did not lose eEF1B binding were identified using co-
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immunoprecipitation. More cases and clinical information would be required to see 
if a difference in severity/phenotype can be seen between these groups based on their 
eEF1B interaction. As interaction analysis implicated protein synthesis as possibly 
dysregulated in neurons, translation assays were optimised in vivo and in vitro to 
assess the impact of the D252H mutation on eEF1A2 canonical function. These 
protein synthesis experiments did not provide a conclusive result.  
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6.2 Aim 1: Protein interactome analysis of eEF1A2 
This chapter aimed to establish the protein-protein interactions of eEF1A2 and 
how they varied when eEF1A2 was mutated. Any loss or gain of binding might 
elucidate a loss or gain of function and reveal the molecular mechanism underlying 
different mutations. 
Interactome analysis of eEF1A2 generated a protein network with clusters of 
proteins involved in previously reported functions of eEF1A2. This thesis is the first 
work to examine the interactome of eEF1A2 using AP-MS.  
After appropriate normalisation of the AP-MS data, dysregulation in binding to 
eEF1B subunits in the D252H, but not G70S, mutation was identified. The 
consequences of this altered interaction have been discussed extensively throughout 
this thesis, and the functional consequence was subsequently tested using protein 
synthesis assays. Further exploration of this finding seems vital to elucidate the role 
of specific mutations in the function of eEF1A2. Given the clinical reports of 
neurodevelopmental disorders arising from mutations in other eEF1B subunits, and 
the neuronal specific phenotypes displayed by eEF1Bα and eEF1BδL knock-out 
mice, recent evidence for the role of eEF1B suggests it is not essential in all but 
neuronal cells (72,102–105). Given this finding, it would be likely that disruption to 
eEF1B interaction in the D252H mutation would be more problematic in neurons 
than other cell types (i.e. skeletal and cardiac muscle). It was therefore imperative to 
assess the impact of eEF1A2 clinical mutations on protein synthesis. 
Another result from the AP-MS analysis was the disruption of interactions with 
ribosomal subunits in both mutant forms compared to WT eEF1A2. Co-
immunoprecipitation experiments failed to pull down ribosomal subunits, despite 
extensive testing, suggesting these interactions are too transient for co-
immunoprecipitation. Other papers have reported successful immunoprecipitation 
experiments of ribosomal subunits (207). Dysregulation in ribosomal homeostasis 
has long been implicated in a range of clinical disorders – often with surprisingly 
specific phenotypes (208). Ribosomes are, unsurprisingly, critical for growth and 
maintenance in neurons. Impairments in ribosomal biogenesis in neurons lead to 
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translational inhibition, stress granule formation and neuronal outgrowth deficits 
(209). Given it has been previously established that eEF1A2 interacts with 
ribosomes (156,157), dysregulation of these interactions could compound any 
protein synthesis deficits resulting from eEF1A2 mutations. If mutations led to 
inappropriate interaction with the ribosome, this might even lead to 'stalling' of 
ribosomes which are prevented from functioning normally. If this was occurring 
prior to eEF1A1 down-regulation in Eef1a2D252H/D252H, ribosomal stalling might 
impair eEF1A1 from performing sufficient translation elongation and could possibly 
be the cause for the gain-of-function element seen in D252H/D252H mice prior to 
p21. Indeed, ribosomal stalling was proven to be a contributing factor in similar 
neurodevelopmental disorder fragile X syndrome (FXS). Research shows that RNA-
binding protein fragile X mental retardation protein (FMRP) binds to RNA and is 
transported to the ribosome. At the ribosome FMRP binds to ribosomal subunit 
RPL5 and prevents the interaction of other translational machinery with the 
ribosome. This action induces ribosome stalling and inhibits protein synthesis. This 
mechanism occurs under normal physiological conditions as a measure of controlling 
protein synthesis rates (99). In the case of FXS a 5'UTR 'CGG' expansion repeat 
results in loss of FMRP expression. Without FMRP to mediate ribosome stalling and 
control levels of protein synthesis, an excess of translation creates a homeostatic 
imbalance and consequently neurodevelopmental difficulties (210). Although in this 
instance, the consequence is an increase in protein synthesis, it is conceivable the 
reverse is happening in the case of eEF1A2. Research on protein synthesis deficits in 
neurodevelopmental disorders has previously shown that mutations resulting in 
either increases or  decreases in synaptic protein synthesis result in a similar 
neurodevelopmental phenotype (211). If time constraints had not been an issue in the 
project, proximity ligation assay, assessing mutations and their effect on ribosomal 
subunits using a 'Ribosomal P' antibody and ribosomal profiling would have been 
insightful. 
RNA binding proteins also showed an increased association with eEF1A2 in 
mutant conditions compared to WT. Again, my co-immunoprecipitation experiments 
for these proteins were inconclusive, likely because these RNA binding proteins are 
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associated with eEF1A2 at a much lower concentration than that of translation factor 
subunits. RNA binding proteins are critical to neuronal homeostasis, by regulating 
processes such as mRNA transport in axons and dendrites, RNA editing and local 
protein synthesis (212). Under stress-induced translational arrest, mRNA is freed 
from disassembled polysomes and interacts with RNA binding proteins in aggregates 
termed stress granules (SGs). SGs then trigger global translational silencing to help 
mediate cellular stress  (213). RNA and associated binding proteins have been 
implicated in several neurodevelopmental, degenerative and psychiatric conditions, 
including FXS and FTD-ALS (212). Research on eEF1A and stress granules has 
focussed on eEF1A1. The cell type used in experiments (HeLa cells) does not 
express the eEF1A2 isoform, making it possible to conclude that the antibody is only 
detecting eEF1A1. Evidence suggests that the isoform does not associate with SGs 
during a translational inhibition stress response (214). It would be interesting to 
expand upon this research by examining if eEF1A2 associates with SGs during the 
cellular stress response and if this changes with mutant forms of the protein.  
Interactome analysis, while not entirely conclusive in determining the mechanism 
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6.3 Aim 2: Further analysis of protein interactions and the mechanism behind 
mutations 
The aim of this chapter was to expand on the disruption of eEF1B binding result 
identified in the D252H but not G70S mutation and to examine if Eef1a2D252H/D252H 
mice demonstrated a loss of function mechanism which would correlate with eEF1B 
binding disruption.  
 
Eef1a2/del22ex3 and Eef1a2/D252H mouse lines were compared to assess 
whether the eEF1A2D252H mutation resulted in a different phenotype from null mice. 
Eef1a2D252H/D252H mice exhibited an initially more severe phenotype than Eef1a2-/- 
mice. After the ablation of eEF1A1 expression both lines quickly succumb to a 
neurodegenerative phenotype which results in death. This rapid decline in the 
homozygotes from both lines suggests that eEF1A2D252H cannot compensate for WT 
eEF1A2, resulting in a loss-of-function mechanism. However before eEF1A1 down-
regulation, mutant eEF1A2D252H exerts an additional gain-of-function or dominant 
negative mechanism.  
 
One crucial question to ask is, do all mutations operate in the same manner as 
D252H? Given that protein interaction results vary between mutations, it is almost 
certain that mutations operate through different mechanisms. It appears from my 
results that in vitro analysis of mutations may not be able to identify functional 
deficits (owing to the confounding presence of eEF1A1 in cell lines). Therefore in 
vivo research may be required to determine the answer to this question. The only 
other mutant Eef1a2 model generated by our lab was the Eef1a2/G70S mouse line 
which failed to generate any founder mice for breeding. Only one homozygote G70S 
mouse was created making any conclusion impossible. However, it is interesting to 
note that this homozygote mouse demonstrated a more severe phenotype and had to 
be culled days before any of the null or G70S/- mice (140). Although it would not be 
feasible to generate every eEF1A2 mutation in a mouse model, generation of more 
eEF1A2 missense mutations in mouse models may be vital for clarifying whether all 
mutations operate like D252H in both a gain- and loss-of-function mechanism.  
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Unlike Eef1a2+/- or Eef1a2+/wst mice, Eef1a2D252H/+ mice show a weight deficit 
compared to WT during the p14-p23 testing period. Further testing of aged D252H/+ 
and WT littermates has confirmed this deficit is lifelong (personal communication 
with Professor Abbott). This suggests that the mutant copy of the protein is exerting 
a dominant negative/gain-of-function mechanism. Expanding upon this by 
examining D252H/+ mice in greater detail could provide an insight into this 
additional element to the mutation mechanism. Testing aged (1 year and older) 
D252H/+ mice for neurological deficits which might accrue over time would be 
interesting in helping determine what is happening in the heterozygous patients. Jilly 
Hope performed initial behavioural testing of these mice as part of her doctoral 
thesis (121). Although Jilly found no deficits in social cognition or increased anxiety 
behaviours, work on the novel object recognition test (a learning and memory assay) 
was inconclusive. It would be interesting to repeat these experiments in a bid to 
assess whether prolonged exposure of neurons to one copy of the D252H protein 
hindered the ability of eEF1A2 to perform in late-LTP formation.  
Assessing neuron growth in D252H/D252H, or D252H/+ mice over an extended 
period could identify underlying deficits in neurodevelopment. Images of 
neuroanatomy could be measured in mice using micro-imaging magnetic resonance 
imaging (mi-MRI). mi-MRI in mice is a well-established technique which could be 
useful for in-depth analysis of structural differences between WT and D252H mutant 
mice (215).  
Evaluating the electrophysiological properties of hippocampal slices from Eef1a2 
mutant mice might identify aberrant neuronal activity. Mice which overexpress 
eIF4E have been shown to have an increase in protein synthesis. These mice 
consequentially show electrophysiological dysfunction, changes to dendritic spine 
density and altered synaptic plasticity which culminate in autism-spectrum like 
behaviours (216).   
Neither Eef1a2D252H/D252H or Eef1a2D252H/+ mice exhibit seizures. The clinical 
cases of eEF1A2D252H  do report epilepsy, however the onset is reported to be much 
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later than in other mutations (123). It would be interesting to see if seizures were 
more inducible in these mice than WT counterparts.  
Given that Eef1a2D252H/D252H mice are far more severely affected than 
Eef1a2D252H/+ littermates, it suggests mutations are disrupting the function of a 
mechanism other than the WT allele, making it unlikely the mutation operates 
through a classical dominant negative function. Crucially one of the main differences 
between Eef1a2D252H/D252H and Eef1a2-/- mice at p14-p21 is that eEF1A2 is present in 
D252H mice when eEF1A1 is still expressed. There is a possibility that mutant 
eEF1A2 is acting upon eEF1A1, forming an aberrant heterodimer which is 
analogous to a dominant negative effect. Homodimerisation (eEF1A2 – eEF1A2) 
and heterodimerisation (eEF1A2 – eEF1A1) have been reported (25,217,218). It 
would be important to assess whether mutant eEF1A2 acts upon eEF1A1, inhibiting 
its function. It may sequester the isoform and impede the normal function of the 
heterodimeric complex. Alternatively, as eEF1A is suggested to function in 
translation as a monomer (219), mutant eEF1A2 may sequester eEF1A1 in a dimer, 
reducing the rate of protein synthesis at an earlier time point than in the Eef1a2-/- 
mice. Identifying these dimers has not been proven using co-immunoprecipitation. 
Using more sensitive techniques such as FRET analysis may be insightful in 
answering this question (218).  
It is vital that this additional mechanism in the D252H mutation is identified to 
ensure any treatment strategy does not exacerbate the toxic activity which the 
mutation exerts. Given that it is possible mutant eEF1A2 might act upon eEF1A1 
when it is still present, but additionally cannot compensate for eEF1A1 when it is 
down-regulated, it is possible different treatment strategies would be required at 
different stages of development.    
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6.4 Aim 3: Functional analysis of disrupted protein interactions 
In this chapter I aimed to generate eEF1A2 mutations in LUHMES cells and 
assess whether mutations impeded protein synthesis.   
I used genetic editing technique CRISPR/Cas9 to introduce missense and deletion 
mutations into the EEF1A2 gene in neuronal precursor cell line LUHMES. Although 
the G70S template was not successfully introduced, two lines showed D252H 
mutation incorporation with no indels. One line was a D252H/D252H homozygous 
line, while the other had the equivalent of the patient genotype D252H/+. These lines 
were instrumental in assessing whether LUHMES cells would be an appropriate 
model for measuring eEF1A2 mutations. Additionally, two eEF1A2 null lines, and a 
+/- line were generated. A line which had undergone CRISPR/Cas9 treatment but 
remained unedited (WT) was also examined to ensure there was no difference 
between this line and an unedited line. Using null lines for comparison was useful 
for determining whether eEF1A1 would mask any deficits seen by the eEF1A2 
deletion. Comparing multiple lines in a more extensive pilot study than initially 
trialled before (141) also controlled for clonal variability which can be a factor in 
neuronal cell lines (220).    
The most significant caveat to the use of immortalised cell lines is the ubiquitous 
expression of eEF1A1. RNAseq analysis of differentiated neuronal induced 
pluripotent stem cells (iPSCs) revealed that while eEF1A2 mRNA expression is 
upregulated as differentiation continues, eEF1A1 levels do not down-regulate 
substantially over time, and remain in excess of eEF1A2 (221).  
 A significant issue with protein expression analysis in LUHMES cells is the 
inability to detect eEF1A2 at the protein level. eEF1A protein and eEF1A2 mRNA 
analysis revealed that null cell lines showed significant reduction in expression. 
However, no antibody detecting eEF1A2 exclusively in vitro could be found. 
Without this, it would be difficult to fully validate LUHMES as an appropriate 
model for assessing eEF1A2 mutations. Nevertheless, the problem of eEF1A1 
expression is not specific to LUHMES cells, and would occur in all in vitro testing. 
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Therefore, it was imperative to continue to see if deficits in protein synthesis or other 
mechanisms could still be seen regardless of the eEF1A1 confound.  
Interaction analysis led to the discovery that eEF1B binding was disrupted, 
leading to the hypothesis that protein synthesis might be inhibited. It is highly likely 
that protein synthesis is disrupted by mutations, however this needs to be formally 
proven. Clonal variability was found to be an issue when measuring protein 
synthesis using either puromycin tagging or AHA click-it chemistry in LUHMES 
cells. Protein synthesis inhibitors cycloheximide and anisomycin verified that 
although the techniques were successfully measuring protein synthesis, LUHMES 
cells were not a viable model for functional testing, likely because of eEF1A1 
expression.  
Owing to this result, I aimed to test protein synthesis in Eef1a2/D252H and 
Eef1a2/WAR mouse lines. No deficit could be seen in the skeletal muscle of 
Eef1a2wst/wst mice at p22, demonstrating the lack of sensitivity of the puromycin 
tagging system. Puromycin tagging is reported to be one of the less sensitive 
techniques for measuring protein synthesis (202). Given the in vitro results of this 
thesis, assessing protein synthesis in neurons of Eef1a2/D252H and Eef1a2/WAR 
mice (using a different method to puromycin tagging) is the most likely method for 
measuring any potential protein synthesis deficits.   
There are several techniques which would be suited to measuring protein 
synthesis in Eef1a2 mutant and null mouse neurons. Recently protein synthesis 
measurements were performed in primary neurons taken from transgenic mice. Most 
primary neuron studies utilise rat neurons to measure protein synthesis, often 
transfected with lentiviral vectors containing genes of interest. Recently, however, a 
growing number of experiments have been published examining the protein 
synthesis capacity of primary neurons cultured from WT and transgenic mice 
(222,223). The degree of residual eEF1A1 in neurons would have to be established. 
Given that there is currently no commercial antibody which can detect the difference 
between eEF1A1 and eEF1A2 in cells, this might be difficult to achieve at the 
protein level. However, the down-regulation of eEF1A1 is more likely to occur in 
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these neurons if taken after p21 than in vitro and is more likely to reflect the levels of 
protein synthesis in vivo. 
Other techniques involving the study of ribosomes would be an interesting avenue 
to pursue. Ribosome profiling involves isolating and purifying the short mRNA 
segments which are protected within ribosomes. Deep-sequencing of these fragments 
can determine which ribosomes at any point are active, what proteins are being 
created and by measuring the number of ribosomes translating any given mRNA, a 
measure of total translation can be obtained (224). On whole brain lysates, ribosome 
profiling would have the same issue of eEF1A1 expression in glial cells. If 
centrifugation steps could be performed to isolate neurons, this may be a possible 
option, but may cause cellular stress which would impede results.    
Recently, a technique termed tandem ribosome affinity purification – RNAseq 
(TRAP-seq) was used in ex vivo hippocampal tissue to measure protein synthesis. 
Experimenters could control for the cell type by dissecting just the hippocampus 
from mice (225). This method might be appropriate for future experiments, as it 
would provide a sample enriched with neurons.  
An adaptation of the SUnSET technique has recently been reported. The 
SUnSET-based Ribosome Speed of Elongation (SUnRISE) technique uses 
puromycin tagging combined with a ribosomal run-off to measure translation 
elongation rates. Initiation is blocked by the drug harringtone. Doses of puromycin 
are subsequently administered at specific time points after translation initiation is 
blocked. This puromycin is incorporated into nascent elongating chains. When all 
the residual polypeptide chains have completed their elongation, ribosomes are 
deemed to have 'run-off' their mRNA, and no new mRNA translation can begin. The 
level of puromycin incorporation in polypeptides can be measured and used as an 
inverse correlation of elongation rates. Puromycin detection can be measured either 
through immunoblotting, or flow cytometry. The latter supplies a more specific 
technique for measuring detection. 
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Recent advances in measuring protein synthesis mean there are several options for 
measuring the effect eEF1A2 mutations might have. In this thesis, I have worked to 
narrow the experimental assays which might detect possible deficits in translation.  
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6.5 Conclusions 
The work presented in this thesis helped expand upon the mechanism behind 
mutations in eEF1A2. Although no definitive conclusion of gain or loss-of-function 
mechanism can be determined from these results, my results suggest several 
hypotheses and have opened avenues for further exploration. It is possible that not all 
mutations operate through the same mechanism of action, or to the same degree. No 
correlation between mutations with or without eEF1B interaction disruptions and 
severity/seizure occurrence can be made yet, but with more cases and information, it 
will become easier to identify differences. The protein interaction analysis was 
insightful for determining the mechanism by which protein synthesis will be affected 
in mutant neurons. A clear gain-of-function element is seen in D252H/D252H mice 
when comparing their phenotype with age-matched null mice. It is not established 
whether this gain-of-function element is a mark of protein synthesis disruption 
occurring at an earlier timepoint, or if the D252H mutation impacts upon another 
biological process besides. 
Moving forward from the findings of this thesis, there are several future 
experiments which would help establish the role of eEF1A2 in missense mutations. 
Given the difficulty in discriminating between eEF1A2 and eEF1A1, using 
CRISPR/Cas9 to introduce epitope tags to isoforms might be useful for establishing 
the endogenous expression during development and localisation of isoforms. This 
would require subsequent CRISPR/Cas9 engineering to introduce mutations but 
would be worth developing. My results also suggest that mutations may operate 
through different functions. To explore the impact all mutations have on eEF1A2 
function, it is essential to generate more Eef1a2 mouse lines with different eEF1A2 
mutations. It would be important to determine if all mutations, like D252H, operate 
through a loss and dominant negative/gain-of-function.  
More work on the mutation mechanisms is required before a treatment strategy 
could be established. It is key to determine whether mutant eEF1A2 interferes with 
eEF1A1. If this is the case different treatment strategies might be required at 
different neurodevelopmental stages. As with many neurodevelopmental disorders, 
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the solution to treating individuals with eEF1A2 missense mutations might be gene 
therapy.  
The work in this thesis provides avenues for further research in examining the 
role of eEF1A2 mutations in neurodevelopmental disorders. 
  
 
Appendices  Page | 192 
Appendices 
Appendix A 
Appendix A.1 Hierarchical clustering of technical repeats reveals G70S outlier 
 
Figure A.1 – Heatmap showing hierarchical clustering of technical repeats in 
affinity-purification mass spectrometry. Heatmap of z-scores for all proteins 
identified as ‘confident interactors’ (above empty vector filtering). Hierarchical 
clustering demonstrates that one G70S mutant (G70S.1) clusters with the empty 
vector technical repeats.  This was used as evidence to identify G70S.1 as an outlier.    
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A.2 Transfection of eEF1A2-V5 constructs does not result in nuclear staining 
 
Figure A.2: Staining of HEK293T cells transfected with eEF1A2-V5 constructs. 
Staining for V5 shows only cytoplasmic staining (green). This contrasts with the 
DAPI staining which marks the nucleus (blue).  
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A.3 Most-Likely Ratio normalisation strategy of AP-MS data 
Most Likely Ratio normalisation analysis as described by Lambert et al (145). 
Comparing all sample protein intensities against one WT sample (A), shows 
distribution of all samples and how they vary compared to WT. The principal of 
MLR is that only a minority of proteins will be impacted by mutations whilst most 
protein intensities will remain equal. The closer the density plot is to zero and the 
narrower it is, the closer overall to the WT sample this condition is. Using this 
comparison technique, the most representative sample for both technical replicates 
and biological repeats can be identified and used for normalisation. Initially within-
group normalisation is done, as these samples should be statistically most similar. As 
one G70S sample had already been identified as an outlier, only one comparison was 
able to be made and therefore the most representative sample was not able to be 
determined. In this instance, sample 2 was simply scaled using the apex ratio of 
sample 1, the distribution of comparison scores pre- and post- this normalisation are 
displayed in D and G respectively. For D252H and WT however, 3 samples were 
included in analysis and therefore were all comparable with each other. Distribution 
pre-normalisation for each comparison (1 vs 2, 2 vs 3 and 1 vs 3) were plotted and 
are seen in B and C respectively. Scores for each comparison were reported in Table 
A.1. Histogram width and delta from zero for each comparison were calculated. For 
WT and D252H the most representative sample (highlighted in Table A.1) for each 
genotype was determined. The apex ratio of this sample was then used to normalise 
the LFQ intensities of all the samples within the respective genotype. After this, 
comparison between technical replicates for all genotypes was repeated (D252H, E, 
WT, F, and G70S, G). In E and F a better overlap of repeats can now be seen all 
peaking closer to zero. Comparison of all technical repeat normalised samples to the 
same WT sample, as before in A, now shows better alignment of all technical repeats 
(H). The process above highlighted for technical replicates was then repeated 
comparing between genotypes. As WT is the genotype both mutants should be 
normalised to, all G70S and D252H samples were compared to all WT samples (I 
and J) to assess which WT sample was the most representative sample for all repeats 
to be normalised to. Table A.2 shows histogram scores for comparisons. In bold is 
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the WT sample selected as overall most reflective. All mutant samples and 
remaining WT samples were then scaled using the apex ratio to normalise between 
genotypes. All mutant versus WT comparisons were then repeated post-
normalisation (K and L). Much better alignment closer to zero was seen post 
normalisation as compared to pre-. Finally, all samples were compared to the 
original WT sample (as in A) to check how normalisation steps had impacted overall 
alignment (M). MLR has achieved better alignment of samples overall, normalising 
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Figure A.3: Most likely ratio normalisation steps. A comparison of protein LFQ 
scores (log-10 of comparative score)  for each condition compared to one WT 
sample. Comparison of each technical repeat against the others in respective 
genotype pre-normalisation for D252H (B), WT (C) and G70S (D). After 
determination of the most representative sample and scaling of intensities 
appropriately, comparison between technical replicates is repeated for D252H (E), 
WT (F) and G70S (G). After technical normalisation all samples were compared to 
the same WT sample as in (A). Distributions after within-group normalisation are 
displayed in (H). After technical repeat normalisation, biological repeat 
normalisation was carried out. For each mutant, all repeats were compared to all 
WT repeats to find the WT sample which best correlates with all mutants. Before 
normalisation, comparisons were visualised for both D252H (I) and G70S (J). 
Scores for each histogram of distributions were calculated and are presented in 
Table A.2. Once a representative WT sample has been decided and scaling of all 
other samples conducted, comparison of the distributions are re-visualised for 
D252H and G70S (K and L, respectively). M, After final normalisation step. 
Intensities for all conditions are compared to the same WT sample as in (A and H).  
 
 
Table A.1: Histogram scores of technical repeat comparisons for each genotype. Width of histogram is calculated by measuring the 
distance between minimum and maximum values. This value along with the delta of the histogram from zero are used to measure and 
assess the most representative sample. As decided using this method, the sample chosen and its representative scores have been 
highlighted in bold.   
WT Rep1 vs Rep2 Rep 2 vs Rep 3 Rep 1 vs Rep 3 
min -0.0314 -0.03505 -0.04278 
max 0.052866 0.053216 0.021538 
width 0.084266 0.088271 0.064316 
delta 1.63E-05 -6.53E-05 -8.16E-05     
D252H Rep1 vs Rep2 Rep 2 vs Rep 3 Rep 1 vs Rep 3 
min -0.0317 -0.03305 -0.04044 
max 0.062431 0.06712 0.043424 
width 1.548756 1.62399 1.405513 
delta 1.52E-05 -0.00015 -0.00016     
G70S Rep1 vs Rep2   
min -0.4992   
max 0.616918   
width 1.11612   
delta -0.0054   
 
 
Table A.2: Histogram scores of technical repeat comparisons for each mutant compared to WT. Width of histogram is calculated by 
measuring distance between minimum and maximum values. This value along with the delta of the histogram from zero are used to 
measure and assess the most representative sample (the same WT sample for both G70S and D252H). The most reflective WT sample 





vs WT 1 
D252H 2 vs 
WT 1 
D252H 3 vs 
WT 1 
D252H 1 vs 
WT 2 
D252H 2 vs 
WT 2 
D252H 3 
vs WT 2 
D252H 1 
vs WT 3 
D252H 2 
vs WT 3 
D252H 3 
vs WT 3 
Min -0.1191 -0.1597 -0.0351 -0.1330 -0.1736 -0.1466 -0.1300 -0.1706 -0.1436 
Max 0.0497 0.0288 0.0699 0.0583 0.0528 0.0615 0.0651 0.0529 0.0694 
width 0.1688 0.1885 0.1049 0.1914 0.2265 0.2081 0.1951 0.2235 0.2130 
delta 0.0001 0.0001 -0.0097 0.0001 0.0001 0.0002 0.0000 0.0000 0.0002 
          














   
Min -0.028 -0.036 -0.035 -0.049 -0.028 -0.047    
Max 0.059 0.066 0.070 0.071 0.071 0.069    
width 0.087 0.102 0.105 0.120 0.099 0.116    
delta -0.010 -0.010 -0.010 -0.010 -0.010 -0.010    
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A.4 Proteins which were most dysregulated in mutant conditions as 
compared with WT and were identified in both bait and MLR 
normalisation techniques. 
A total list of proteins which show the same differentially expressed 
trend in mutant compared to WT after normalisation by both bait and MLR 
techniques. Proteins which had a 0.5 fold change (log2) in mutant as 
compared to WT was seen in both normalisation techniques. Figure A.3 
demonstrates the correlation of proteins using two normalisation methods. 
Good correlation is seen between normalisation methods. Proteins with 
greater than 0.5 fold change in both normalisation techniques were 
highlighted in red. These proteins are reported in Table A.3 and A.4 for 
D252H and G70S respectively. 
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Figure A.4: Correlation of fold change of mutant (A, D252H and B, 
G70S) log2 values for each protein compared with WT in dataset as 
normalised by bait and MLR. Proteins which had a fold change difference 
of 0.5 (log2) in both conditions were coloured red. 
 
 
Table A.3: List of proteins with greater than 0.5 log2 fold change in both normalisation techniques identified with 
differential expression for D252H mutation as compared to WT.  














ACAT1 2.053364 0.983462 NOP58 1.98363 1.119742 RPS14 1.932471 0.86676 
AKAP17A 1.360616 0.484124 PAICS 1.372918 0.655804 RPS15A 1.45722 0.558429 
CPSF1 1.763163 0.926144 PDCD6 -0.51105 -1.5839 RPS2 2.443886 1.320149 
DDOST 1.672959 0.613464 PGAM5 1.798381 0.888874 RPS27 1.751548 0.765991 
DDX3X; 
DDX3Y 1.524089 0.50026 PNN 0.426506 1.363454 RPS3 2.638967 1.546385 
DDX50 1.407688 0.453551 
PPP2R2A; 
PPP2R2C 1.339535 0.445536 RPS3A 1.944617 0.82938 
EEF1B2 -8.14295 -9.43204 PRDX6 2.165308 1.202484 RPS4X 1.809334 0.728728 
EEF1D -8.01752 -9.21745 PYCRL -0.77824 -0.69642 RPS5 3.553587 2.46505 
EEF1G -6.13795 -7.31046 RANBP1 1.578624 0.463749 RPS7 1.717133 0.639744 
EEF2 1.723167 0.703827 RBM28 1.240622 0.785508 RPS8 1.825246 0.843491 
EHD1 0.988205 0.98744 RPL13A 1.805868 0.713027 RPS9 1.784788 0.697645 
EIF2S1 0.744631 0.719907 RPL14 1.908939 0.868244 RSL1D1 1.635425 0.619999 
ENO1 1.785864 0.790423 RPL21 1.84937 0.735727 SAP18 1.742427 0.815406 
FARSB 2.461828 1.551497 RPL26 1.656099 0.535884 SLU7 1.528104 0.573113 
FHL3 2.268656 1.342084 RPL28 1.84022 0.770248 SRP72 1.676206 0.704083 
GMPS 1.462789 0.539015 RPL30 1.185843 1.206601 SRSF6 1.628464 0.767132 







HNRNPUL2 2.002699 0.874478 
RPL36A-
HNRNPH2; 
RPL36A 1.475431 0.441056 STOML2 1.358155 0.708756 
HSP90AA1 1.535131 0.437101 RPL38 1.316425 0.592517 TCEB3 0.767465 0.952573 
KIF21A 1.59971 0.482717 RPL4 2.265216 1.287739 TNPO1 2.253471 1.108984 
KMT2A -2.61213 -3.9066 RPL5 2.673188 1.646299 VARS -6.93822 -8.05306 
KPNA2 1.709574 0.788982 RPL7A 2.019287 1.010565 
LBR 1.50039 0.554587 RPL8 2.09498 1.025901    
LGALS1 1.205743 0.47737 RPN1 1.519261 0.471981    
LLPH 1.087212 1.885158 RPS11 1.752172 0.73054    
NEFM 1.789243 0.881793 RPS13 1.805436 0.7643    
 
 
Table A.4: List of proteins with greater than 0.5 log2 fold change in both normalisation techniques identified with 
differential expression for G70S mutation as compared to WT. 
Genes 
Fold Change (Log2) 
Genes 









ACTA1;ACTC1;ACTG2;ACTA2 1.99247883 0.64555009 RPL23 2.19337157 0.64504546 
AKAP17A 1.86180485 0.52989751 RPL26 2.14034553 0.5731495 
ARHGAP1 2.0668352 0.512865 RPL28 2.18706194 0.71246792 
BOLA2 1.88120464 0.54204594 RPL30 1.81235487 1.56997006 
BUD13 1.85944237 0.50126164 RPL34 2.10037337 0.76646773 
CPSF1 2.65569826 1.41016897 RPL36A 2.61160825 1.12856125 
DLD 0.57516822 2.05287751 RPL38 2.45937738 1.23079693 
DYNLT1 1.21559023 1.12083954 RPL4 2.09490544 0.7637137 
EIF2S1 1.23623595 0.82857935 RPL5 2.8784672 1.51439644 
FARSB 2.11037782 0.80059388 RPL7A 2.22112588 0.83807931 
FHL3 2.03232656 0.7590388 RPL8 2.10357423 0.63686272 
IDH2 2.24991023 0.7792197 RPLP1 1.96961922 0.5414913 
KPNA2 1.99355594 0.65924633 RPS11 2.26000237 0.82296717 
LGALS1 1.95713279 0.5394422 RPS13 2.78200056 1.31635887 
LLPH 2.41069684 2.86541141 RPS14 2.70358769 1.24888216 
LRPPRC 3.20848393 1.32396555 RPS15A 2.25141617 0.8969454 
METTL13 2.2873711 0.93688316 RPS2 3.39513485 1.95031421 
NEFM 1.97561272 0.73926829 RPS27 2.24886403 0.88963337 
NOP58 2.00090926 0.82526735 RPS3 3.48954623 2.0230625 
PDCD6 0.70172411 2.14002125 RPS3A 2.82706855 1.29568981 
 
 
PNN 0.71749446 1.25316493 RPS4X 2.83587969 1.33236003 
POLR2C 1.3564562 0.6296095 RPS5 3.77112358 2.42043193 
PRPF4 1.64718694 1.50139457 RPS7 2.54359453 1.04451527 
RPL11 2.19558739 0.79852408 RPS8 2.05294872 0.67154099 
RPL12 2.00037982 0.71097451 RPS9 2.15493897 0.68693705 
RPL13A 2.12727898 0.6154282 SLU7 1.93938426 0.52934296 
RPL14 2.25950243 0.86963172 TCEB3 0.62529127 0.53309241 
 
Appendices  Page | 206 
Appendix B 
B.1 BeAtMuSIC prediction theoretical residues with greatest increase and 
decrease in binding affinity (174).  
Table B.1: Top 25 residue alterations in eEF1A2 which would exert the greatest 










424 F → D 5.20 2.24 % 0 % 
424 F → E 5.14 2.24 % 0 % 
435 V → E 5.07 10.03 % 0 % 
71 I → P 4.95 59.115 % 5.52 % 
73 I → G 4.92 83.7 % 17.96 % 
424 F → K 4.91 2.24 % 0 % 
71 I → G 4.84 59.115 % 5.52 % 
254 Y → S 4.75 48.35 % 16.68 % 
435 V → K 4.71 10.03 % 0 % 
254 Y → G 4.65 48.35 % 16.68 % 
435 V → D 4.58 10.03 % 0 % 
424 F → N 4.19 2.24 % 0 % 
254 Y → D 4.18 48.35 % 16.68 % 
86 Y → G 4.13 29.35 % 9.71 % 
32 G → P 4.12 64.695 % 42.57 % 
71 I → D 4.08 59.115 % 5.52 % 
424 F → P 4.06 2.24 % 0 % 
424 F → Q 4.05 2.24 % 0 % 
254 Y → P 3.98 48.35 % 16.68 % 
71 I → S 3.95 59.115 % 5.52 % 
78 W → P 3.89 0.565 % 0.56 % 
254 Y → A 3.82 48.35 % 16.68 % 
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254 Y → N 3.78 48.35 % 16.68 % 
424 F → G 3.76 2.24 % 0 % 
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Table B.2: Top 25 residue alterations in eEF1A2 which would exert the greatest 










252 D → W -2.75 40.645 % 2.21 % 
252 D → F -2.74 40.645 % 2.21 % 
427 R → I -2.56 34.765 % 2.93 % 
252 D → Y -2.53 40.645 % 2.21 % 
427 R → W -2.53 34.765 % 2.93 % 
427 R → F -2.51 34.765 % 2.93 % 
427 R → Y -2.39 34.765 % 2.93 % 
413 E → Y -2.28 0.27 % 0.27 % 
413 E → F -2.26 0.27 % 0.27 % 
413 E → I -2.25 0.27 % 0.27 % 
413 E → L -2.17 0.27 % 0.27 % 
413 E → M -2.15 0.27 % 0.27 % 
413 E → W -2.11 0.27 % 0.27 % 
427 R → L -2.06 34.765 % 2.93 % 
66 E → F -2.05 40.01 % 9.94 % 
342 S → F -2.05 0 % 0 % 
252 D → M -2.04 40.645 % 2.21 % 
436 G → F -2.04 0 % 0 % 
413 E → V -1.99 0.27 % 0.27 % 
436 G → W -1.98 0 % 0 % 
252 D → I -1.97 40.645 % 2.21 % 
436 G → Y -1.97 0 % 0 % 
342 S → Y -1.91 0 % 0 % 
342 S → I -1.90 0 % 0 % 
252 D → V -1.89 40.645 % 2.21 % 
 
 
Appendices  Page | 209 
Appendix C  
C.1 Sequence Alignment of alleles from LUHMES clones which had undergone 
CRISPR/Cas9 to mutate eEF1A2 
Clustal OMEGA alignments of sequences identified from sequencing and TOPO cloning of 
LUHMES genomic DNA. Cells lines are as follows: A – 2.5, B – 2.7, C – 2.8, D – 2.13, E – 
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Figure C.1: Alignments of alleles from LUHMES clones which had been genetically 
edited using CRISPR/Cas9. A-C shows lines created from gRNAs which targeted 
exon 3. D-F shows lines created from gRNAs which targeted exon 5. Green 
highlighted bases reflect missense mutations and ‘-‘ represents a deletion.   
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C.2 qPCR standard and melt curves for eEF1A2 mRNA quantification and 
housekeeping genes. 
Figure C.2 standard and melt curves for RPL34, TOP1 and eEF1A2. R2, gradient and 
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Figure C.2: Melt curve and standard curve plots for qPCR of RPL34 (A & B), TOP1 
(C & D) and eEF1A2 mRNA (E & F). 
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